Amedisys

WHY WE DO 
WHAT WE DO

2015  
ANNUAL  
REPORT

Dear Shareholders,

The turnaround of Amedisys that we kicked off in 2014 picked up fresh momentum in 2015, as we defined and 
began to implement our strategy to continue our transformation into a world-class market leader in post-
acute healthcare.

I am very pleased with our financial performance in 2015. Amedisys realized increases in revenue by 6%, in 
adjusted EBITDA by 51% and in adjusted earnings per share by 103%. As a result, we finished the year with a 
strong, unlevered balance sheet and significant financial flexibility allowing us to pursue accretive acquisition 
opportunities.

In broad strokes, we saw an increase in our Medicare Quality of Patient Care and Patient Satisfaction STAR 
ratings, grew organically and executed on our first acquisitions in years, and moved toward best in class 
technology to streamline administrative work for our clinicians so they can focus on what they do best – 
patient care. Throughout the year, our more than 16,000 employees made no fewer than eight million visits. As 
a bonus, NASDAQ invited us to ring the opening bell this past December. 

We also made significant progress in all four of our key strategies:

Achieve Clinical Distinction
When it comes to achieving outstanding patient outcomes – the very heart of our overall strategy – nothing 
speaks louder in the markets we serve than our clinical results. And the benchmark numbers for the all-
important STAR ratings from Medicare are in. 

Our average score for quality of patient care across all home health care centers in our January 2016 update 
was 3.49, our best performance to date, compared to an industry average of 3.25 – and 30% of our centers 
attained a rating of 4 STARS or better. Equally positive, our patient survey rating of 4.35 STARS in our January 
2016 update was higher than the industry average of 4.03. As CMS and other healthcare payers continue to 
transition to value and outcomes-based reimbursement, we will continue to invest in quality. 

But we have no intention of stopping there. By the end of 2017 our goal is for all of our home health care 
centers to achieve a quality STAR rating of 4 or higher. 

Become An Employer of Choice
To be the best company we can be, we took steps in 2015 to create an environment that will inspire our 
employees to bring the best of themselves to the job each day, to better serve our patients, our colleagues, 
and our referring physicians and hospitals. In other words, we need to recruit, develop and retain outstanding, 
talented people. People are our most important asset, representing a large majority of our costs. We are 
executing on several fronts to improve our return on human capital.

To start, we conducted a survey among our employees to measure their level of engagement – how 
emotionally committed they are to Amedisys and its mission. Our overall engagement score, reflecting 
responses about employee pride, advocacy, loyalty and satisfaction, was 72% – slightly higher than the Kenexa 
World Norm average of 70% – with pride about working for Amedisys, the factor that ranked the highest. 

This baseline data lent insight into how we are doing but also showed what we need to keep doing and how 
we can perform even better. Employee retention will improve as we understand more about key drivers of 
employee satisfaction. Our industry generally experiences high turnover and the direct and indirect costs of 
turnover are high. During the year, we lowered turnover by 4% with a goal of another 4% reduction by the end 
of 2016. 

Operational Excellence and Efficiency
In May, we announced the decision to move away from our proprietary software and transition to HomeCare 
HomeBase (HCHB), a leading home health and hospice IT platform that enables our clinicians to better focus 
on care delivery. Our experience with implementation thus far has been outstanding,with positive feedback 

from our clinical staff and minimal disruption to operations. This move has also enabled us to take a closer look 
at inefficient processes that have become ingrained in our operations. As we look into the rest of 2016 and 
2017, we have a detailed plan to deliver approximately $46 million of cost savings, mostly from reductions in 
IT-related G&A expense and other efficiencies enabled by HCHB.

As I mentioned, we’ve received positive feedback from the 209 locations that have implemented HCHB, as well 
as others now in the process of doing so. As of April, all hospice care centers have implemented the software. 
To fulfill its maximum potential and achieve all the benefits available, we’re accelerating our roll-out timeline 
for home health as well. By November 1, 2016, seven months ahead of our original plan, all of our care centers 
will be live on HCHB. 

Driving Growth
We delivered on organic growth in both of our business units during the year. Home health Medicare 
admissions grew 3% and hospice admissions grew by 16%. In home health, we will continue to emphasize 
organic growth in traditional Medicare fee-for-service patients. In hospice, we look to build on a strong 2015 
and are confident in the trends we are seeing in the business.

We completed our first significant acquisition in several years in December, acquiring Infinity HomeCare in 
Florida. Infinity is a market leader in Florida and complements our geographic footprint. In March 2016, we 
also acquired Associated Home Care, the leading personal care agency in Massachusetts, a move in line with 
our long-term strategy to broaden our scope of clinical services that can be delivered at home. 

With our three lines of business – home health, hospice and now, personal care – we are extending the 
traditional continuum of care to give patients unprecedented opportunities to stay at home. This versatility 
will allow us to better coordinate our services and transition patients as needed to just the right level of care. 

Orchestrating Our Strategies 
Simply put, we want to do more in the home. If care is provided in the home, we want to understand it, 
participate in it and eventually coordinate it. This means further expansion of our capabilities and services 
to treat both higher and lower acuity patients in our traditional post-acute space, expansion into the pre-
acute space and going even as far as providing some acute services inside the home to patients who have 
traditionally been treated in the emergency room or hospital. We are at the innovation forefront of this new 
world of home health and plan to develop organically and inorganically a capability set that allows Amedisys 
to do the most, for the most, all inside of the patient’s home. 

We have a solid strategy in place and the right leadership team to help us realize it, but none of this would 
be possible without the dedication of our more than 16,000 employees who either see patients every day or 
support those who do. I am amazed at the compassion and dedication I see from this team every day – and 
want to take this opportunity to thank them for doing what they do each and every day.   

We are privileged to take care of those who need our help the most – and will continue to focus on bringing 
the best care possible to them. It’s a virtuous circle – the better we perform for our patients and employees, 
the better we perform as a company. And the better we operate as a company, the better we can all ultimately 
serve our patients.

Paul Kusserow 
President and Chief Executive Officer

FINANCIAL HIGHLIGHTS - AMEDISYS, INC. 2015
(Adjusted - amounts in millions, except per share data)¹

YEAR ENDED DECEMBER 31,

2015

2014

Home Health revenue

Hospice revenue

Total net service revenue

Gross Margin %

EBITDA

EPS2

Free cash flow3

Total revenue growth

Same store growth:

Home Health Medicare admissions

Home Health non-Medicare admissions

Hospice admissions

Hospice average daily census

Outstanding Debt and Liquidity as of December 31, 2015:
Credit Facility - Total

Term Loan

Outstanding Revolver

Letters of Credit

Available Revolver

Cash Balance

Available Liquidity4

 1,004.1 

 275.4 

 $1,279.5 

43.3%

 $112.0 

8.8%

 $1.48 

 $80.4 

 956.9 

 247.6 

 $1,204.5 

42.6%

 $74.3 

6.2%

 $0.73 

 $(89.5)

6%

(4%)

0%

17%

(3%)

(4%)

3%

18%

16%

12%

 300.0 

 100.0 

 -   

 21.0 

 179.0 

 27.5 

 206.5 

1 The financial results for 2015 and 2014 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these 

non-GAAP financial measures is included in the 8-K earnings release filed on March 8, 2016.

2 EPS from continuing operations of $(0.09) in 2015 and $0.40 in 2014 on a GAAP basis.

3 Free cash flow defined as cash flow from operations less capital expenditures and required debt repayments. Free cash flow in 2014 includes impact of 

Department of Justice settlement.

4 Liquidity defined as the sum of cash balance and available revolving line of credit.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-K
È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934
For the fiscal year ended: December 31, 2015

OR
‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934
For the transition period from

to

Commission File Number: 0-24260

AMEDISYS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

11-3131700
(I.R.S. Employer
Identification No.)

5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225) 292-2031 or (800) 467-2662
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

The NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes È No ‘
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ‘ No È
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes È No ‘
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit and post such files). Yes È No ‘
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in
Part III of this Form 10-K or any amendment to this Form 10-K. È
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer ‘

Non-accelerated filer ‘
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ‘ No È
The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, based on the last sale price as
quoted by the NASDAQ Global Select Market on June 30, 2015 (the last business day of the registrant’s most recently completed second fiscal
quarter) was $679,670,884. For purposes of this determination shares beneficially owned by executive officers, directors and ten percent
stockholders have been excluded, which does not constitute a determination that such persons are affiliates.
As of March 4, 2016, the registrant had 33,329,102 shares of Common Stock outstanding.

Smaller reporting company ‘

Accelerated filer È

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement for its 2016 Annual Meeting of Stockholders (the “2016 Proxy Statement”) to be filed
pursuant to the Securities Exchange Act of 1934 with the Securities and Exchange Commission within 120 days of December 31, 2015 are
incorporated herein by reference into Part III of this Annual Report on Form 10-K.

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS . . . . . . . . . . . . . . . . . . . . .

1

TABLE OF CONTENTS

PART I.
ITEM 1.
ITEM 1A.
ITEM 1B.
ITEM 2.
ITEM 3.
ITEM 4.

PART II.
ITEM 5.

ITEM 6.
ITEM 7.

ITEM 7A.
ITEM 8.
ITEM 9.

ITEM 9A.
ITEM 9B.

PART III.
ITEM 10.
ITEM 11.
ITEM 12.

ITEM 13.

ITEM 14.

PART IV.

BUSINESS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RISK FACTORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
UNRESOLVED STAFF COMMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PROPERTIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LEGAL PROCEEDINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MINE SAFETY DISCLOSURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES . . . . . . . . . . . . . . . . . .
SELECTED FINANCIAL DATA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK . . . . . . .
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA . . . . . . . . . . . . . . . . . . . . . .
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CONTROLS AND PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OTHER INFORMATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE . . . . . . . . . .
EXECUTIVE COMPENSATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS . . . . . . . . . . . . . . . . . . . . .
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PRINCIPAL ACCOUNTING FEES AND SERVICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2
13
28
28
29
29

30
32

33
53
53

98
98
101

101
101

101

101
101

ITEM 15.

EXHIBITS, FINANCIAL STATEMENT SCHEDULES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

102

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

103

EXHIBIT INDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

104

EX-21.1 LIST OF SUBSIDIAIRES
EX-23.1 CONSENT OF KPMG LLP
EX-31.1 SECTION 302 CERTIFICATION OF PEO
EX-31.2 SECTION 302 CERTIFICATION OF PFO
EX-32.1 SECTION 906 CERTIFICATION OF PEO
EX-32.2 SECTION 906 CERTIFICATION OF PFO
EX-101 INTERACTIVE DATA FILE

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

When included in this Annual Report on Form 10-K, or in other documents that we file with the Securities and
Exchange Commission (“SEC”) or in statements made by or on behalf of the Company, words like “believes,”
“belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,”
“should” and similar expressions are intended to identify forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and
uncertainties that could cause actual results to differ materially from those described therein. These risks and
uncertainties include, but are not limited to the following: changes in Medicare and other medical payment
levels, our ability to open care centers, acquire additional care centers and integrate and operate these care
centers effectively, changes in or our failure to comply with existing federal and state laws or regulations or the
inability to comply with new government regulations on a timely basis, competition in the home health industry,
changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated
with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to
attract and retain qualified personnel, changes in payments and covered services due to the economic downturn
and deficit spending by federal and state governments, future cost containment initiatives undertaken by third-
party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our
ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions
due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, our
ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or
developments with respect to any litigation relating to the Company, including various other matters, many of
which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be
predicted or quantified, you should not rely on any forward-looking statement as a prediction of future
events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates
or changes in our expectations concerning the forward-looking statements or any changes in events, conditions
or circumstances upon which any forward-looking statement may be based, except as required by law. For a
discussion of some of the factors discussed above as well as additional factors, see Part I, Item 1A, “Risk
Factors” and Part II, Item 7, “Critical Accounting Estimates” within “Management’s Discussion and Analysis
of Financial Condition and Results of Operations.”

Unless otherwise provided, “Amedisys,” “we,” “us,” “our,” and the “Company” refer to Amedisys, Inc. and
our consolidated subsidiaries and when we refer to 2015, 2014 and 2013, we mean the twelve month period then
ended December 31, unless otherwise provided.

A copy of this Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC,
including all exhibits, is available on our internet website at http://www.amedisys.com on the “Investors” page
under the “SEC Filings” link.

1

ITEM 1. BUSINESS

Overview

PART I

Amedisys, Inc. is a leading healthcare at home company, providing outstanding home health, hospice and
personal care. We deliver the care that is best for our patients, whether that is home-based recovery and
rehabilitation after an operation or injury, care that empowers patients to manage a chronic disease, or hospice
care at the end of life.

We are among the largest, best established and most advanced providers of home health and hospice care in the
United States, with 408 care centers in 34 states. Our 16,100 employees deliver the highest quality of care to the
doorsteps of patients in need, making more than 7.5 million patient visits to 360,000 patients annually. Over
2,200 hospitals and 61,900 physicians nationwide have chosen us as a partner in post-acute care.

Amedisys is headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee. Our
common stock is currently traded on NASDAQ Global Select Market under the trading symbol “AMED”.
Founded and incorporated in Louisiana in 1982, Amedisys was reincorporated as a Delaware corporation prior to
becoming a publicly traded company in August, 1994.

The company’s continuous quality improvement efforts show in outcomes and publicly reported quality
measures. We’re standardizing our clinical care, streamlining how we operate and partnering as a post-acute care
provider to an increasing number of hospitals and health systems across the country. Our mission is nothing less
than putting the best clinicians in the home, with the tools needed to provide the best possible care and outcomes.
Ultimately, we are in the business of delivering superior value to employees, referral sources, payors – and most
of all – patients and their families.

We are privileged to take care of our patients wherever they call home – a private house, an apartment, a
rehabilitation facility or an assisted living community. Our clinicians go behind the scenes to enter otherwise
private spaces, caring for patients who feel safe and cared for and for others who are struggling with poverty and
dysfunction. We see it all – we get the whole picture of our patients – which enables us to develop and administer
the right care plan for each one in conjunctions with primary care physicians and other providers.

Our services are primarily paid for by Medicare due to the age demographics of our patient base (average
age 81). Medicare represented approximately 80% to 84% of our net service revenue over the last three years.
We remain focused on maintaining a profitable and strategically important managed care contract portfolio.

Our Home Health Segment:

Amedisys Home Health provides experienced, compassionate healthcare to help our patients recover from
surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. Our care team
includes skilled nurses who are trained and certified to administer medications, care for wounds, monitor vital
therapists specialized in physical, speech and
signs and provide a wide range of other nursing services;
occupational therapy; and aides who assist our patients with completing important personal tasks.

We take an empowering approach to helping our patients and their families understand their condition, how to
manage it and how to live life to the fullest with a chronic disease or other health condition. Our professional and
compassionate clinicians are trained to understand the whole patient – not just their medical diagnosis.

This commitment to clinical distinction is evident in our clinical performance measures such as Star Ratings.
Amedisys has an average Quality Star Rating of 3.5 and an average Patient Survey Overall Star Rating of 4.4.
Our goal is to have all of our care centers achieve a 4.0 Quality Star Rating, and we are implementing targeted
action plans to continue to improve the quality of care we deliver for our patients across the country.

2

Our Hospice Segment:

Hospice is a special form of care that is designed to provide comfort and support for those who are dealing with a
terminal illness. It is a compassionate form of care that promotes dignity and affirms quality of life for the
patient, family members and other loved ones.

Individuals with a terminal illness such as heart disease, pulmonary disease, Alzheimer’s, HIV/AIDS or cancer
may be eligible for hospice care, if they have a life expectancy of six months or less.

At Amedisys Hospice, our focus is on building and retaining an exceptional team, delivering the highest quality
care and service to our patients and their families, and establishing Amedisys as the preferred and preeminent
hospice provider in each community we serve. In order to realize these goals, we invest in tailored training,
development, and recognition programs for our employees, with specific focus on our clinicians and
caregivers. This has led to our team’s consistent achievement at or above the national average in family
satisfaction results and quality scores.

Another element of our approach is our outreach strategy to more fully reach the entire community of eligible
patients. These outreach efforts have built our hospice patient population to more accurately represent the causes
of death in the communities we serve, with a specific focus on heart disease, lung disease, and dementia in order
to address the historical underrepresentation of non-cancer diagnoses.

By working to accept every patient with a life expectancy of six months or less who wants our compassionate
care, we fulfill our hospice mission and strengthen our standing in the community.

Our Personal Care Segment:

On March 1, 2016, Amedisys acquired its first private-duty – an important step in executing our strategy of
improving the continuity of care our patients receive as their clinical needs change.

We believe that private duty services are highly synergistic with our core skilled home health and hospice
businesses, and that by acquiring these capabilities in one of our most successful regions we will realize these
benefits quickly.

Responding to Changing Regulatory and Reimbursement Environment:

Effective October 2012, Medicare began to impose a financial penalty on hospitals that have excessive rates of
patient readmissions within 30 days after hospital discharge. We believe this regulation provides an opportunity
for providers of post-acute care who can demonstrate the ability to maintain or reduce patient acute care hospital
readmission rates. We are working to take advantage of this opportunity further improving the quality of care we
provide and implementing disease management programs designed to be responsive to the needs of patients
served by the hospitals we call upon.

The passage of the Patient Protection and Affordable Care Act (“PPACA”) has resulted in several programs
being introduced by the Centers for Medicare and Medicaid Services (“CMS”) that offer the opportunity to
participate in initiatives that align home health providers with hospitals, physicians, managed care payors and
other referral sources to coordinate care and/or pilot alternative reimbursement structures. One such program is
the CMS Bundled Payments for Care Improvement Initiative (“BPCI”). We participated in a “Model 3 – 90-Day
Post-Acute” BPCI bundle across two regions during 2014. This is an at-risk model in which CMS sets a bundle
target price based on historical costs. On October 29, 2014, we notified CMS of our plan to withdraw from the
two Model 3 bundles.

In addition to the BPCI program, PPACA introduced Accountable Care Organization (“ACO”) programs. An
ACO is a group of doctors, hospitals and other health care providers who come together voluntarily to give

3

coordinated high-quality care to Medicare patients. The goal of coordinated care is to ensure that patients,
especially the chronically ill, get the right care at the right time, while avoiding unnecessary duplication of
services and preventing medical errors. While these programs are presently not material to our business or our
financial results, we are currently participating in several ACOs and monitoring their results.

AMS3/Homecare Homebase Implementation:

During 2015, we made the strategic decision to discontinue AMS3, our third generation, proprietary operating
system, and transition to Homecare Homebase (“HCHB”), a leading home health and hospice platform. As of
December 31, 2015, we have 84 care centers on HCHB (44 home health care centers and 40 hospice care
centers). We will continue the rollout during 2016, with an anticipated completion date of November 1, 2016.

Acquisitions:

On July 24, 2015, we acquired one hospice care center in Tennessee for a total purchase price of $5.8 million.

On October 2, 2015, we acquired the regulatory assets of home health care center in Georgia for a total purchase
price of $0.3 million.

On December 31, 2015, we acquired Infinity HomeCare (“Infinity”) for a total purchase price of $63 million.
Infinity owned and operated 15 home health care centers servicing the state of Florida.

Financial Information:

Financial information for our home health and hospice segments can be found in our consolidated financial
statements included in this Annual Report on Form 10-K.

Our Employees

As of March 4, 2016, we employed approximately 16,100 employees, consisting of approximately 11,200 home
health care employees, 2,600 hospice care employees, 1,500 personal care employees and 800 corporate and
divisional support employees.

Payment for Our Services

Home Health Medicare

The Medicare home health benefit is available both for patients who need care following discharge from a
hospital and patients who suffer from chronic conditions that require ongoing but intermittent care. As a
condition of participation under Medicare, beneficiaries must be homebound (meaning that the beneficiary is
unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing,
physical
therapy or speech therapy services, and receive treatment under a plan of care established and
periodically reviewed by a physician. Medicare rates are based on the severity of the patient’s condition, his or
her service needs and other factors relating to the cost of providing services and supplies, bundled into 60-day
episodes of care. An episode starts with the first day a billable visit is performed and ends 60 days later or upon
discharge, if earlier. If a patient is still in treatment on the 60th day, a recertification assessment is undertaken to
determine whether the patient needs additional care. If the patient’s physician determines that further care is
necessary, another episode begins on the 61st day (regardless of whether a billable visit is rendered on that day)
and ends 60 days later. The first day of a consecutive episode, therefore, is not necessarily the new episode’s first
billable visit.

Annually, the Medicare program base episodic rates are set through federal legislation, as follows:

Period

January 1, 2013 through December 31, 2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
January 1, 2014 through December 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
January 1, 2015 through December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
January 1, 2016 through December 31, 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Base episode
payment

2,138
2,869
2,961
2,965

4

Payments can be adjusted for: (a) an outlier payment if our patient’s care was unusually costly (capped at 10% of
total reimbursement per provider number); (b) a low utilization payment adjustment (“LUPA”) if the number of
visits during the episode was fewer than five; (c) a partial payment if our patient transferred to another provider
or we received a patient from another provider before an episode was complete; (d) a payment adjustment based
upon the level of therapy services required (with various incremental adjustments made for additional visits, with
larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) a payment
adjustment if we are unable to perform periodic therapy assessments; (f) the number of episodes of care provided
to a patient, regardless of whether the same home health provider provided care for the entire series of episodes;
(g) changes in the base episode payments established by the Medicare program; (h) adjustments to the base
episode payments for case mix and geographic wages; and (i) recoveries of overpayments. Medicare can also
make various adjustments to payments received if we are unable to produce appropriate billing documentation or
acceptable authorizations. In addition, we make adjustments to Medicare revenue if we find that we are unable to
obtain appropriate billing documentation, authorizations or face to face documentation.

Home Health Non-Medicare

Payments from Medicaid and private insurance carriers are episodic-based rates (60-day episode of care) or per-
visit rates depending upon the terms and conditions established with such payors. Episodic-based rates paid by
our non-Medicare payors are paid in a similar manner and subject to the same adjustments as discussed above for
Medicare; however, these rates can vary based upon negotiated terms.

Hospice Medicare

The Medicare hospice benefit is also available to Medicare-eligible patients with terminal illnesses, certified by a
physician, where life expectancy is six months or less. Medicare rates are based on standard prospective rates for
delivering care over a base 90-day or 60-day period (90-day episodes of care for the first two episodes and
60-day episodes of care for any subsequent episodes). Payments are based on daily rates for each day a
beneficiary is enrolled in the hospice benefit. Rates are set based on specific levels of care, are adjusted by a
wage index to reflect health care labor costs across the country and are established annually through federal
legislation. We make adjustments to Medicare revenue when we find we are unable to obtain appropriate billing
documentation, authorizations or face to face documentation and other reasons unrelated to credit risk. The levels
of care are routine care, general inpatient care, continuous home care and respite care. Beginning January 1,
2016, CMS has provided for two separate payment rates for routine care: payments for the first 60 days of care
and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also
reimbursing for a service intensity add-on (“SIA”). The SIA is based on visits made in the last seven days of life
by a registered nurse (“RN”) or medical social worker (“MSW”) for patients in a routine level of care.

We bill Medicare for hospice services on a monthly basis and our payments are subject to two fixed annual caps,
which are assessed on a provider number basis. Generally, each hospice care center has its own provider number.
However, where we have created branch care centers to help our parent care centers serve a geographic location,
the parent and branch may have the same provider number. The annual caps per patient, known as hospice caps,
are calculated and published by the Medicare fiscal intermediary on an annual basis and cover the twelve month
period from November 1 through October 31. The caps can be subject to annual and retroactive adjustments,
which can cause providers to be required to reimburse the Medicare program if such caps are exceeded.

The two caps are detailed below:

•

Inpatient Cap. When we provide hospice care on an inpatient basis, the payments that we are entitled
to receive at the higher inpatient reimbursement rate are subject to a cap. This cap limits the number of
days that are paid at the inpatient care rate (both respite and general) under a provider number to 20%
of the total number of days of hospice care (both inpatient and in-home) that is furnished to all
Medicare patients served by the provider. The daily Medicare payment rate for any inpatient days of
service that exceed the cap is at the routine home care rate, and the provider is required to reimburse
Medicare for any amounts it receives in excess of the cap; and

5

• Overall Payment Cap. This cap is calculated by the Medicare fiscal intermediary at the end of each
hospice cap period to determine the maximum allowable payments per provider number. We estimate
our potential cap exposure using information available for both inpatient day limits as well as per
beneficiary cap amounts. The total cap amount for each provider is calculated by multiplying the
number of beneficiaries electing hospice care during the period by a statutory amount that is indexed
for inflation.

Our ability to stay within these limitations depends on a number of factors, each determined on a provider
number basis, including the average length of stay and mix in level of care.

Hospice Non-Medicare

Non-Medicare payors pay at rates different from established Medicare rates for hospice services, which are based
on separate, negotiated agreements. We bill and are paid by these non-Medicare payors based on such negotiated
agreements.

Controls over Our Business System Infrastructure

We establish and maintain processes and controls over coding, clinical operations, billing, patient recertifications
and compliance to help monitor and promote compliance with Medicare requirements.

• Coding – Specified diagnosis codes are assigned to each of our patients based on their particular health
condition and ailment (such as diabetes, coronary artery disease or congestive heart failure). Because
coding regulations are complex and are subject to frequent change, we maintain controls surrounding
our coding process. In order to reduce associated risk of coding failures, we provide coding training
and annual update training to clinical assessment managers; provide coding training during orientation
for new employees; provide monthly specialized coding education; obtain outside expert coding
instruction; utilize coding software in our POC system; and have automated coding edits based on pre-
defined compliance metrics in our POC system.

• Clinical Operations – Regulatory requirements allow patients to be admitted to home health care if
they are considered homebound and require certain clinical services. These clinical services include:
educating the patient about their disease; assessment and observation of disease status; delivery of
clinical skills such as wound care; administration of injections or intravenous fluids; and management
and evaluation of a patient’s plan of care. In order to help monitor and promote compliance with
regulatory requirements, we complete audits of patient charts; administer survey guideline education;
hold recurrent homecare regulatory education; utilize outside expert regulatory services; and have a
toll-free hotline to offer additional assistance.

• Billing – We maintain controls over our billing processes to help promote accurate and complete
billing. In order to promote the accuracy and completeness of our billing, we have annual billing
compliance testing; use formalized billing attestations; limit access to billing systems; hold weekly
operational meetings; use automated daily billing operational indicators; and take prompt corrective
action with employees who knowingly fail to follow our billing policies and procedures in accordance
with a well-publicized “Zero Tolerance Policy”.

• Patient Recertification – In order to be recertified for an additional episode of care, a patient must
continue to meet qualifying criteria and have a continuing medical need. This could be caused by
changes in the patient’s condition requiring changes to the patient’s medical regimen or modified care
protocols within the episode of care. The patient’s progress towards goals is evaluated prior to
recertification. As with the initial episode of care, a recertification requires orders from the patient’s
physician. Before any employee recommends recertification to a physician, we conduct a care center
level, multidisciplinary care team conference. We also monitor centralized automated compliance
recertification metrics to identify, monitor, and, where we deem appropriate, audit care centers that
have relatively high recertification levels.

6

• Compliance – The quality and reputation of our personnel and operations are critical to our success.
We develop, implement and maintain ethics, compliance and quality improvement programs as a
component of the centralized corporate services provided to our home health and hospice care
centers. Our ethics and compliance program includes a Code of Ethical Business Conduct for our
employees, officers, directors and affiliates and a process for reporting regulatory or ethical concerns to
our Chief Compliance Officer through a confidential hotline, which is augmented by exit interviews of
departing employees and monthly interviews with randomly-selected, current employees. We promote
a culture of compliance within our company through persistent messages from our senior leadership to
our employees stressing the importance of strict compliance with legal requirements and company
policies and procedures. We also employ a comprehensive compliance training program that includes
mandatory compliance training and testing for all new employees upon hire and annually for all staff
thereafter. In addition to our compliance training, we also conduct numerous proactive, compliance
audits focusing on key risk areas, which are conducted by clinical auditors who work for our
Compliance Department.

Our Regulatory Environment

We are highly regulated by federal, state and local authorities. Regulations and policies frequently change, and
we monitor changes through trade and governmental publications and associations. Our home health and hospice
subsidiaries are certified by CMS and therefore are eligible to receive payment for services through the Medicare
system.

We are also subject to federal, state and local laws and regulations dealing with issues such as occupational
safety, employment, medical leave, insurance, civil rights, discrimination, building codes, environmental issues
and adverse event reporting and recordkeeping. Federal, state and local governments are expanding the number
of regulatory requirements on businesses.

We have set forth below a discussion of the regulations that we believe most significantly affect our home health
and hospice businesses.

Licensure, Certificates of Need (CON) and Permits of Approval (POA)

Home health and hospice care centers operate under licenses granted by the health authorities of their respective
states. Additionally, certain states, including a number in which we operate, carefully restrict new entrants into
the market based on demographic and/or competitive changes. In such states, expansion by existing providers or
entry into the market by new providers is permitted only where a given amount of unmet need exists, resulting
either from population increases or a reduction in competing providers. These states ration the entry of new
providers or services and the expansion of existing providers or services in their markets through a CON process,
which is periodically evaluated. Currently, state health authorities in 17 states and the District of Columbia
require a CON or, in the State of Arkansas, a POA, in order to establish and operate a home health care center,
and state health authorities in 11 states and the District of Columbia require a CON to operate a hospice care
center.

We operate home health care centers in the following CON states: Alabama, Arkansas (POA), Georgia,
Kentucky, Maryland, Mississippi, New Jersey, New York, North Carolina, South Carolina, Tennessee and West
Virginia, as well as the District of Columbia. We provide hospice related services in the following CON states:
Alabama, Maryland, North Carolina, Tennessee and West Virginia.

In every state where required, our locations possess a license and/or CON or POA issued by the state health
authority that determines the local service areas for the home health or hospice care center. In general, the
process for opening a home health or hospice care center begins by a provider submitting an application for
licensure and certification to the state and federal regulatory bodies, which is followed by a testing period of

7

transmitting data from the applicant to CMS. Once this process is complete, the care center receives a provider
agreement and corresponding number and can begin billing for services that it provides unless a CON or POA is
required. For those states that require a CON or POA, the provider must also complete a separate application
process before billing can commence and receive required approvals for capital expenditures exceeding amounts
above prescribed thresholds.

State CON and POA laws generally provide that, prior to the addition of new capacity, the construction of new
facilities or the introduction of new services, a designated state health planning agency must determine that a
need exists for those beds, facilities or services. The process is intended to promote comprehensive health care
planning, assist
the lowest possible cost and avoid unnecessary
duplication by ensuring that only those health care facilities and operations that are needed will be built and
opened.

in providing high-quality health care at

Medicare Participation

Our care centers must comply with regulations promulgated by the United States Department of Health and
Human Services in order to participate in the Medicare program and receive Medicare payments. Among other
things, these regulations, known as “conditions of participation,” relate to the type of facility, its personnel and
its standards of medical care, as well as its compliance with state and local laws and regulations. CMS has
adopted alternative sanction enforcement options which allow CMS (i) effective as of July 1, 2013, to impose
temporary management, direct plans of correction, or direct training, and (ii) effective as of July 1, 2014, to
impose payment suspensions and civil monetary penalties in each case on providers out of compliance with the
conditions of participation. CMS issued a proposed rule on October 9, 2014, revising the current home health
conditions of participation. We provided public comments on the proposed changes, but we cannot predict the
content or effective date of any final rule revising the home health conditions of participation. As of the date of
this filing, the proposed rule has not been finalized.

CMS has engaged a number of third party firms, including Recovery Audit Contractors (“RACs”), Program
Safeguard Contractors (“PSCs”), Zone Program Integrity Contractors (“ZPICs”) and Medicaid Integrity
Contributors (“MICs”), to conduct extensive reviews of claims data and state and Federal Government health
care program laws and regulations applicable to healthcare providers. These audits evaluate the appropriateness
of billings submitted for payment. In addition to identifying overpayments, audit contractors can refer suspected
violations of law to government enforcement authorities.

Federal and State Anti-Fraud and Anti-Kickback Laws

As a provider under the Medicare and Medicaid systems, we are subject to various anti-fraud and abuse laws,
its state law
including the Federal health care programs’ anti-kickback statute and, where applicable,
counterparts. Subject to certain exceptions, these laws prohibit any offer, payment, solicitation or receipt of any
form of remuneration to induce or reward the referral of business payable under a government health care
program or in return for the purchase, lease, order, arranging for, or recommendation of items or services covered
under a government health care program. Affected government health care programs include any health care
plans or programs that are funded by the United States government (other than certain federal employee health
insurance benefits/programs), including certain state health care programs that receive federal funds, such as
Medicaid. A related law forbids the offer or transfer of anything of value, including certain waivers of co-
payment obligations and deductible amounts, to a beneficiary of Medicare or Medicaid that is likely to influence
the beneficiary’s selection of health care providers, again subject to certain exceptions. Violations of the anti-
fraud and abuse laws can result in the imposition of substantial civil and criminal penalties and, potentially,
exclusion from furnishing services under any government health care program. In addition, the states in which
we operate generally have laws that prohibit certain direct or indirect payments or fee-splitting arrangements
between health care providers where they are designed to obtain the referral of patients from a particular
provider.

8

Stark Laws

Congress adopted legislation in 1989, known as the “Stark Law,” that generally prohibited a physician from
ordering clinical laboratory services for a Medicare beneficiary where the entity providing that service has a
financial relationship (including direct or indirect ownership or compensation relationships) with the physician
(or a member of his/her immediate family), and further prohibits such entity from billing for or receiving
payment for such services, unless a specified exception is available. The Stark Law was amended through
additional legislation, known as “Stark II,” which became effective January 1, 1993. That legislation extended
the Stark Law prohibitions beyond clinical laboratory services to a more extensive list of statutorily defined
“designated health services,” which includes, among other things, home health services, durable medical
equipment and outpatient prescription drugs. Violations of the Stark Law result in payment denials and may also
trigger civil monetary penalties and program exclusion. Several of the states in which we conduct business have
also enacted statutes similar in scope and purpose to the federal fraud and abuse laws and the Stark Laws. These
state laws may mirror the Federal Stark Laws or may be different in scope. The available guidance and
enforcement activity associated with such state laws varies considerably.

Federal and State Privacy and Security Laws

The Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996,
as amended (“HIPAA”), directed that the Secretary of the U.S. Department of Health and Human Services
(“HHS”) promulgate regulations prescribing standard requirements for electronic health care transactions and
establishing protections for the privacy and security of individually identifiable health information, known as
“protected health information.” The HIPAA transactions regulations establish form, format and data content
requirements for most electronic health care transactions, such as health care claims that are submitted
electronically. The HIPAA privacy regulations establish comprehensive requirements relating to the use and
disclosure of protected health information. The HIPAA security regulations establish minimum standards for the
protection of protected health information that is stored or transmitted electronically. Violations of the privacy
and security regulations are punishable by civil and criminal penalties.

The American Recovery and Economic Reinvestment Act of 2009 (“ARRA”), signed into law by President
Obama on February 17, 2009, contained significant changes to the privacy and security provisions of HIPAA,
including major changes to the enforcement provisions. Among other things, ARRA significantly increased the
amount of civil monetary penalties that can be imposed for violations of HIPAA. ARRA also authorized state
attorneys general to bring civil enforcement actions under HIPAA. These enhanced penalties and enforcement
provisions went into effect immediately upon enactment of ARRA. ARRA also required that HHS promulgate
regulations requiring that certain notifications be made to individuals, to HHS and potentially to the media in the
event of breaches of the privacy of protected health information. These breach notification regulations went into
effect on September 23, 2009, and HHS began to enforce violations on February 22, 2010. Violations of the
breach notification provisions of HIPAA can trigger the increased civil monetary penalties described above.

ARRA’s numerous other changes to HIPAA have delayed effective dates and require the issuance of
implementing regulations by HHS. The Health Information Technology for Economic and Clinical Health
(“HITECH”) Act was enacted in conjunction with ARRA. On January 25, 2013, HHS issued final modifications
to the HIPAA Privacy, Security, and Enforcement Rules mandated by the HITECH Act, which had been
previously issued as a proposed rule on July 14, 2010. Among other things, these modifications make business
associates of covered entities directly liable for compliance with certain HIPAA requirements, strengthen the
limitations on the use and disclosure of protected health information without individual authorizations, and adopt
the additional HITECH Act enhancements, including enforcement of noncompliance with HIPAA due to willful
neglect. The changes to HIPAA enacted as part of ARRA reflect a Congressional intent that HIPAA’s privacy
and security provisions be more strictly enforced. It is likely that these changes will stimulate increased
enforcement activity and enhance the potential that health care providers will be subject to financial penalties for
violations of HIPAA.

9

In addition to the federal HIPAA regulations, most states also have laws that protect the confidentiality of health
information. Also, in response to concerns about identity theft, many states have adopted so-called “security
breach” notification laws that may impose requirements regarding the safeguarding of personal information, such
as social security numbers and bank and credit card account numbers, and that impose an obligation to notify
persons when their personal information has or may have been accessed by an unauthorized person. Some state
security breach notification laws may also impose physical and electronic security requirements. Violation of
state security breach notification laws can trigger significant monetary penalties.

The False Claims Act

The Federal False Claims Act gives the Federal Government an additional way to police false bills or requests for
payment for health care services. Under the False Claims Act, the government may fine any person who
knowingly submits, or participates in submitting, claims for payment to the Federal Government which are false
or fraudulent, or which contain false or misleading information. Any person who knowingly makes or uses a
false record or statement to avoid paying the Federal Government, or knowingly conceals or avoids an obligation
to pay money to the Federal Government, may also be subject to fines under the False Claims Act. Under the
False Claims Act, the term “person” means an individual, company, or corporation. The Federal Government has
widely used the False Claims Act to prosecute Medicare and other governmental program fraud in areas such as
violations of the Federal anti-kickback statute or the Stark Laws, coding errors, billing for services not provided,
and submitting false cost reports. The False Claims Act has also been used to prosecute people or entities that bill
services at a higher reimbursement rate than is allowed and that bill for care that is not medically necessary. In
addition to government enforcement, the False Claims Act authorizes private citizens to bring qui tam or
“whistleblower” lawsuits, greatly extending the practical reach of the False Claims Act. The penalty for violation
of the False Claims Act is a minimum of $5,500 for each fraudulent claim plus three times the amount of
damages caused to the government as a result of each fraudulent claim.

The Fraud Enforcement and Recovery Act of 2009 (“FERA”) amended the False Claims Act with the intent of
enhancing the powers of government enforcement authorities and whistleblowers to bring False Claims Act
cases. In particular, FERA attempts to clarify that liability may be established not only for false claims submitted
directly to the government, but also for claims submitted to government contractors and grantees. FERA also
seeks to clarify that liability exists for attempts to avoid repayment of overpayments, including improper
retention of federal funds. FERA also included amendments to False Claims Act procedures, expanding the
government’s ability to use the Civil Investigative Demand process to investigate defendants, and permitting
government complaints in intervention to relate back to the filing of the whistleblower’s original complaint.
FERA is likely to increase both the volume and liability exposure of False Claims Act cases brought against
health care providers.

On February 12, 2016, CMS finalized the so-called “60-day rule,” which is the obligation of providers to report
and return Medicare overpayments within 60 days of identifying the same. A provider who retains overpayments
beyond 60 days may be liable under the False Claims Act. “Identification” is identified as when a person “has, or
should have through the exercise of reasonable diligence,” identified and quantified the amount of an
overpayment. Providers must report and return overpayments even if they did not cause the overpayment.

In addition to the False Claims Act, the Federal Government may use several criminal statutes to prosecute the
submission of false or fraudulent claims for payment to the Federal Government. Many states have similar false
claims statutes that impose liability for the types of acts prohibited by the False Claims Act. As part of the Deficit
Reduction Act of 2005 (the “DRA”), Congress provided states an incentive to adopt state false claims acts
consistent with the Federal False Claims Act. Additionally, the DRA required providers who receive $5 million
or more annually from Medicaid to include information on Federal and state false claims acts, whistleblower
protections and the providers’ own policies on detecting and preventing fraud in their written employee policies.

10

Civil Monetary Penalties

The United States Department of Health and Human Services may impose civil monetary penalties upon any
person or entity who presents, or causes to be presented, certain ineligible claims for medical items or services.
The amount of penalties varies, depending on the offense, from $2,000 to $50,000 per violation. In addition,
persons who have been excluded from the Medicare or Medicaid program and still retain ownership in a
participating entity, or who contract with excluded persons, may be penalized. Penalties also are applicable in
certain other cases, including violations of the Federal anti-kickback statute, payments to limit certain patient
services and improper execution of statements of medical necessity.

FDA Regulation

The U.S. Food and Drug Administration (“FDA”) regulates medical device user facilities, which include home
health care providers. FDA regulations require user facilities to report patient deaths and serious injuries to FDA
and/or the manufacturer of a device used by the facility if the device may have caused or contributed to the death
or serious injury of any patient. FDA regulations also require user facilities to maintain files related to adverse
events and to establish and implement appropriate procedures to ensure compliance with the above reporting and
recordkeeping requirements. User facilities are subject to FDA inspection, and noncompliance with applicable
requirements may result in warning letters or sanctions including civil monetary penalties, injunction, product
seizure, criminal fines and/or imprisonment.

Patient Protection and Affordable Care Act

In March 2010, comprehensive health care reform legislation was signed into law in the United States through
the passage of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation
Act (collectively, “PPACA”). Even as of December 31, 2015, it is difficult to predict the full impact of PPACA
due to the law’s complexity and phased in effective dates, as well as our inability to foresee how CMS and other
participants in the health care industry will respond to the choices available to them under the law. PPACA calls
for a number of changes to be made over time that will likely have a significant impact upon the health care
delivery system. For example, PPACA mandates decreases in home health reimbursement rates, including a four-
year phased rebasing of the home health payment system that began in 2014 and will continue through 2017.
These reimbursement changes are described in detail in Part II, Item 7, “Management’s Discussion and Analysis
of Financial Condition and Results of Operations: Overview – Economic and Industry Factors.” PPACA has
established a number of new requirements impacting our business operations, and promises to give rise to other
changes that could significantly impact our businesses in the future. For example, PPACA also mandates the
creation of a home health value-based purchasing program, the development of quality measures, and the testing
of alternative payment and delivery models, including ACOs and the Bundled Payments for Care Improvement
initiative. See Part I, Item 1A, “Risk Factors: Risks Related to Laws and Government Regulations” for a more
complete discussion of PPACA and the risks it presents to our businesses.

Our Competitors

There are few barriers to entry in the home health and hospice jurisdictions that do not require certificates of
need or permits of approval. Our primary competition in these jurisdictions comes from local privately and
publicly-owned and hospital-owned health care providers. We compete based on the availability of personnel, the
quality of services, expertise of visiting staff, and, in certain instances, on the price of our services. In addition,
we compete with a number of non-profit organizations that finance acquisitions and capital expenditures on a
tax-exempt basis or receive charitable contributions that are unavailable to us.

Available Information

Our company website address is www.amedisys.com. We use our website as a channel of distribution for
important company information. Important information, including press releases, analyst presentations and

11

financial information regarding our company, is routinely posted on and accessible on the Investor Relations
subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page.
We also use our website to expedite public access to time-critical information regarding our company in advance
of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore,
investors should look to the “Investors” subpage of our website for important and time-critical information.
Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when
new information is made available on the “Investors” subpage of our website. In addition, we make available on
the Investors subpage of our website (under the link “SEC Filings”), free of charge, our annual reports on Form
10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and
any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such
reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical
Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation,
Nominating and Corporate Governance and Quality of Care Committees of our Board are also available on the
Investors subpage of our website (under the link “Corporate Governance”). Reference to our website does not
constitute incorporation by reference of the information contained on the website and should not be considered
part of this document.

Additionally, the public may read and copy any of the materials we file with the SEC at the SEC’s Public
Reference Room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. Information on the operation of the
Public Reference Room may be obtained by calling the SEC at (800) SEC-0330. Our electronically filed reports
can also be obtained on the SEC’s internet site at http://www.sec.gov.

12

ITEM 1A. RISK FACTORS

The risks described below, and risks described elsewhere in this Form 10-K, could have a material adverse effect
on our business and consolidated financial condition, results of operations and cash flows and the actual
outcome of matters as to which forward-looking statements are made in this Form 10-K. The risk factors
described below and elsewhere in this Form 10-K are not the only risks faced by Amedisys. Our business and
consolidated financial condition, results of operations and cash flows may also be materially adversely affected
by factors that are not currently known to us, by factors that we currently consider immaterial or by factors that
are not specific to us, such as general economic conditions.

If any of the following risks are actually realized, our business and consolidated financial condition, results of
operations and cash flows could be materially adversely affected. In that case, the trading price of our common
stock could decline.

You should refer to the explanation of the qualifications and limitations on forward-looking statements under
“Special Caution Concerning Forward-Looking Statements.” All forward-looking statements made by us are
qualified by the risk factors described below.

Risks Related to Reimbursement

Because a high percentage of our revenue is derived from Medicare, reductions in Medicare rates, rate
increases that do not cover cost increases and/or significant changes to the Medicare payment methodology or
eligibility requirements could have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows.

Our net service revenue is primarily derived from Medicare, which accounted for 80%, 82% and 84% of our
revenue during 2015, 2014 and 2013, respectively. Payments received from Medicare are subject to changes
made through federal legislation. When such changes are implemented, we must also modify our internal billing
processes and procedures accordingly, which can require significant time and expense. These changes, as further
detailed in Part I, Item 1, “Business: Payment for Our Services,” can include changes to base episode payments
and adjustments for home health services, changes to cap limits and per diem rates for hospice services and
changes to Medicare eligibility and documentation requirements or changes designed to restrict utilization. Any
such changes, including retroactive adjustments, adopted in the future by CMS could have a material adverse
effect on our business and consolidated financial condition, results of operations and cash flows.

There are continuing efforts to reform governmental health care programs that could result in major changes in
the health care delivery and reimbursement system on a national and state level, including changes directly
impacting the reimbursement systems for our home health and hospice care centers. Though we cannot predict
what, if any, reform proposals will be adopted, health care reform and legislation may have a material adverse
effect on our business and our financial condition, results of operations and cash flows through decreasing
payments made for our services.

We could be affected adversely by the continuing efforts of governmental payors to contain health care costs. We
cannot assure you that reimbursement payments under governmental payor programs, including Medicare
supplemental insurance policies, will remain at levels comparable to present levels or will be sufficient to cover
the costs allocable to patients eligible for reimbursement pursuant to these programs. Any such changes could
have a material adverse effect on our business and consolidated financial condition, results of operations and
cash flows.

Our hospice operations are subject to two annual Medicare caps. If such caps were to be exceeded by any of
our hospice providers, our business and consolidated financial condition, results of operations and cash flows
could be materially adversely affected.

With respect to our hospice operations, overall payments made by Medicare to each provider number (generally
corresponding to a hospice care center) are subject to an inpatient cap amount and an overall payment cap, which

13

are calculated and published by the Medicare fiscal intermediary on an annual basis covering the period from
November 1 through October 31. If payments received by any one of our hospice provider numbers exceeds
either of these caps, we may be required to reimburse the Medicare program for payments received in excess of
the caps, which could have a material adverse effect on our business and consolidated financial condition, results
of operations and cash flows.

Any economic downturn, deepening of an economic downturn, continued deficit spending by the Federal
Government or state budget pressures may result in a reduction in payments and covered services.

Adverse developments in the United States could lead to a reduction in Federal Government expenditures,
including governmentally funded programs in which we participate, such as Medicare and Medicaid. In addition,
if at any time the Federal Government is not able to meet its debt payments unless the federal debt ceiling is
raised, and legislation increasing the debt ceiling is not enacted, the Federal Government may stop or delay
making payments on its obligations, including funding for government programs in which we participate, such as
Medicare and Medicaid. Failure of the government to make payments under these programs could have a
material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
Further, any failure by the United States Congress to complete the federal budget process and fund government
operations may result in a Federal Government shutdown, potentially causing us to incur substantial costs
without reimbursement under the Medicare program, which could have a material adverse effect on our business
and consolidated financial condition, results of operations and cash flows. As an example, the failure of the 2011
Joint Select Committee to meet its Deficit Reduction goal resulted in an automatic reduction in Medicare home
and hospice payments of 2% beginning April 1, 2013.

Historically, state budget pressures have resulted in reductions in state spending. Given that Medicaid outlays are
a significant component of state budgets, we can expect continuing cost containment pressures on Medicaid
outlays for our services.

In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed
care programs and the profitability of managed care companies, which could result in reduced payment rates and
could have a material adverse effect on our business and consolidated financial condition, results of operations
and cash flows.

Future cost containment initiatives undertaken by private third party payors may limit our future revenue and
profitability.

Our non-Medicare revenue and profitability are affected by continuing efforts of third party payors to maintain or
reduce costs of health care by lowering payment rates, narrowing the scope of covered services, increasing case
management review of services and negotiating pricing. There can be no assurance that third party payors will
make timely payments for our services, and there is no assurance that we will continue to maintain our current
payor or revenue mix. We are continuing our efforts to develop our non-Medicare sources of revenue and any
changes in payment levels from current or future third party payors could have a material adverse effect on our
business and consolidated financial condition, results of operations and cash flows.

Risks Related to Laws and Government Regulations

We are operating under a Corporate Integrity Agreement. Violations of this agreement could result in
substantial penalties or exclusion from participation in the Medicare program.

On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the
U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry
into this agreement, we entered into a Corporate Integrity Agreement (“CIA”) with the Office of Inspector
General-HHS (“OIG”). The CIA, which has a term of five years, formalizes various aspects of our already
existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing

14

compliance with federal health care program requirements. Among other things, the CIA requires us to maintain
our existing compliance program, executive compliance committee and compliance committee of the Board of
Directors; provide certain compliance training; continue screening new and current employees to ensure they are
eligible to participate in federal health care programs; engage an independent review organization (“IRO”) to
perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health
care programs, our billing submissions to federal health care programs and our compliance and risk mitigation
programs; and provide certain reports and management certifications to the OIG. Additionally,
the CIA
specifically requires that we report substantial overpayments that we discover we have received from the federal
health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we
could become liable for payment of certain stipulated penalties, or could be excluded from participation in
federal health care programs. Although we believe that we are currently in compliance with the CIA, any
violations of the agreement could have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows.

Pending civil litigation could have a material adverse effect on the Company.

We and certain of our current and former directors, senior executives and other employees are defendants in a
federal securities class action. We are also a defendant in several wage and hour law putative collective and class
action lawsuits. See Part II, Item 8, Note 10 – Commitments and Contingencies for a more detailed description of
these proceedings. These actions remain in preliminary stages and it is not yet possible to assess their probable
outcome or our potential liability, if any. We cannot provide any assurances that the legal and other costs
associated with the defense of these actions, the amount of time required to be spent by management on these
matters and the ultimate outcome of these actions will not have a material adverse effect on our business and
consolidated financial condition, results of operations and cash flows.

Our insurance may not cover all of the costs associated with defending the pending federal securities class
action, and any potential liability costs associated with this matter, and we maintain no insurance that covers
any portion of the pending wage and hour putative collective and class action lawsuits.

With respect to the pending securities class action, we may be obligated to indemnify (and advance legal
expenses to) both current and former officers, employees and directors in connection with this matter. We
maintain directors’ and officers’ liability insurance that we believe should cover a portion of the legal costs and
potential liability costs associated with this matter. However, such insurance coverage does not extend to all of
these expenditures, and the insurance limits may be insufficient even with respect to expenditures that would
otherwise be covered. Furthermore, our insurance carriers may seek to deny coverage in this matter, in which
case we may have to fund the indemnification amounts owed to such directors and officers ourselves. We do not
maintain any insurance that will cover any part of the wage and hour putative collective and class action lawsuits
in which we are defendants. If our insurance coverage is denied or is not adequate, it may have a material adverse
effect on our business and consolidated financial condition, results of operations and cash flows.

We are subject to extensive government regulation. Any changes to the laws and regulations governing our
business, or to the interpretation and enforcement of those laws or regulations, could have a material adverse
effect on our business and consolidated financial condition, results of operations and cash flows.

Our industry is subject to extensive federal and state laws and regulations. See Part I, Item 1, “Our Regulatory
Environment” for additional information on such laws and regulations. Federal and state laws and regulations
impact how we conduct our business, the services we offer and our interactions with patients, our employees and
the public and impose certain requirements on us such as:

•

•

•

licensure and certification;

adequacy and quality of health care services;

qualifications of health care and support personnel;

15

•

•

•

•

•

•

•

•

•

•

quality and safety of medical equipment;

confidentiality, maintenance and security issues associated with medical records and claims processing;

relationships with physicians and other referral sources;

operating policies and procedures;

policies and procedures regarding employee relations;

addition of facilities and services;

billing for services;

requirements for utilization of services;

documentation required for billing and patient care; and

reporting and maintaining records regarding adverse events.

These laws and regulations, and their interpretations, are subject to change. Changes in existing laws and
regulations, or their interpretations, or the enactment of new laws or regulations could have a material adverse
effect on our business and consolidated financial condition, results of operations and cash flows by:

•

•

•

•

•

•

increasing our administrative and other costs;

increasing or decreasing mandated services;

causing us to abandon business opportunities we might have otherwise pursued;

decreasing utilization of services;

forcing us to restructure our relationships with referral sources and providers; or

requiring us to implement additional or different programs and systems.

Additionally, we are subject to various routine and non-routine reviews, audits and investigations by the
Medicare and Medicaid programs and other federal and state governmental agencies, which have various rights
and remedies against us if they establish that we have overcharged the programs or failed to comply with
program requirements. Violation of the laws governing our operations, or changes in interpretations of those
laws, could result in the imposition of fines, civil or criminal penalties, and the termination of our rights to
participate in federal and state-sponsored programs and/or the suspension or revocation of our licenses. If we
become subject to material fines, or if other sanctions or other corrective actions are imposed on us, our business
and consolidated financial condition, results of operations and cash flows could be materially adversely affected.

We face periodic and routine reviews, audits and investigations under our contracts with federal and state
government agencies and private payors, and these audits could have adverse findings that may negatively
impact our business.

As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental
reviews, audits and investigations to verify our compliance with these programs and applicable laws and
regulations. We also are subject to audits under various government programs, including the RAC, ZPIC, PSC
and MIC programs as well as in accordance with the requirements of our CIA, in which third party firms engaged
by CMS or by the Company conduct extensive reviews of claims data and medical and other records to identify
potential improper payments under the Medicare program. Private pay sources also reserve the right to conduct
audits. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all
claims filed which could result in a larger overpayment than originally identified in the sample of reviewed
claims. Our costs to respond to and defend reviews, audits and investigations may be significant and could have a

16

material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
Moreover, an adverse review, audit or investigation could result in:

•

•

•

•

required refunding or retroactive adjustment of amounts we have been paid pursuant to the federal or
state programs or from private payors;

state or federal agencies imposing fines, penalties and other sanctions on us;

loss of our right to participate in the Medicare program, state programs, or one or more private payor
networks; or

damage to our business and reputation in various markets.

These results could have a material adverse effect on our business and consolidated financial condition, results of
operations and cash flows.

If a care center fails to comply with the conditions of participation in the Medicare program, that care center
could be subjected to sanctions or terminated from the Medicare program.

Each of our care centers must comply with required conditions of participation in the Medicare program. If we fail
to meet the conditions of participation at a care center, we may receive a notice of deficiency from the applicable
state surveyor. If that care center then fails to institute an acceptable plan of correction to remediate the deficiency
within the correction period provided by the state surveyor, that care center could be terminated from the Medicare
program or subjected to alternative sanctions. CMS outlined its alternative sanction enforcement options for home
health care centers through a regulation published in 2012; under the regulation, CMS may impose temporary
management, direct a plan of correction, direct training or impose payment suspensions and civil monetary
penalties, in each case, upon providers who fail to comply with the conditions of participation. Termination of one
or more of our care centers from the Medicare program for failure to satisfy the program’s conditions of
participation, or the imposition of alternative sanctions, could disrupt operations, require significant attention by
management, or have a material adverse effect on our business and reputation and consolidated financial condition,
results of operations and cash flows. CMS issued a proposed rule on October 9, 2014, revising the Medicare
conditions of participation for home health care centers across the industry, with an unknown effective date. We
provided public comments on the proposed changes, but do not know at this time what effect the finalized revisions
will have on our operations, and there can be no assurances that the revisions will not have a material adverse effect
on our business and consolidated financial condition, results of operations and cash flows.

We are subject to federal and state laws that govern our financial relationships with physicians and other
health care providers, including potential or current referral sources.

We are required to comply with federal and state laws, generally referred to as “anti-kickback laws,” that prohibit
certain direct and indirect payments or other financial arrangements between health care providers that are
designed to encourage the referral of patients to a particular provider for medical services. In addition to these
anti-kickback laws, the Federal Government has enacted specific legislation, commonly known as the “Stark
Law,” that prohibits certain financial relationships, specifically including ownership interests and compensation
arrangements, between physicians (and the immediate family members of physicians) and providers of
designated health services, such as home health care centers, to whom the physicians refer patients. Some of
these same financial relationships are also subject to additional regulation by states. Although we believe we
have structured our relationships with physicians and other potential referral sources to comply with these laws
where applicable, we cannot assure you that courts or regulatory agencies will not interpret state and federal anti-
kickback laws and/or the Stark Law and similar state laws regulating relationships between health care providers
and physicians in ways that will adversely implicate our practices or that isolated instances of noncompliance
will not occur. Violations of federal or state Stark or anti-kickback laws could lead to criminal or civil fines or
other sanctions, including denials of government program reimbursement or even exclusion from participation in
governmental health care programs, which could have a material adverse effect on our business and consolidated
financial condition, results of operations and cash flows.

17

We may face significant uncertainty in the industry due to government health care reform.

The health care industry in the United States is subject to fundamental changes due to ongoing health care reform
efforts and related political, economic and regulatory influences. In March 2010, comprehensive health care
reform legislation was signed into law in the United States through the passage of the Patient Protection and
Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, “PPACA”).
However, it is difficult to predict the full impact of PPACA due to the law’s complexity and phased-in effective
dates, as well as our inability to foresee how CMS and other participants in the health care industry will respond
to the choices available to them under the law.

PPACA makes a number of changes to Medicare payment rates and also calls for a rebasing of the home health
payment system that began in 2014 and will continue through 2017. These reimbursement changes are described
in detail in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of
Operations: Overview – Economic and Industry Factors.”

For example, as a result of the PPACA, CMS added two regulations that became effective April 1, 2011: (1) a
face-to-face encounter requirement for home health and hospice services and (2) changes to the home health
therapy assessment schedule, which requires additional patient evaluations and certifications. These and other
regulations implementing the provisions of the PPACA may similarly increase our costs, decrease our revenues,
expose us to expanded liability or require us to revise the ways in which we conduct our business.

PPACA also calls for a number of other changes to be made over time that will likely have a significant impact
upon the health care delivery system. For example, PPACA mandates creation of a home health value-based
purchasing program, the development of quality measures, and decreases in home health reimbursement rates,
including rebasing, as further described in Part II, Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations: Overview – Economic and Industry Factors.” In addition, PPACA requires
the Secretary of Health and Human Services to test different models for delivery of care, some of which will
involve home health services. It also requires the Secretary to establish a national pilot program for integrated
care for patients with certain conditions, bundling payment for acute hospital care, physician services, outpatient
hospital services (including emergency department services) and post-acute care services, which would include
home health. PPACA created the Center for Medicare and Medicaid Innovation (“CMMI”), which has launched
the Bundled Payments for Care Improvement initiative designed to encourage doctors, hospitals and other health
care providers, including home health providers, to work together to better coordinate care for patients both when
they are in the hospital and after they are discharged. In October 2011 CMS published final Medicare Shared
Savings Program regulations, which use accountable care organizations (“ACOs”) to facilitate coordination and
cooperation among providers to improve the quality of care for Medicare fee-for-service beneficiaries and reduce
unnecessary costs. PPACA further directs the Secretary to conduct a study to evaluate cost and quality of care
among efficient home health care centers and specifically focusing on access to care and treating Medicare
beneficiaries with varying severity levels of illness, and provide a report to Congress no later than March 1,
2014, which report was issued in 2014 after the March 1 deadline. At this time, it is not possible to predict with
any certainty how these initiatives will be implemented and what impact they may have on our business.

In addition, various health care reform proposals similar to the federal reforms described above have also
emerged at the state level, including in several states which we operate. Moreover, in January 2011, the Medicare
Payment Advisory Commission voted to recommend to Congress that it make additional changes to the home
health payment system, noting that such recommendations may include further payment reductions and/or a
beneficiary copayment obligation. We cannot predict with certainty what health care initiatives, if any, will be
implemented at the state level, or what the ultimate effect of federal health care reform or any future legislation
or regulation may have on us or on our business and consolidated financial condition, results of operations and
cash flows.

Finally, in addition to impacting our Medicare businesses, PPACA may also significantly affect our non-
Medicare businesses. PPACA makes many changes to the underwriting and marketing practices of private

18

rates of
payors. The resulting economic pressures could prompt
reimbursement for the services we provide. At this time, it is not possible to estimate what impact PPACA may
have on our non-Medicare businesses.

these payors to seek to lower their

Risks Related to our Growth Strategies

Our growth strategy depends on our ability to acquire additional care centers and integrate and operate these
care centers effectively. If our growth strategy is unsuccessful or we are not able to successfully integrate
newly acquired care centers into our existing operations, our business and consolidated financial condition,
results of operations and cash flows could be materially adversely affected.

We may not be able to fully integrate the operations of our acquired businesses with our current business
structure in an efficient and cost-effective manner. Acquisitions involve significant risks and uncertainties,
including difficulties in recouping partial episode payments and other types of misdirected payments for services
from the previous owners; difficulties integrating acquired personnel and business practices into our business; the
potential loss of key employees, referral sources or patients of acquired care centers; the delay in payments
associated with change in ownership, control and the internal process of the Medicare fiscal intermediary; and
the assumption of liabilities and exposure to unforeseen liabilities of acquired care centers. Further, the financial
benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve
clinical performance, overcome regulatory deficiencies, improve the reputation of the acquired business in the
community and control costs. The failure to accomplish any of these objectives or to effectively integrate any of
these businesses could have a material adverse effect on our business and consolidated financial condition,
results of operations and cash flows.

State efforts to regulate the establishment or expansion of health care providers could impair our ability to
expand our operations.

Some states require health care providers (including skilled nursing facilities, hospice care centers, home health
care centers and assisted living facilities) to obtain prior approval, known as a CON or POA, in order to
commence operations. See Part I, Item 1, “Our Regulatory Environment” for additional information on CONs
and POAs. If we are not able to obtain such approvals, our ability to expand our operations could be impaired,
which could have a material adverse effect on our business and consolidated financial condition, results of
operations and cash flows.

Federal regulation may impair our ability to consummate acquisitions or open new care centers.

Changes in federal laws or regulations may materially adversely impact our ability to acquire care centers or
open new start-up care centers. For example, PPACA authorized CMS to impose temporary moratoria on the
enrollment of new Medicare providers, if deemed necessary to combat fraud, waste or abuse under government
programs. The moratoria on new enrollments may be applied to categories of providers or to specific geographic
regions. For example, in 2014, CMS adopted a temporary moratorium on new provider locations in certain
regions of Texas, Michigan, Florida and Illinois. If a moratorium is imposed on the enrollment of new home
health or hospice providers in a geographic area we desire to service, it could have a material impact on our
ability to open new care centers. Additionally, in 2010, CMS implemented and amended a regulation known as
the “36 Month Rule” that is applicable to home health care center acquisitions. Subject to certain exceptions, the
36 Month Rule prohibits buyers of certain home health care centers – those that either enrolled in Medicare or
underwent a change in majority ownership fewer than 36 months prior to the acquisition – from assuming the
Medicare billing privileges of the acquired care center. These changes in federal laws and regulations, and
similar future changes, may further increase competition for acquisition targets and could have a material
detrimental impact on our acquisition strategy.

19

Risks Related to our Operations

Because we are limited in our ability to control rates received for our services, our business and consolidated
financial condition, results of operations and cash flows could be materially adversely affected if we are not
able to maintain or reduce our costs to provide such services.

As Medicare is our primary payor and rates are established through federal legislation, we have to manage our
costs of providing care to achieve a desired level of profitability. Additionally, non-Medicare rates are difficult
for us to negotiate as such payors are under pressure to reduce their own costs. As a result, we manage our costs
in order to achieve a desired level of profitability including, but not limited to, centralization of various
processes, the use of technology and management of the number of employees utilized. If we are not able to
continue to streamline our processes and reduce our costs, our business and consolidated financial condition,
results of operations and cash flows could be materially adversely affected.

Our industry is highly competitive, with few barriers to entry in certain states.

There are few barriers to entry in home health markets that do not require a CON or POA. Our primary
competition comes from local privately-owned and hospital-owned health care providers. We compete based on
the availability of personnel; the quality of services, expertise of visiting staff; and in certain instances, on the
price of our services. Increased competition in the future may limit our ability to maintain or increase our market
share.

Further, the introduction of new and enhanced service offerings by others, in combination with industry
consolidation and the development of strategic relationships by our competitors, could cause a decline in revenue
or loss of market acceptance of our services or make our services less attractive. Additionally, we compete with a
number of non-profit organizations that can finance acquisitions and capital expenditures on a tax-exempt basis
or receive charitable contributions that are unavailable to us.

Managed care organizations and other third party payors continue to consolidate, which enhances their ability to
influence the delivery of health care services. Consequently, the health care needs of patients in the United States
are increasingly served by a smaller number of managed care organizations. These organizations generally enter
into service agreements with a limited number of providers. Our business and consolidated financial condition,
results of operations and cash flows could be materially adversely affected if these organizations terminate us as
a provider and/or engage our competitors as a preferred or exclusive provider. In addition, should private payors,
including managed care payors, seek to negotiate additional discounted fee structures or the assumption by health
care providers of all or a portion of the financial risk through prepaid capitation arrangements, our business and
consolidated financial condition, results of operations and cash flows could be materially adversely affected.

If we are unable to react competitively to new developments, our operating results may suffer. Further, if states
remove existing CONs or POAs, we would face increased competition in these states. For example, in 2013, the
Governor of South Carolina vetoed funding for that state’s CON program, effectively shutting down the program.
Following a judicial challenge, the South Carolina Supreme Court ruled in April 2014 that the South Carolina
Department of Health and Environmental Control was statutorily obligated to administer the CON program,
regardless of the Governor’s veto. Following this ruling, legislation has been introduced in the South Carolina
House of Representatives for the purpose of limiting the application of that state’s CON program. We do not
know at this time what the outcome of this matter will be in South Carolina, and whether this will have any
impact upon our operations. Similarly, there can be no assurances that other states will not seek to eliminate or
limit their existing CON or POA programs in a similar manner, leading to increased competition in these states,
Further, we cannot assure you that we will be able to compete successfully against current or future competitors,
which could have a material adverse effect on our business and consolidated financial condition, results of
operations and cash flows.

20

If we are unable to maintain relationships with existing patient referral sources, our business and
consolidated financial condition, results of operations and cash flows could be materially adversely affected.

Our success depends on referrals from physicians, hospitals and other sources in the communities we serve and
on our ability to maintain good relationships with existing referral sources. Our referral sources are not
contractually obligated to refer patients to us and may refer their patients to other providers. Our growth and
profitability depends, in part, on our ability to establish and maintain close working relationships with these
patient referral sources and to increase awareness and acceptance of the benefits of home health and hospice care
by our referral sources and their patients. Our loss of, or failure to maintain, existing relationships or our failure
to develop new referral relationships could have a material adverse effect on our business and consolidated
financial condition, results of operations and cash flows.

If we are unable to provide consistently high quality of care, our business will be adversely impacted.

Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other
referral sources refer patients to us in large part because of our reputation for delivering quality care. Clinical
quality is becoming increasingly important within our industry. Effective October 2012, Medicare began to
impose a financial penalty upon hospitals that have excessive rates of patient readmissions within 30 days from
hospital discharge. We believe this new regulation provides a competitive advantage to home health providers
who can differentiate themselves based upon quality, particularly by achieving low patient acute care
hospitalization readmission rates and by implementing disease management programs designed to be responsive
to the needs of patients served by referring hospitals. We are focused intently upon improving our patient
outcomes, particularly our patient acute care hospitalization readmission rates. If we should fail to attain our
goals regarding acute care hospitalization readmission rates and other quality metrics, we expect our ability to
generate referrals would be adversely impacted, which could have a material adverse effect upon our business
and consolidated financial condition, results of operations and cash flows.

Our business depends on our information systems. Our inability to effectively integrate, manage and keep our
information systems secure and operational could disrupt our operations.

Our business depends on effective, secure and operational information systems which include software that was
developed in-house and systems provided by external contractors and other service providers. We have
developed and use a proprietary Windows™-based clinical software system with our POC system to collect
assessment data, schedule and log patient visits, communicate with patients’ physicians regarding their plan of
care and monitor treatments and outcomes in accordance with established medical standards. Our clinical
software system integrates several of the key processes critical
to our business: billing and collections
functionality; accounting; human resources; payroll; and employee benefits programs provided by third parties.
During 2015, we made the strategic decision to discontinue our proprietary operating system and transition to a
leading home health and hospice platform. While we anticipate the completion of the rollout of this new platform
to all of our care centers during 2016, we continue to operate on both systems as of the date of this filing.
Problems with, or the failure of, our technology and systems or any system upgrades or programming changes
associated with such technology and systems,
including any problems we may experience with the
implementation of the new clinical software system, could have a material adverse effect on data capture,
medical documentation, billing, collections, assessment of internal controls and management and reporting
capabilities. Any such problems or failures and the costs incurred in correcting any such problems or failures,
could have a material adverse effect on our business and consolidated financial condition, results of operations
and cash flows. Further, to the extent our external information technology contractors or other service providers
become insolvent or fail to support the software or systems we have licensed from them, our operations could be
materially adversely affected.

Our care centers also depend upon our information systems for accounting, billing, collections, risk management,
quality assurance, human resources, payroll and other information. If we experience a reduction in the

21

performance, reliability, or availability of our information systems, our operations and ability to produce timely
and accurate reports could be materially adversely affected.

Our information systems and applications require continual maintenance, upgrading and enhancement to meet
our operational needs. Our acquisition activity requires transitions and integration of various information
systems. We regularly upgrade and expand our information systems’ capabilities. If we experience difficulties
with the transition and integration of information systems or are unable to implement, maintain, or expand our
systems properly, we could suffer from, among other things, operational disruptions, regulatory problems and
increases in administrative expenses.

We may be required to expend significant capital and other resources to protect against the threat of security
breaches or to alleviate problems caused by breaches,
including unauthorized access to patient data and
personally identifiable information stored in our information systems, and the introduction of computer viruses to
our systems. Our security measures may be inadequate to prevent security breaches and our business operations
could be materially adversely affected by federal and state fines and penalties, cancellation of contracts and loss
of patients if security breaches are not prevented.

We have installed privacy protection systems and devices on our network and POC laptops in an attempt to
prevent unauthorized access to information in our database. However, our technology may fail to adequately
secure the confidential health information and personally identifiable information we maintain in our databases.
In such circumstances, we may be held liable to our patients and regulators, which could result in fines, litigation
or adverse publicity that could have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows. Even if we are not held liable, any resulting negative publicity
could harm our business and distract the attention of management.

Further, our information systems are vulnerable to damage or interruption from fire, flood, power loss,
telecommunications failure, break-ins and similar events. A failure to restore our information systems after the
occurrence of any of these events could have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows. Because of the confidential health information we store and
transmit, loss of electronically stored information for any reason could expose us to a risk of regulatory action
and litigation and possible liability and loss.

We believe we have all the necessary licenses from third parties to use technology and software that we do not
own. A third party could, however, allege that we are infringing its rights, which may deter our ability to obtain
licenses on commercially reasonable terms from the third party, if at all, or cause the third party to commence
litigation against us. In addition, we may find it necessary to initiate litigation to protect our trade secrets, to
enforce our intellectual property rights and to determine the scope and validity of any proprietary rights of others.
Any such litigation, or the failure to obtain any necessary licenses or other rights, could materially and adversely
affect our business.

Possible changes in the case mix of patients, as well as payor mix and payment methodologies, could have a
material adverse effect on our business and consolidated financial condition, results of operations and cash
flows.

Our revenue is determined by a number of factors, including our mix of patients and the rates of payment among
payors. Changes in the case mix of our patients, payment methodologies or the payor mix among Medicare,
Medicaid and private payors could have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows.

22

Our failure to negotiate favorable managed care contracts, or our loss of existing favorable managed care
contracts, could have a material adverse effect on our business and consolidated financial condition, results of
operations and cash flows.

One of our strategies is to diversify our payor sources by increasing the business we do with managed care
companies, and we strive to put in place favorable contracts with managed care payors. However, we may not be
successful in these efforts. Additionally, there is a risk that the favorable managed care contracts that we put in
place may be terminated, and managed care contracts typically permit the payor to terminate the contract without
cause, on very short notice, typically 60 days, which can provide payors leverage to reduce volume or obtain
favorable pricing. Our failure to negotiate and put in place favorable managed care contracts, or our failure to
maintain in place favorable managed care contracts, could have a material adverse effect on our business and
consolidated financial condition, results of operations and cash flows.

A write off of a significant amount of intangible assets or long-lived assets could have a material adverse
effect on our consolidated financial condition and results of operations.

A significant and sustained decline in our stock price and market capitalization, a significant decline in our
expected future cash flows, a significant adverse change in the business climate, or slower growth rates could
result in the need to perform an impairment analysis under Accounting Standard Codification (“ASC”) Topic 350
“Intangibles – Goodwill and Other” in future periods in addition to our annual impairment test. If we were to
conclude that a write down of goodwill is necessary, then we would record the appropriate charge, which could
result in material charges that are adverse to our consolidated financial condition and results of operations. See
Part II, Item 8, Note 5 – Goodwill and Other Intangible Assets, Net to our consolidated financial statements for
additional information.

Because we have grown in part through acquisitions, goodwill and other acquired intangible assets represent a
substantial portion of our assets. Goodwill was approximately $261.7 million as of December 31, 2015 and if we
make additional acquisitions, it is likely that we will record additional intangible assets in our consolidated
financial statements. We also have long-lived assets consisting of property and equipment and other identifiable
intangible assets of $86.7 million as of December 31, 2015, which we review both on a periodic basis for
indefinite lived intangible assets as well as when events or circumstances indicate that the carrying amount of an
asset may not be recoverable. If a determination that a significant impairment in value of our unamortized
intangible assets or long-lived assets occurs, such determination could require us to write off a substantial portion
of our assets. A write off of these assets could have a material adverse effect on our consolidated financial
condition and results of operations.

A shortage of qualified registered nursing staff and other clinicians, such as therapists and nurse
practitioners, could materially impact our ability to attract, train and retain qualified personnel and could
increase operating costs.

We compete for qualified personnel with other healthcare providers. Our ability to attract and retain clinicians
depends on several factors, including our ability to provide these personnel with attractive assignments and
competitive salaries and benefits. We cannot be assured we will succeed in any of these areas. In addition, there
are shortages of qualified health care personnel in some of our markets. As a result, we may face higher costs of
attracting clinicians and providing them with attractive benefit packages than we originally anticipated which
could have a material adverse effect on our business and consolidated financial condition, results of operations
and cash flows. In addition, if we expand our operations into geographic areas where health care providers
historically have been unionized, or if any of our care center employees become unionized, being subject to a
collective bargaining agreement may have a negative impact on our ability to timely and successfully recruit
qualified personnel and may increase our operating costs. Generally, if we are unable to attract and retain
clinicians, the quality of our services may decline and we could lose patients and referral sources, which could
have a material adverse effect on our business and consolidated financial condition, results of operations and
cash flows.

23

Our insurance liability coverage may not be sufficient for our business needs.

As a result of operating in the home health industry, our business entails an inherent risk of claims, losses and
potential lawsuits alleging incidents involving our employees that are likely to occur in a patient’s home. We
maintain professional liability insurance to provide coverage to us and our subsidiaries against these risks.
However, we cannot assure you claims will not be made in the future in excess of the limits of our insurance, nor
can we assure you that any such claims, if successful and in excess of such limits, will not have a material
adverse effect on our business and consolidated financial condition, results of operations and cash flows. Our
insurance coverage also includes fire, property damage and general liability with varying limits. We cannot
assure you that the insurance we maintain will satisfy claims made against us or that insurance coverage will
continue to be available to us at commercially reasonable rates, in adequate amounts or on satisfactory terms.
Any claims made against us, regardless of their merit or eventual outcome, could damage our reputation and
business.

We may be subject to substantial malpractice or other similar claims.

The services we offer involve an inherent risk of professional liability and related substantial damage awards. As
of March 4, 2016, we had approximately 16,100 employees (11,200 home health, 2,600 hospice, 1,500 personal
care and 800 corporate employees). In addition, we employ direct care workers on a contractual basis to support
our existing workforce. Due to the nature of our business, we, through our employees and caregivers who
provide services on our behalf, may be the subject of medical malpractice claims. A court could find these
individuals should be considered our agents, and, as a result, we could be held liable for their acts or omissions.
We cannot predict the effect that any claims of this nature, regardless of their ultimate outcome, could have on
our business or reputation or on our ability to attract and retain patients and employees. While we maintain
malpractice liability coverage that we believe is appropriate given the nature and breadth of our operations, any
claims against us in excess of insurance limits, or multiple claims requiring us to pay deductibles could have a
material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

If we are unable to maintain our corporate reputation, our business may suffer.

Our success depends on our ability to maintain our corporate reputation, including our reputation for providing
quality patient care and for compliance with Medicare requirements and the other laws to which we are subject.
Adverse publicity surrounding any aspect of our business, including the death or disability of any of our patients
due to our failure to provide proper care, or due to any failure on our part to comply with Medicare requirements
or other laws to which we are subject, could negatively affect our Company’s overall reputation and the
willingness of referral sources to refer patients to us.

We depend on the services of our executive officers and other key employees.

We depend greatly on the efforts of our executive officers and other key employees to manage our operations.
The loss or departure of any one of these executives or other key employees could have a material adverse effect
on our business and consolidated financial condition, results of operations and cash flows.

Our operations could be impacted by natural disasters.

The occurrence of natural disasters in the markets in which we operate could not only impact the day-to-day
operations of our care centers, but could also disrupt our relationships with patients, employees and referral
sources located in the affected areas and, in the case of our corporate office, our ability to provide administrative
support services, including billing and collection services. In addition, any episode of care that is not completed
due to the impact of a natural disaster will generally result in lower revenue for the episode. For example, our
corporate office and a number of our care centers are located in the southeastern United States and the Gulf Coast
Region, increasing our exposure to hurricanes. Future hurricanes or other natural disasters may have a material
adverse effect on our business and consolidated financial condition, results of operations and cash flows.

24

Risks Related to Liquidity

Delays in payment may cause liquidity problems.

Our business is characterized by delays from the time we provide services to the time we receive payment for
these services. If we have difficulty in obtaining documentation, such as physician orders, experience
information system problems or experience other issues that arise with Medicare or other payors, we may
encounter additional delays in our payment cycle.

In addition, timing delays in billings and collections may cause working capital shortages. Working capital
management, including prompt and diligent billing and collection, is an important factor in achieving our
financial results and maintaining liquidity. It is possible that documentation support, system problems, Medicare
or other provider issues or industry trends may extend our collection period, which may materially adversely
affect our working capital, and our working capital management procedures may not successfully mitigate this
risk.

Additionally, our hospice operations may experience payment delays. We have experienced payment delays
when attempting to collect funds from state Medicaid programs in certain instances. Delays in receiving
payments from these programs may also materially adversely affect our working capital.

The volatility and disruption of the capital and credit markets and adverse changes in the United States and
global economies could impact our ability to access both available and affordable financing, and without such
financing, we may be unable to achieve our objectives for strategic acquisitions and internal growth.

While we intend to finance strategic acquisitions and internal growth with cash flows from operations and
borrowings under our revolving credit facility, we may require sources of capital in addition to those presently
available to us. Uncertainty in the capital and credit markets may impact our ability to access capital on terms
acceptable to us (i.e. at attractive/affordable rates) or at all, and this may result in our inability to achieve present
objectives for strategic acquisitions and internal growth. Further, in the event we need additional funds, and we
are unable to raise the necessary funds on acceptable terms, our business and consolidated financial condition,
results of operations and cash flows could be materially adversely affected.

Our indebtedness could impact our financial condition and impair our ability to fulfill other obligations.

As of December 31, 2015, we had total outstanding indebtedness of approximately $100.0 million, comprised
mainly of indebtedness incurred in connection with our April 23, 2014 settlement agreement with the
U.S. Department of Justice relating to certain of our clinical and business operations. Our level of indebtedness
could have a material adverse effect on our business and consolidated financial position, results of operations and
cash flows and impair our ability to fulfill other obligations in several ways, including:

•

•

•

•

•

it could require us to dedicate a portion of our cash flow from operations to payments on our
indebtedness, which could reduce the availability of cash flow to fund acquisitions, start-ups, working
capital, capital expenditures and other general corporate purposes;

it could limit our ability to borrow money or sell stock for working capital, capital expenditures, debt
service requirements and other purposes;

it could limit our flexibility in planning for, and reacting to, changes in our industry or business;

it could make us more vulnerable to unfavorable economic or business conditions; and

it could limit our ability to make acquisitions or take advantage of other business opportunities.

In the event we incur additional indebtedness, the risks described above could increase.

25

The agreements governing our indebtedness contain various covenants that limit our discretion in the
operation of our business and our failure to satisfy requirements in these agreements could have a material
adverse effect on our business and consolidated financial condition, results of operations and cash flows.

The agreements governing our indebtedness (the “Debt Agreements”) contain certain obligations, including
restrictive covenants that require us to comply with or maintain certain financial covenants and ratios and restrict
our ability to:

•

•

incur additional debt;

redeem or repurchase stock, pay dividends or make other distributions;

• make certain investments;

•

•

create liens;

enter into transactions with affiliates;

• make acquisitions;

•

enter into joint ventures;

• merge or consolidate;

•

•

•

invest in foreign subsidiaries;

amend acquisition documents;

enter into certain swap agreements;

• make certain restricted payments;

•

transfer, sell or leaseback assets; and

• make fundamental changes in our corporate existence and principal business.

In addition, events beyond our control could affect our ability to comply with the Debt Agreements. Any failure
by us to comply with or maintain all applicable financial covenants and ratios and to comply with all other
applicable covenants could result in an event of default with respect to the Debt Agreements. If we are unable to
obtain a waiver from our lenders in the event of any non-compliance, our lenders could accelerate the maturity of
any outstanding indebtedness and terminate the commitments to make further extensions of credit (including our
ability to borrow under our revolving credit facility). Any failure to comply with these covenants could have a
material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

Risks Related to Ownership of Our Common Stock

The price of our common stock may be volatile.

The price at which our common stock trades may be volatile. The stock market from time to time experiences
significant price and volume fluctuations that impact the market prices of securities, particularly those of health
care companies. The market price of our common stock may be influenced by many factors, including:

•

•

•

•

•

our operating and financial performance;

variances in our quarterly financial results compared to research analyst expectations;

the depth and liquidity of the market for our common stock;

future sales of common stock by the Company or large stockholders or the perception that such sales
could occur;

investor, analyst and media perception of our business and our prospects;

26

•

•

•

•

•

•

developments relating to litigation or governmental investigations;

changes or proposed changes in health care laws or regulations or enforcement of these laws and
regulations, or announcements relating to these matters;

departure of key personnel;

changes in the Medicare, Medicaid and private insurance payment rates for home health and hospice;

announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships,
joint ventures or capital commitments; or

general economic and stock market conditions.

In addition, the stock market in general, and the NASDAQ Global Select Market (“NASDAQ”) in particular, has
experienced price and volume fluctuations that we believe have often been unrelated or disproportionate to the
operating performance of health care provider companies. These broad market and industry factors may
materially reduce the market price of our common stock, regardless of our operating performance. Securities
class-action cases have often been brought against companies following periods of volatility in the market price
of their securities.

The activities of short sellers could reduce the price or prevent increases in the price of our common stock.
“Short sale” is defined as the sale of stock by an investor that the investor does not own. Typically, investors who
sell short believe the price of the stock will fall, and anticipate selling shares at a higher price than the purchase
price at which they will buy the stock. As of December 31, 2015, investors held a short position of approximately
1.2 million shares of our common stock which represented 3.7% of our outstanding common stock. The
anticipated downward pressure on our stock price due to actual or anticipated sales of our stock by some
institutions or individuals who engage in short sales of our common stock could cause our stock price to decline.

Sales of substantial amounts of our common stock or the availability of those shares for future sale, could
materially impact our stock price and limit our ability to raise capital.

The following table presents information about our outstanding common and preferred stock and our outstanding
securities exercisable for or convertible into shares of common stock:

Common stock outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Preferred stock outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Common stock available under 2008 Omnibus Incentive Compensation Plan . . . . .
Stock options outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stock options exercisable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-vested stock outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-vested stock units outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of December 31,
2015

33,607,282
—
1,274,934
838,494
62,500
500,888
498,929

If we were to sell substantial amounts of our common stock in the public market or if there was a public
perception that substantial sales could occur, the market price of our common stock could decline. These sales or
the perception of substantial future sales may also make it difficult for us to sell common stock in the future to
raise capital.

Our Board of Directors may use anti-takeover provisions or issue stock to discourage a change of control.

Our certificate of incorporation currently authorizes us to issue up to 60,000,000 shares of common stock and
5,000,000 shares of undesignated preferred stock. Our Board of Directors may cause us to issue additional stock
to discourage an attempt to obtain control of our company. For example, shares of stock could be sold to

27

purchasers who might support our Board of Directors in a control contest or to dilute the voting or other rights of
a person seeking to obtain control. In addition, our Board of Directors could cause us to issue preferred stock
entitling holders to vote separately on any proposed transaction, convert preferred stock into common stock,
demand redemption at a specified price in connection with a change in control, or exercise other rights designed
to impede a takeover.

The issuance of additional shares may, among other things, dilute the earnings and equity per share of our
common stock and the voting rights of common stockholders.

We have implemented other anti-takeover provisions or provisions that could have an anti-takeover effect,
including advance notice requirements for director nominations and stockholder proposals. These provisions, and
others that our Board of Directors may adopt hereafter, may discourage offers to acquire us and may permit our
Board of Directors to choose not to entertain offers to purchase us, even if such offers include a substantial
premium to the market price of our stock. Therefore, our stockholders may be deprived of opportunities to profit
from a sale of control.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

Our executive office is located in Nashville, Tennessee in a leased property consisting of approximately 15,825
square feet; our corporate headquarters is located in Baton Rouge, Louisiana in a leased property consisting of
approximately 110,000 square feet. We believe we have adequate space to accommodate our corporate staff
located in these locations for the foreseeable future.

In addition to our executive office and corporate headquarters, we also lease facilities for our home health and
hospice care centers. Generally, these leases have an initial term of five years with a three year early termination
option, but range from one to seven years. Most of these leases also contain an option to extend the lease period.
The following table shows the location of our 329 Medicare-certified home health care centers and 79 hospice
care centers at December 31, 2015:

State

Home Health Hospice

State

Home Health Hospice

Alabama . . . . . . . . . . . . . . . . . . .
Arkansas . . . . . . . . . . . . . . . . . . .
Arizona . . . . . . . . . . . . . . . . . . . .
California . . . . . . . . . . . . . . . . . .
Connecticut . . . . . . . . . . . . . . . . .
Delaware . . . . . . . . . . . . . . . . . . .
Florida . . . . . . . . . . . . . . . . . . . . .
Georgia . . . . . . . . . . . . . . . . . . . .
Illinois . . . . . . . . . . . . . . . . . . . . .
Indiana . . . . . . . . . . . . . . . . . . . . .
Kansas . . . . . . . . . . . . . . . . . . . . .
Kentucky . . . . . . . . . . . . . . . . . . .
Louisiana . . . . . . . . . . . . . . . . . . .
Massachusetts . . . . . . . . . . . . . . .
Maine . . . . . . . . . . . . . . . . . . . . .
Maryland . . . . . . . . . . . . . . . . . . .

Mississippi

. . . . . . . . . . . . . . . . .

Missouri

. . . . . . . . . . . . . . . . . . .

30
5
3
4
4
2
28
62
3
5
1
17
11
5
2
8

10

6

6

1

7

New Jersey . . . . . . . . . . . . . . .
— New York . . . . . . . . . . . . . . . .
— New Hampshire . . . . . . . . . . . .
— North Carolina . . . . . . . . . . . . .
Ohio . . . . . . . . . . . . . . . . . . . . .
— Oklahoma . . . . . . . . . . . . . . . .
— Oregon . . . . . . . . . . . . . . . . . . .
Pennsylvania . . . . . . . . . . . . . .
— Rhode Island . . . . . . . . . . . . . .
South Carolina . . . . . . . . . . . . .
Tennessee . . . . . . . . . . . . . . . .
— Texas . . . . . . . . . . . . . . . . . . . .
4
Virginia . . . . . . . . . . . . . . . . . .
8 West Virginia . . . . . . . . . . . . .
4 Wisconsin . . . . . . . . . . . . . . . .
. . . . . . . . . .
2 Washington, D.C.

1
1

Total

. . . . . . . . . . . . . . . .

—

—

28

2
4
2
8

—

6
4
7
1
19
43
—
14
11
1
1

329

1

2
6
1

—

—

1
6
2
7
11
1
1
6

—
—

79

ITEM 3. LEGAL PROCEEDINGS

See Part II, Item 8, Note 10 – Commitments and Contingencies for information concerning our legal proceedings.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

29

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER

MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

PART II

Market Information and Holders

Our common stock trades on the NASDAQ under the trading symbol “AMED.” The following table presents the
range of high and low sales prices for our common stock for the periods indicated as reported on NASDAQ:

Year Ended December 31, 2015:

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
First Quarter
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31, 2014:

First Quarter
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Second Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth Quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Price Range of
Common Stock

High

Low

$31.27
43.61
48.34
45.00

$17.61
18.20
22.58
30.48

$25.83
24.81
36.11
34.72

$13.85
12.86
15.31
19.03

As of March 4, 2016, there were approximately 521 holders of record of our common stock.

Dividend Policy

We have not declared or paid any cash dividends on our common stock or any other of our securities and do not
expect to pay cash dividends for the foreseeable future. We currently intend to retain our future earnings, if any,
to fund the development and growth of our business. Future decisions concerning the payment of dividends will
depend upon our results of operations, financial condition, capital expenditure plans and debt service
requirements, as well as such other factors as our Board of Directors, in its sole discretion, may consider relevant.
In addition, our outstanding indebtedness restricts, and we anticipate any additional future indebtedness may
restrict, our ability to pay cash dividends.

Purchases of Equity Securities

The following table provides the information with respect to purchases made by us of shares of our common
stock during each of the months during the three-month period ended December 31, 2015:

Period

October 1, 2015 to October 31,

2015 . . . . . . . . . . . . . . . . . . . . . . .
November 1, 2015 to November 30,
2015 . . . . . . . . . . . . . . . . . . . . . . .
December 1, 2015 to December 31,
2015 . . . . . . . . . . . . . . . . . . . . . . .

(a)
Total Number
of Share (or Units)
Purchased

(b)
Average Price
Paid per Share (or Unit)

(c)
Total Number of
Shares (or Units)
Purchased as Part of
Publicly Announced
Plans or Programs

(d)
Maximum Number (or
Approximate Dollar
Value) of Shares (or
Units) That May Yet Be
Purchased Under the
Plans or Programs

—

2,474

6,360

8,834(1)

$ —

39.58

40.61

$40.32

—

—

$

—

—

116,859

116,859

70,418,957

$70,418,957

(1)

Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the
vesting of stock previously awarded to such employees under our 2008 Omnibus Incentive Compensation Plan.

30

Stock Performance Graph

The Performance Graph below compares the cumulative total stockholder return on our common stock, $0.001
par value per share, for the five-year period ended December 31, 2015, with the cumulative total return on the
NASDAQ composite index and an industry peer group over the same period (assuming the investment of $100 in
our common stock, the NASDAQ composite index and the industry peer group) on December 31, 2010 and the
reinvestment of dividends. The peer group we selected is comprised of: LHC Group, Inc. (“LHCG”) and Almost
Family, Inc. (“AFAM”). The cumulative total stockholder return on the following graph is historical and is not
necessarily indicative of future stock price performance. No cash dividends have been paid on our common
stock.

Cumulative Total Return as of  December 31

$250

$200

$150

$100

$50

$0

31-Dec-2010

31-Dec-2011

31-Dec-2012

31-Dec-2013

31-Dec-2014

31-Dec-2015

Amedisys, Inc. 

NASDAQ Composite

Peer Group

Amedisys, Inc. . . . . . . . . . . . . . . . . . . . . . . .
NASDAQ Composite . . . . . . . . . . . . . . . . . .
Peer Group . . . . . . . . . . . . . . . . . . . . . . . . . .

$100.00
$100.00
$100.00

$ 32.57
$100.53
$ 42.92

$ 33.75
$116.92
$ 65.93

$ 43.67
$166.19
$ 84.73

$ 87.61
$188.78
$ 95.67

$117.37
$199.95
$134.79

12/31/2010

12/31/2011

12/31/2012

12/31/2013

12/31/2014

12/31/2015

This stock performance information is “furnished” and shall not be deemed to be “soliciting material” or
subject to Regulation 14A under the Securities Exchange Act of 1934 (the “Exchange Act”), shall not be deemed
“filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and
shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date of this report and irrespective of any general incorporation
by reference language in any such filing, except to the extent we specifically incorporate the information by
reference.

31

ITEM 6. SELECTED FINANCIAL DATA

The selected consolidated financial data presented below is derived from our audited consolidated financial
statements for the five-year period ended December 31, 2015, based on our continuing operations. The financial
data for the years ended December 31, 2015, 2014 and 2013 should be read together with our consolidated
financial statements and related notes included in Item 8, “Financial Statements and Supplementary Data” and
the information included in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” herein.

2015 (1)

2014 (2)

2013 (3)

2012 (4)

2011 (5)

(Amounts in thousands, except per share data)

Income Statement Data:
Net service revenue . . . . . . . . . . . . . . . . . . . . . . $1,280,541 $1,204,554 $1,249,344 $1,440,836 $1,418,464
Operating (loss) income from continuing

operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

(9,166) $

24,047 $ (154,971) $ (108,855) $ (469,190)

Net (loss) income from continuing operations

attributable to Amedisys, Inc. . . . . . . . . . . . . . $

(3,021) $

12,992 $ (93,105) $ (80,262) $ (374,430)

Net (loss) income from continuing operations
attributable to Amedisys, Inc. per basic
share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

Net (loss) income from continuing operations
attributable to Amedisys, Inc. per diluted
share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

(0.09) $

0.40 $

(2.98) $

(2.68) $

(13.05)

(0.09) $

0.40 $

(2.98) $

(2.68) $

(13.05)

(1) During 2015, we recorded non-cash charges to write off the software costs incurred related to the
development of AMS3 Home Health and Hospice in the amount of $75.2 million ($45.5 million, net of tax)
and to reduce the carrying value of our corporate headquarters in the amount of $2.1 million ($1.2 million,
net of tax).

(2) During 2014, we recorded charges for relators’ fees and exit and restructuring activity in the amount of
$13.9 million ($8.5 million, net of tax) and recognized non-cash other intangibles impairment charges of
$3.1 million ($2.0 million, net of tax).

(3) During 2013, we recorded a charge for the accrual for the U.S. Department of Justice settlement, which
amounted to $150.0 million ($93.9 million, net of tax) and recognized non-cash goodwill and other
intangibles impairment charges of $9.5 million ($5.8 million, net of tax).

(4) During 2012, we recorded a $162.1 million ($110.2 million, net of tax and non-controlling interests) charge
for the impairment of goodwill and other intangibles and incurred certain costs associated with our exit
activities in the amount of $2.7 million ($1.6 million, net of tax).

(5) During 2011, we recorded a $579.9 million ($438.4 million, net of tax) charge for the impairment of
goodwill and other intangibles and incurred certain costs associated with our exit activities in the amount of
$6.6 million ($4.0 million, net of tax).

2015

2014

2013

2012

2011

(Amounts in thousands)

Balance Sheet Data:
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total debt, including current portion . . . . . . . . . . . . . .
Total Amedisys, Inc. stockholders’ equity . . . . . . . . . .
Cash dividends declared per common share . . . . . . . .

$858,285
$726,406
$685,085
$145,439
$ 46,904
$100,000
$409,568
$518,868
$372,201
$ — $ — $ — $ — $ —

$669,742
$116,372
$397,167

$730,595
$102,711
$452,340

32

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

The following discussion and analysis provides information we believe is relevant to an assessment and
understanding of our results of operations and financial condition for 2015, 2014 and 2013. This discussion
should be read in conjunction with our audited financial statements included in Item 8, “Financial Statements
and Supplementary Data” and Part I, Item 1, “Business” of this Annual Report on Form 10-K. The following
analysis contains forward-looking statements about our future revenues, operating results and expectations. See
“Special Caution Concerning Forward-Looking Statements” for a discussion of the risks, assumptions and
uncertainties affecting these statements as well as Part I, Item 1A, “Risk Factors.”

Overview

We are a provider of high-quality, low-cost home health services to the chronic, co-morbid, aging American
population, with approximately 80%, 82% and 84% of our revenue derived from Medicare for 2015, 2014 and
2013, respectively.

Our operations involve servicing patients through our two reportable business segments: home health and
hospice. Our home health segment delivers a wide range of services in the homes of individuals who may be
recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide
comfort and support for those who are facing a terminal illness. As of December 31, 2015, we owned and
operated 329 Medicare-certified home health care centers and 79 Medicare-certified hospice care centers in 34
states within the United States and the District of Columbia, including 15 home health care centers acquired from
Infinity HomeCare on December 31, 2015, which are not included in our operating results.

2015 Developments

• Discontinued AMS3, our third generation, proprietary operating system and transitioned to Homecare

Homebase (“HCHB”), a leading platform for home health and hospice companies.

• Entered into new Credit Agreement that provides for senior secured facilities in an initial aggregate
principal amount of up to $300 million and terminated each of our Prior Credit Agreement and Second
Lien Credit Agreement.

• Operationalized the transition to the 10th revision of the International Classification of Diseases

(“ICD-10”)

• Closed the acquisition of Infinity HomeCare on December 31, 2015 (Infinity HomeCare is not included

in our operating results).

2016 Outlook

• Continue the rollout of HCHB with anticipated completion date in the second half of 2016.

• Renew focus on potential acquisitions.

•

•

1.4% reduction in Medicare reimbursement payments for home health industry.

1.1% increase in Medicare reimbursement payments for hospice industry.

• Transition to new hospice payment methodology

Financial Performance

The year ended December 31, 2015 continued our significant operational improvement that began during 2014.
Our improvement began with the closure and/or consolidation of care centers that had a material, negative impact
on our operating results. The reduction in the number of operating care centers enabled us to restructure our

33

regional and corporate support functions. Additionally, we have seen improvement in the remaining care centers
in both of our operating segments with a return to home health same store Medicare admissions growth and a
significant increase in hospice admissions and average daily census.

Our home health care centers have experienced same store Medicare revenue and admissions growth. The home
health segment has seen a significant increase in non-Medicare revenue, an increase in revenue per episode while
maintaining a relatively flat cost per visit and reductions in operating expenses which have helped deliver a $29
million improvement
in our operating results over the year ended December 31, 2014 (see “Results of
Operations”).

Our hospice segment has shown consistent growth in admissions and average daily census combined with strong
cost controls, all of which have helped deliver a $13 million improvement in our operating results over the year
ended December 31, 2014 (see “Results of Operations”).

Owned and Operated Care Centers

Home Health

Hospice

At December 31, 2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisitions/Startups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Closed/Consolidated . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

At December 31, 2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Closed/Consolidated/Sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

At December 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisitions (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Closed/Consolidated/Sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

At December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

435
2
(70)

367
(51)

316
15
(2)

329

97
1
(6)

92
(12)

80
1
(2)

79

(1) The 15 home health care centers acquired from Infinity HomeCare on December 31, 2015 are not included

in our operating results.

When we refer to “same store business,” we mean home health and hospice care centers that we have operated
for at least the last twelve months; when we refer to “acquisitions,” we mean home health and hospice care
centers that we acquired within the last twelve months; and when we refer to “start-ups,” we mean home health
or hospice care centers opened by us in the last twelve months. Once a care center has been in operation for a
twelve month period, the results for that particular care center are included as part of our same store business
from that date forward. Non-Medicare revenue, admissions, recertifications or completed episodes, includes
home health revenue, admissions, recertifications or completed episodes of care for those payors that pay on an
episodic or per visit basis, which includes Medicare Advantage programs and private payors.

Economic and Industry Factors

Home health and hospice services are a highly fragmented, highly competitive industry. The degree of
competiveness varies depending upon whether our care centers operate in states that require a certificate of need
(CON) or permit of approval (POA). In such states, expansion by existing providers or entry into the market by
new providers is permitted only where determination is made by state health authorities that a given amount of
unmet need exists. Currently, 67% and 40% of our home health and hospice care centers, respectively operate in
CON/POA states.

As the Federal government continues to debate a reduction in expenditures and a reform of the Medicare system,
our industry continues to face reimbursement pressures. Specifically, the industry has been impacted by a 2%
sequestration payment reduction beginning April 1, 2013. In addition to the sequestration cut, the Centers for

34

Medicare and Medicaid Services (“CMS”) instituted a rebasing cut of approximately $81 (2.7%) per year for
2014 – 2017; however, we do expect some offset from a market basket updated in each of these years. The
following payment adjustments are effective for the years indicated based on CMS’s final rules relative to
Medicare reimbursement:

Home Health(1)

Hospice

2016

2015

2014

2016(2)

2015

2014

Market Basket Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rebasing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ICD-9 Coding Change . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . —
50/50 Blend of Wage Index . . . . . . . . . . . . . . . . . . . . . . . . . . —
Nominal Case Mix Adjustment . . . . . . . . . . . . . . . . . . . . . . .
PPACA Adjustment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . —
Budget Neutrality Adjustment Factor . . . . . . . . . . . . . . . . . . —
Productivity Adjustment

. . . . . . . . . . . . . . . . . . . . . . . . . . . .

(2.7)
(2.8)
(0.6)
—
—
—
—
(0.9) —
—
—
0.4 —
(0.5) —

(0.4)

—
—
0.2
—
(0.3)
(0.7)
(0.5)

—
—
—
—
(0.3)
(0.7)
(0.5)

—
—
—
—
(0.3)
(0.7)
(0.5)

2.3 % 2.6 % 2.3 % 2.4 % 2.9 % 2.5 %
(2.4)

(1) Our impact could differ depending on differences in the wage index and coding changes.
(2) Effective for services provided from October 1, 2015 to September 30, 2016.

(1.4)% (0.3)% (1.0)% 1.1 % 1.4 % 1.0 %

As part of the 2016 final rule issued in October 2015, CMS finalized their proposal to implement a Home Health
Value-Based Purchasing model in nine states that seeks to test whether incentives for better care can improve
outcomes in the delivery of home health services. Financial impacts from this change, either positive or negative,
would begin January 1, 2018, applied to that calendar year based on 2015 performance data. Currently, care
centers operating in the states included in the proposed model account for approximately 26% of our home health
Medicare revenue.

Governmental Inquiries and Investigations and Other Litigation

September 2010 Civil Investigative Demand Issued by the U.S. Department of Justice

On September 27, 2010, we received a Civil Investigative Demand (“CID”) issued by the U.S. Department of
Justice pursuant to the federal False Claims Act. The CID required the delivery of a wide range of documents and
information relating to the Company’s clinical and business operations, including reimbursement and billing
claims submitted to Medicare for home health services, and related compliance activities. The CID generally
covered the period from January 1, 2003. On April 26, 2011, we received a second CID related to the CID issued
in September 2010, which generally covered the same time period as the previous CID and required the
production of additional documents. Such CIDs are often associated with previously filed qui tam actions, or
lawsuits filed under seal under the False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq. Qui tam actions are
brought by private plaintiffs suing on behalf of the federal government for alleged FCA violations. Subsequently,
the Company and certain current and former employees received additional CIDs for additional documents and/
or testimony.

In May 2012, we made a disclosure to CMS under the agency’s Stark Law Self-Referral Disclosure Protocol
relating to certain services agreements between a subsidiary of ours and a large physician group (the “Stark Law
Self-Referral Matter”). During some period of time since December 2007, the arrangements appear not to have
complied in certain respects with an applicable exemption to the Stark Law referral prohibition. Medicare
revenue earned as a result of referrals from the physician group from May 2008 to May 2012, the relevant four
year “lookback” period under the Stark Law Self-Referral Disclosure Protocol, was approximately $4 million.
On January 11, 2013, one of our subsidiaries received a CID from the United States Attorney’s Office for the
Northern District of Georgia seeking certain information relating to that subsidiary’s relationship with this
physician group

35

On April 23, 2014, with no admission of liability on our part, we entered into a settlement agreement to resolve
both the U.S. Department of Justice investigation and the Stark Law Self-Referral Matter. Pursuant to the
settlement agreement, on May 2, 2014, we paid the United States an initial payment in the amount of $116.5
million representing the first
thereon due under the settlement
agreement, and on October 23, 2014, we paid the United States an additional payment in the amount of $35.8
million, representing the second and final installment of $35 million plus interest thereon due under the
settlement agreement.

installment of $115 million plus interest

The settlement agreement also resolves allegations made against us by various qui tam relators, who are required
to dismiss their claims with prejudice. We accrued and paid various relators’ attorneys’ fees and expenses in the
aggregate sum of approximately $3.9 million during 2014.

In connection with the settlement agreement, on April 23, 2014, we entered into a corporate integrity agreement
(“CIA”) with the Office of Inspector General-HHS (“OIG”). The CIA formalizes various aspects of our already
existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing
compliance with federal health care program requirements. Among other things, the CIA requires us to maintain
our existing compliance program, executive compliance committee and compliance committee of the Board of
Directors; provide certain compliance training; continue screening new and current employees to ensure they are
eligible to participate in federal health care programs; engage an independent review organization to perform
certain auditing and reviews and prepare certain reports regarding our compliance with federal health care
programs, our billing submissions to federal health care programs and our compliance and risk mitigation
the CIA
programs; and provide certain reports and management certifications to the OIG. Additionally,
specifically requires that we report substantial overpayments that we discover we have received from federal
health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we
could become liable for payment of certain stipulated penalties, or could be excluded from participation in
federal health care programs. The CIA has a term of five years. We expect the CIA to impact operating expenses
by approximately $1 to $2 million annually.

May 2015 Subpoena Duces Tecum Issued by the U.S. Department of Justice

On May 21, 2015, we received a Subpoena Duces Tecum (“Subpoena”) issued by the U.S. Department of Justice.
The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States
Attorney’s Office for the District of Massachusetts. It also requests the delivery of documents relating to our
hospice clinical and business operations and related compliance activities.

November 2015 Civil Investigative Demand Issued by the U.S. Department of Justice

On November 3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False
Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through
designated facilities in the Morgantown, West Virginia area.

See Item 8, Note 10 – Commitments and Contingencies to our consolidated financial statements for additional
information regarding our April 2014 CIA, the May 2015 Subpoena issued by the U.S. Department of Justice, the
November 2015 CID issued by the U.S. Department of Justice and for a discussion of and updates regarding
class action litigation we are involved in. No assurances can be given as to the timing or outcome of these items.

36

Results of Operations

Consolidated

The following table summarizes our results from continuing operations (amounts in millions):

For the Years Ended December 31,

2015

2014

2013

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross margin, excluding depreciation and amortization . . . . . . . . .
% of revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
% of revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Department of Justice settlement
. . . . . . . . . . . . . . . . . . . . . .
Asset impairment charge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,280.5
554.6
43.3%
486.5
38.0%
—
77.3

$1,204.5
513.4
42.6%
486.3
40.4%
—
3.1

Operating (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total other income (expense), net . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax (expense) benefit
Effective income tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(Loss) income from continuing operations . . . . . . . . . . . . . . . . . . .

Net loss from discontinued operations . . . . . . . . . . . . . . . . . . . . . .
Net (income) loss attributable to noncontrolling interests . . . . . . .

Net (loss) income attributable to Amedisys, Inc.

. . . . . . . . . . . . . .

$

(9.2)

8.9
(2.0)
650.6%

(2.3)

—
(0.7)

(3.0)

24.0

(3.1)
(7.7)
36.6%

13.3

(0.2)
(0.3)

$1,249.3
531.3
42.5%
526.8
42.2%
150.0
9.5

(155.0)

1.5
58.8
(38.3%)

(94.7)

(3.1)
1.6

$

12.8

$ (96.2)

Year Ended December 31, 2015 Compared to the Year Ended December 31, 2014

Our 2015 results were impacted by a $75 million non-cash charge to write off the software costs incurred related
to the development of AMS3 Home Health and Hospice and a $2 million non-cash charge to reduce the carrying
value of our corporate headquarters.

During the first quarter of 2014, we committed to a plan to consolidate 21 operating home health care centers and
four operating hospice care centers with care centers servicing the same markets and close 23 home health care
centers and six hospice care centers. As a result of this exit activity, we reduced our regional leadership structure
and corporate support functions. Separate from the restructuring costs, we also recorded severance costs
associated with the departure of our former Chief Executive Officer, a charge for relator fees associated with our
U.S. Department of Justice settlement during the first quarter of 2014 and a non-cash other intangibles
impairment charge during the fourth quarter of 2014. The following details the costs associated with these
activities (amounts in millions):

For the Year Ended December 31, 2014

Home Health Hospice Corporate

Total

Severance(a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restructuring severance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lease terminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other intangibles impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exit and restructuring activities cost . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Department of Justice Settlement/Relator Fees . . . . . . . . . . . . . . .

$ 2.0
2.1
1.9
1.6

7.6
—

$ 0.1
0.6
0.2
1.5

2.4
—

$—
3.0
—
—

3.0
3.9

$ 2.1
5.7
2.1
3.1

13.0
3.9

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 7.6

$ 2.4

$ 6.9

$16.9

(a)

Includes $0.8 million and $0.1 million for severance included in cost of service for home health and
hospice, respectively.

37

Our operating results have been impacted by the sale, closure and consolidation of numerous care centers as
mentioned above. Accordingly, our results for the year ended December 31, 2015 are not fully comparable to the
year ended December 31, 2014.

Our operating income, excluding the $77 million asset impairment charges in 2015 and the $17 million in costs
incurred in 2014 noted above, increased $27 million as our home health operating income increased $29 million,
our hospice operating income increased $13 million and our corporate operating expense increased $15 million.
The primary drivers of our improvement in performance were the closure/consolidation of care centers that had a
negative operating contribution, an increase in our revenue per episode, an increase in non-Medicare revenue,
growth in hospice census and a reduction in operating expenses. The increase in corporate operating expenses is
primarily due to the $6 million Wage and Hour Litigation settlement accrual and HCHB maintenance and hosting
and implementation costs of $8 million. The increase in HCHB maintenance and hosting is offset by a $4 million
decrease in depreciation and amortization as we move from our proprietary software to HCHB.

Total other income (expense), net decreased $1 million from prior year after considering the impact of the
following items (amounts in millions):

Legal settlements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
Equity in earnings from equity method investment
Life insurance proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Debt refinance costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain (loss) on disposal of property and equipment or sale of care centers . . . .

For the Years Ended
December 31,

2015

$ 7.4
6.7
1.0
(3.2)
0.2

$12.1

2014

$ 1.1
—
—
(0.5)
0.7

$ 1.3

The difference in income tax expense in 2015 and 2014 is driven primarily by the decrease in income before
income taxes. Additionally, the effective tax rate for the year ended December 31, 2015 does not provide a
meaningful comparison to other periods. The effective tax rate for the year is influenced by the relationship of
the amount of “effective tax rate drivers” (i.e. non-deductible expenses, non-taxable income, tax credits,
valuation allowance, uncertain tax positions, etc.) to (loss) income before income taxes. A significant asset
impairment was recorded during the three-month period ended March 31, 2015, resulting in a scenario where the
company’s (loss) income before income taxes for 2015 was near zero. Consequently, for 2015, the relationship
between the “effective tax rate drivers” and (loss) income before income taxes is distorted.

Year Ended December 31, 2014 Compared to the Year Ended December 31, 2013

Our operating results have been impacted by the sale, closure and consolidation of 54 care centers mentioned
above as well as the closure of an additional 9 care centers since December 31, 2013. Additionally, 76 care
centers were exited during 2013. Accordingly, our results for the year ended December 31, 2014 are not fully
comparable to the year ended December 31, 2013.

Our 2013 results were impacted by an accrual of $150 million and recognition of a deferred tax benefit of
$56 million for the settlement to resolve both the U.S. Department of Justice investigation and the Stark Law
Self-Referral Matter. In addition, we recorded asset impairment charges of $9 million related to other intangibles
during 2013.

Our operating income, excluding the $17 million in costs incurred in 2014 noted above and the U.S. Department
of Justice settlement and the asset impairment charge in 2013, increased $36 million as our home health
operating income increased $27 million, our hospice operating income increased $5 million and corporate

38

expenses decreased $4 million. Additionally, the first quarter of 2013 was not impacted by sequestration as it was
not in effect until April 1, 2013. The estimated impact of sequestration was $21 million for 2014 compared to
$18 million in 2013.

Income tax expense for 2014 and 2013 includes a favorable adjustment of $2 million related to various tax
credits for state employment and training and state and federal research development.

Home Health Division

The following table summarizes our home health segment results from continuing operations:

For the Years Ended December 31,

2015

2014

2013

Financial Information (in millions):
Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

761.4
243.7

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gross margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,005.1
584.2

420.9
280.6

$

751.5
205.4

956.9
559.4

397.5
294.4

Operating income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

140.3

$

103.1

$

803.8
183.9

987.7
578.9

408.8
333.8

75.0

Key Statistical Data:
Medicare:
Same Store Volume (1):
Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Admissions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recertifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total (2):
Admissions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recertifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Completed episodes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Visits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Average revenue per episode (3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Visits per completed episode (4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-Medicare:
Same Store Volume (1):
Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Admissions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recertifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total (2):
Admissions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recertifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Visits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total (2):
Cost per Visit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Visits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3%
3%
(1%)

1%
0%
1%

(10%)
0%
(18%)

178,226
99,762
269,227
4,797,734
2,825
17.5

$

177,243
102,263
272,864
4,794,609
2,768
17.3

$

190,507
107,908
292,984
5,177,976
2,758
17.5

$

21%
18%
14%

19%
17%
13%

(20%)
(13%)
(24%)

96,934
35,870
1,954,543

83,940
32,074
1,651,745

76,669
30,304
1,531,781

$

86.52
6,752,277

$

86.77
6,446,354

$

86.27
6,709,757

(1) Same store Medicare and Non-Medicare revenue, admissions or recertifications growth is the percent
increase (decrease) in our Medicare and Non-Medicare revenue, admissions or recertifications for the period
as a percent of the Medicare and Non-Medicare revenue, admissions or recertifications of the prior period.

(2) Based on continuing operations for all periods presented.

39

(3) Average Medicare revenue per completed episode is the average Medicare revenue earned for each

Medicare completed episode of care which includes the impact of sequestration.

(4) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided

by the home health Medicare episodes completed during the period.

Year Ended December 31, 2015 Compared to the Year Ended December 31, 2014

Overall, our operating income excluding the $8 million in exit activity costs in 2014, increased $29 million on a
$22 million increase in gross margin and a $7 million decline in other operating expenses. 2014 results included
revenue of $16 million and operating losses of $5 million for those care centers that were closed, consolidated or
sold.

Net Service Revenue

Our Medicare revenue increase of approximately $10 million consisted of a $16 million increase due to higher
revenue per episode offset by $6 million due to lower volumes. The decrease in volumes is primarily due to the
sale, closure and consolidation of 51 care centers since December 31, 2013, as we experienced a 3% increase in
same store admissions in 2015. Net service revenue includes a reduction of $1 million for the estimated impact of
the 2016 rate change. The impact for 2016 is estimated to be approximately $14 million.

Our non-Medicare revenue increased $38 million as we have focused on contracted payors with significant
concentrations in our markets and those that add incremental margin to our operations.

As mentioned above, we have closed numerous care centers since December 31, 2013. Accordingly, our results
are not fully comparable to prior year. The following table summarizes our net service revenue for our operating
care centers and those care centers that were closed, consolidated or sold.

For the Years Ended
December 31,

2015

2014

2013

Revenue (in millions):
Operating care centers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Closed/Consolidated/Sold care centers . . . . . . . . . . . . . . . . . . . . . . . . .

$1,005.1
—

$941.2
15.7

$895.6
92.1

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,005.1

956.9

987.7

Cost of Service, Excluding Depreciation and Amortization

Our cost of service, excluding the $1 million in exit activity costs in 2014, increased $26 million primarily as a
result of a 5% increase in visits. Our cost per visit remained relatively flat.

Other Operating Expenses

Other operating expenses, excluding the $7 million in exit activity costs in 2014, decreased $7 million due to
decreases in other care center related expenses as a result of our closure and consolidation strategy and the
reduction in divisional leadership; the majority of the reductions were in salaries and benefits and rent expense,
offset by $5 million increase in legal expense related to the self-disclosure matter. In addition, our provision for
doubtful accounts decreased $3 million and our depreciation and amortization expense decreased $4 million
compared to 2014.

Year Ended December 31, 2014 Compared to the Year Ended December 31, 2013

Overall, our operating income, excluding the $8 million in exit activity costs in 2014 and the $8 million asset
impairment charge in 2013, increased $27 million on an $11 million decline in gross margin offset by a
$38 million decline in other operating expenses.

40

Net Service Revenue

Our Medicare revenue decline of approximately $52 million consisted of $53 million due to lower volumes and
$2 million due to sequestration offset by a $3 million increase related to revenue per episode. The decrease in
volumes is primarily due to the sale, closure and consolidation of 51 care centers since December 31, 2013, as we
experienced an increase in same store revenue and recertifications.

Our non-Medicare revenue increased $21 million which is primarily due to increases in volumes and an increase
in our revenue per visit. We are experiencing significant growth in our non-Medicare business as we have
focused on contract payors with significant concentrations in our markets.

Cost of Service, Excluding Depreciation and Amortization

Our cost of service, excluding the $1 million in exit activity costs in 2014, decreased $20 million primarily as a
result of our decrease in Medicare volumes which was offset by an 8% increase in non-Medicare visits as our
cost per visit remained relatively flat.

Other Operating Expenses

Other operating expenses, excluding the $7 million in exit activity costs in 2014 and the $8 million asset
impairment charge in 2013, decreased $38 million due to a $43 million decrease in other care center related
expenses as a result of our closure and consolidation strategy and the reduction in divisional leadership; the
majority of the reductions were in salaries and benefits, rent expense and travel costs offset by a $5 million
increase in our provision for doubtful accounts due to the increase in non-Medicare revenue.

Hospice Division

The following table summarizes our hospice segment results from continuing operations:

For the Years Ended
December 31,

2015

2014

2013

Financial Information (in millions):
Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gross margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 258.5
16.9

$ 232.6
15.0

$ 246.4
15.2

275.4
141.7

133.7
66.0

247.6
131.7

115.9
63.4

261.6
139.1

122.5
73.5

Operating income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

67.7

$

52.5

$

49.0

Key Statistical Data:
Same Store Volume (1):
Medicare revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-Medicare revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hospice admits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Average daily census . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total (2):
Hospice admits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Average daily census . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Revenue per day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of service per day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Discharge average length of stay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

13%
18%
16%
12%

(2%)
6%
(3%)
(4%)

(9%)
(3%)
(3%)
(8%)

19,205
5,105
$147.78
$ 76.06
92

17,081
4,632
$146.51
$ 77.93
100

18,335
4,987
$143.77
$ 76.45
100

41

(1) Same store Medicare and Non-Medicare revenue, Hospice admits or average daily census volume is the
percent increase (decrease) in our Medicare and Non-Medicare revenue, Hospice admits or average daily
census for the period as a percent of the Medicare and Non-Medicare revenue, Hospice admits or average
daily census of the prior period.

(2) Based on continuing operations for all periods presented.

Year Ended December 31, 2015 Compared to the Year Ended December 31, 2014

Overall, our operating income, excluding the $2 million in exit activity costs in 2014, increased $13 million on
an $18 million increase in gross margin offset by a $5 million increase in other operating expenses.

Net Service Revenue

Our hospice revenue increased $28 million, primarily as the result of an increase in our average daily census as a
result of a 16% increase in hospice admissions. We benefitted from a 1.4% hospice rate increase effective
October 1, 2014. The base rate for hospice services provided from October 1, 2015 to September 30, 2016 will
increase 1.1% as a result of the final rule issued by CMS in August 2015.

As mentioned above, we have closed numerous care centers since December 31, 2013. Accordingly, our results
are not fully comparable to prior year. The following table summarizes our net service revenue for our operating
care centers and those care centers that were closed, consolidated or sold.

For the Years Ended
December 31,

2015

2014

2013

Revenue (in millions):
Operating care centers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Closed/Consolidated/Sold care centers . . . . . . . . . . . . . . . . . . . . . . . . . .

$275.4
—

$243.4
4.2

$243.7
17.9

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

275.4

247.6

261.6

Cost of Service, Excluding Depreciation and Amortization

Our hospice cost of service increased $10 million as the result of a 10% increase in average daily census offset
by a decrease in cost of service per day. We experienced significant improvement in pharmacy and DME cost per
day during 2015.

Other Operating Expenses

Other operating expenses, excluding the $2 million in exit activity costs in 2014, increased $5 million due to
increases in other care center related expenses, primarily salaries and benefits expense and travel costs.

Year Ended December 31, 2014 Compared to the Year Ended December 31, 2013

Overall, our operating income, excluding the $2 million in exit activity costs in 2014 and the $1 million
impairment charge in 2013, increased $5 million on a $14 million decline in revenue, an $8 million decline in
cost of service and an $11 million decline in other operating expenses.

Net Service Revenue

Our hospice revenue decreased $14 million, primarily as the result of a decrease in our average daily census. The
decrease in average daily census is primarily due to the sale, closure and consolidation of 12 care centers since

42

December 31, 2013. The decrease in revenue was offset by a $2 million decrease in our hospice cap expense as
our decline in average daily census and a decrease in admissions has resulted in a decrease in our overall cap
expense. We benefitted from a 1.0% hospice rate increase effective October 1, 2013, and beginning October 1,
2014, the fiscal year 2015 hospice base rate increased approximately 1.4%.

Cost of Service, Excluding Depreciation and Amortization

Our hospice cost of service decreased $8 million, or 5%, as the result of a 7% decrease in average daily census
offset by an increase in cost of service per day. Our cost of service per day has been negatively impacted by an
increase in pharmacy costs as a result of new CMS guidance which became effective on May 1, 2014.

Other Operating Expenses

Other operating expenses, excluding the $2 million in exit activity costs in 2014 and the $1 million impairment
charge in 2013, decreased $11 million due to a $7 million decrease in other care center related expenses due to
our care center closure and consolidation strategy and a $4 million decrease in our provision for doubtful
accounts.

Corporate

The following table summarizes our corporate results from continuing operations:

Financial Information (in millions):
Other operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$126.5
13.4

$114.4
17.2

$104.5
24.5

Total before impairment and U.S. Department of Justice

settlement (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$139.9

$131.6

$129.0

For the Years Ended
December 31,

2015

2014

2013

(1) Total of $217.2 million on a GAAP basis for the year ended December 31, 2015 (including $77.3 million
asset impairment charge). Total of $279.0 million on a GAAP basis for the year ended December 31, 2013
(including $150.0 U.S. Department of Justice settlement).

Corporate expenses consist of cost relating to our executive management and administrative support functions,
primarily information services, accounting, finance, billing and collections, legal, compliance, risk management,
procurement, marketing, clinical administration, training, human resources and administration.

Year Ended December 31, 2015 Compared to the Year Ended December 31, 2014

Excluding the $77 million asset impairment charge in 2015 and the $7 million in exit and restructuring activities
costs and relator fees associated with our U.S. Department of Justice settlement agreement during 2014,
corporate other operating expenses increased $15 million which is inclusive of the $6 million Wage and Hour
Litigation settlement accrual, $4 million in HCHB maintenance and hosting costs, $4 million related to HCHB
implementation and $2 million in severance costs.

Year Ended December 31, 2014 Compared to the Year Ended December 31, 2013

Excluding the 2014 exit and restructuring activities costs and relator fees associated with our U.S. Department of
in 2013, corporate expenses
Justice settlement agreement and the U.S. Department of Justice settlement

43

decreased $4 million primarily due to a decrease in depreciation and amortization. Our corporate salaries and
wages experienced an increase due to the addition of resources for the roll-out of AMS3, our enhanced point of
care system.

Liquidity and Capital Resources

Cash Flows

The following table summarizes our cash flows for the periods indicated (amounts in millions):

Cash provided by (used in) operating activities . . . . . . . . . . . . . . . . . . . .
Cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash (used in) provided by financing activities . . . . . . . . . . . . . . . . . . . .

Net increase (decrease) in cash and cash equivalents . . . . . . . . . . . . . . . .
Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . . . . .

For the Years Ended
December 31,

2015

2014

2013

$107.8
(67.4)
(20.9)

19.5
8.0

$(65.5)
(14.3)
70.5

(9.3)
17.3

$102.3
(46.5)
(53.0)

2.8
14.5

Cash and cash equivalents at end of period . . . . . . . . . . . . . . . . . . . . . . .

$ 27.5

$ 8.0

$ 17.3

Cash provided by operating activities increased $173.3 million during 2015 compared to 2014 primarily due to
an increase in our operating performance as compared to 2014 and the payment of $150.0 million in 2014 under
our settlement agreement with the U.S. Department of Justice. For additional information regarding our operating
performance, see “Results of Operations”. The recognition of the asset impairment charge of $77.3 million,
which resulted in the net loss for 2015 is a non-cash item and therefore has no impact on our cash flow from
operations. Cash used in operating activities increased $167.8 million during 2014 compared to 2013 primarily
due to the payment of the U.S. Department of Justice Settlement. Adjusting for the $152.3 million settlement and
interest payment, we generated $86.8 million in cash from operating activities during 2014.

Cash used in investing activities increased $53.1 million during 2015 compared to 2014 primarily due to our
acquisition activity ($69.1 million) and an increase in capital expenditures ($9.4 million), offset by proceeds from
the sale of property and equipment ($20.0 million) and investments ($5.0 million). Cash used in investing
activities decreased $32.2 million during 2014 compared to 2013 primarily due to a decrease in capital
expenditures of $29.7 million, primarily related to AMS3 development, and a $3.7 million decrease in the
purchase of investments.

Cash used in financing activities increased $91.4 million during 2015 compared to 2014 primarily due to an
increase in our principal payments of long-term obligations, net of borrowings. We decreased our outstanding
long-term obligations, net of borrowings by $16.4 million from December 31, 2014. Cash provided by financing
activities increased $123.5 million during 2014 compared to 2013 primarily due to an increase in our borrowings
on our revolving line of credit and our Second Lien Loan. We increased our outstanding long-term obligations,
net of repayments by $71.1 million from December 31, 2013, primarily to fund the U.S. Department of Justice
settlement payment.

Liquidity

Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through
the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and
do obtain additional sources of liquidity by the incurrence of additional indebtedness.

During 2015, we spent $9.3 million in routine capital expenditures compared to $7.0 million and $6.5 million
during 2014 and 2013, respectively. Routine capital expenditures primarily include equipment and computer

44

software and hardware. In addition, we spent $12.1 million in non-routine capital expenditures related to
software licenses and interfaces compared to $5.0 million and $35.2 million during 2014 and 2013, respectively,
related to enhancements to our point of care software. Our routine and non-routine capital expenditures for 2016
are expected to be approximately $9.1 million and $13.3 million, respectively.

On April 23, 2014, we entered into a settlement agreement to resolve both the U.S. Department of Justice
investigation and the Stark Law Self-Referral Matter. Pursuant to the settlement agreement, on May 2, 2014, we
paid the United States an initial payment in the amount of $116.5 million, representing the first installment of
$115 million plus interest thereon due under the settlement agreement, and on October 23, 2014, we paid the
United States an additional payment in the amount of $35.8 million, representing the second and final installment
of $35 million plus interest thereon due under the settlement agreement.

On August 28, 2015, we entered into a Credit Agreement that provides for senior secured facilities in an initial
aggregate principal amount of up to $300 million comprised of (a) a term loan facility in an initial aggregate
principal amount of $100 million and (b) a revolving credit facility in an initial aggregate principal amount of up
to $200 million. The net proceeds of the term loan and existing cash on hand were used to pay off (i) our existing
term loan under our prior Credit Agreement dated as of October 22, 2012, as amended with a principal balance of
$27 million and (ii) our existing term loan under our prior Second Lien Credit Agreement dated July 28, 2014,
with a principal balance of $70 million.

As of December 31, 2015, we had $27.5 million in cash and cash equivalents and $179.0 million in availability
under our $200.0 million Revolving Credit Facility. Based on our operating forecasts and our new debt service
requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt
service requirements.

Outstanding Patient Accounts Receivable

Our patient accounts receivable, net increased $25.7 million from December 31, 2014 to December 31, 2015. Our
cash collection as a percentage of revenue was 100% and 103% for December 31, 2015 and 2014, respectively.
Our days revenue outstanding, net at December 31, 2015 was 31.9 days which is an increase of 2.5 days from
December 31, 2014. Our days revenue outstanding, net at December 31, 2015 does not include Infinity
HomeCare.

Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date.
We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill
claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition
activity, probe edits or regulatory changes which result in additional information or procedures needed prior to
billing. The timely filing deadline for Medicare is one year from the date the episode was completed and varies
by state for Medicaid-reimbursable services and among insurance companies and other private payors.

Our provision for estimated revenue adjustments (which is deducted from our service revenue to determine net
service revenue) and provision for doubtful accounts were as follows for the periods indicated (amounts in
millions). We fully reserve for both our Medicare and other patient accounts receivable that are aged over 365 days.

Provision for estimated revenue adjustments (1) . . . . . . . . . . . . . . . . .
Provision for doubtful accounts (2) . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For the Years Ended
December 31,

2015

$ 6.1
14.1

$20.2

2014

$ 5.1
16.4

$21.5

As a percent of revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1.6%

1.8%

(1)

Includes $0.1 million from discontinued operations for the year ended December 31, 2014.

45

(2)

Includes $0.1 million from discontinued operations for the year ended December 31, 2014.

The following schedules detail our patient accounts receivable, net of estimated revenue adjustments, by payor
class, aged based upon initial date of service (amounts in millions, except days revenue outstanding, net):

0-90

91-180

181-365 Over 365

Total

At December 31, 2015:
Medicare patient accounts receivable, net (1) . . . . . . . . . . . . . . . . . . .

$73.5

$7.0

$(0.4)

$—

$ 80.1

Other patient accounts receivable:

Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Private . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

12.4
31.2

1.7
8.1

0.9
5.1

—
2.0

15.0
46.4

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$43.6

$9.8

$ 6.0

$ 2.0

$ 61.4

Allowance for doubtful accounts (2)

. . . . . . . . . . . . . . . . . . . . .

Non-Medicare patient accounts receivable, net

. . . . . . . . . . . . . . . . .

Total patient accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . .

Days revenue outstanding, net (3)

. . . . . . . . . . . . . . . . . . . . . . . . . . .

(16.5)

$ 44.9

$125.0

31.9

0-90

91-180

181-365 Over 365

Total

At December 31, 2014:
Medicare patient accounts receivable, net (1) . . . . . . . . . . . . . . . . . . .

$62.1

$6.3

$—

$—

$ 68.4

Other patient accounts receivable:

Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Private . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9.1
23.4

1.4
5.4

0.7
2.5

0.4
2.3

11.6
33.6

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$32.5

$6.8

$ 3.2

$ 2.7

$ 45.2

Allowance for doubtful accounts (2) . . . . . . . . . . . . . . . . . . . . . .

Non-Medicare patient accounts receivable, net . . . . . . . . . . . . . . . . . .

Total patient accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . .

Days revenue outstanding, net (3) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(14.3)

$ 30.9

$ 99.3

29.4

(1) The following table summarizes the activity and ending balances in our estimated revenue adjustments
(amounts in millions), which is recorded to reduce our Medicare outstanding patient accounts receivable to
their estimated net realizable value, as we do not estimate an allowance for doubtful accounts for our
Medicare claims.

Balance at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for estimated revenue adjustments (a) . . . . . . . . . . . . . . . . .
Write offs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balance at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For the Years Ended
December 31,

2015

$ 3.1
6.1
(5.2)

$ 4.0

2014

$ 3.9
5.1
(5.9)

$ 3.1

(a)

Includes $0.1 million from discontinued operations for the year ended December 31, 2014.

Our estimated revenue adjustments were 4.8% and 4.3% of our outstanding Medicare patient accounts
receivable at December 31, 2015 and December 31, 2014, respectively.

46

(2) The following table summarizes the activity and ending balances in our allowance for doubtful accounts
(amounts in millions), which is recorded to reduce only our Medicaid and private payer outstanding patient
accounts receivable to their estimated net realizable value.

For the Years Ended
December 31,

2015

2014

Balance at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for doubtful accounts (a) . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write offs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 14.3
14.1
(11.9)

Balance at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 16.5

$ 14.2
16.4
(16.3)

$ 14.3

(a)

Includes $0.1 million from discontinued operations for the year ended December 31, 2014.

Our allowance for doubtful accounts was 26.9% and 31.6% of our outstanding Medicaid and private patient
accounts receivable at December 31, 2015 and 2014, respectively.

(3) Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts
receivable (i.e., net of estimated revenue adjustments and allowance for doubtful accounts ) at December 31,
2015 and 2014 by our average daily net patient revenue for the three-month periods ended December 31,
2015 and 2014, respectively.

Indebtedness

Credit Agreement

On August 28, 2015, we entered into a Credit Agreement that provides for senior secured facilities in an initial
aggregate principal amount of up to $300 million.

The Credit Facilities are comprised of (a) a term loan facility in an initial aggregate principal amount of $100
million (the “Term Loan”); and (b) a revolving credit facility in an initial aggregate principal amount of up to
$200 million (the “Revolving Credit Facility”). The Revolving Credit Facility provides for and includes within
its $200 million limit a $25 million swingline facility and commitments for up to $50 million in letters of credit.
Upon lender approval, we may increase the aggregate loan amount under the Credit Facilities by a maximum
amount of $150 million.

The net proceeds of the Term Loan and existing cash on hand were used to pay off (i) our existing term loan
under our Prior Credit Agreement, dated as of October 22, 2012, as amended (the “Prior Credit Agreement”)
with a principal balance of $27 million and (ii) our existing term loan under our prior Second Lien Credit
Agreement dated July 28, 2014 (the “Second Lien Credit Agreement”), with a principal balance of $70 million.
The final maturity of the Term Loan is August 28, 2020. The Term Loan will amortize beginning on March 31,
2016 in 18 quarterly installments (eight quarterly installments of $1.25 million followed by eight quarterly
installments of $2.5 million, followed by two quarterly installments of $3.1 million, subject to adjustment for
prepayments), with the remaining balance due upon maturity.

The Revolving Credit Facility may be used to provide ongoing working capital and for general corporate
purposes of the Company and its subsidiaries,
including permitted acquisitions, as defined in the Credit
Agreement. The final maturity of the Revolving Credit Facility is August 28, 2020 and will be payable in full at
that time.

The interest rate in connection with the Credit Facilities shall be selected from the following by us: (i) the Base
Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The “Base Rate” means a
fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime

47

rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate for an interest period of one
month plus 1% per annum. The “Eurodollar Rate” means the rate at which Eurodollar deposits in the London
interbank market for an interest period of one, two, three or six months (as selected by us) are quoted. The
“Applicable Rate” is based on the consolidated leverage ratio and is presented in the table below. As of
December 31, 2015, the Applicable Rate is 1.00% per annum for Base Rate Loans and 2.00% per annum for
Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the
Credit Facilities, as presented in the table below.

Consolidated Leverage Ratio
ÿ 2.75 to 1.0
< 2.75 to 1.0 but ÿ 1.75 to 1.0
< 1.75 to 1.0 but ÿ 0.75 to 1.0
< 0.75 to 1.0

Margin for
ABR Loans

Margin for
Eurodollar Loans

Commitment
Fee

Letter of
Credit Fee

2.00%
1.50%
1.00%
0.50%

3.00%
2.50%
2.00%
1.50%

0.40%
0.35%
0.30%
0.25%

3.00%
2.50%
2.00%
1.50%

Our weighted average interest rate for our $100.0 million Term Loan, under our Credit Agreement, was 2.7% for
the period August 28, 2015 to December 31, 2015.

As of December 31, 2015, our availability under our $200.0 million Revolving Credit Facility was $179.0
million as we had $21.0 million outstanding in letters of credit.

The Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of
funded indebtedness to EBITDA, as defined in the Credit Agreement, and (ii) a consolidated fixed charge
coverage ratio of EBITDA plus rent expense (less cash taxes less capital expenditures) to scheduled debt
repayments plus interest expense plus rent expense, all as defined in the Credit Agreement. Each of these
covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. As
of December 31, 2015, our consolidated leverage ratio was 0.9 and our consolidated fixed charge coverage ratio
was 3.7 and we are in compliance with the Credit Agreement. The Credit Agreement also contains customary
covenants, including, but not limited to, restrictions on: incurrence of liens; incurrence of additional debt; sales of
assets and other fundamental corporate changes; investments; and declarations of dividends. These covenants
contain customary exclusions and baskets.

The Credit Facilities are guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The
Credit Agreement requires at all times that we (i) provide guaranties from wholly-owned subsidiaries that in the
aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-
owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70%
of consolidated adjusted EBITDA, subject to certain exceptions.

In connection with entering into the Credit Agreement, we entered into (i) a Security Agreement with the
Administrative Agent dated August 28, 2015 and (ii) a Pledge Agreement with the Administrative Agent dated as
of August 28, 2015 for the purpose of securing the payment of our obligations under the Credit Agreement.
Pursuant to the Security Agreement and the Pledge Agreement, as of the effective date of the Credit Agreement,
our obligations under the Credit Agreement are secured by (i) the grant of a first lien security interest in the non-
real estate assets of substantially all of our direct and indirect, wholly-owned subsidiaries (subject to exceptions)
and (ii) the pledge of the equity interests in (a) substantially all of our direct and indirect, wholly-owned
corporate, limited liability company and limited partnership subsidiaries and (b) those joint ventures which
constitute subsidiaries under the Credit Agreement (subject, in the case of the Pledge Agreement, to exceptions).

In connection with the entry into the Credit Agreement, on August 28, 2015, each of the Prior Credit Agreement
and the Second Lien Credit Agreement were terminated. The Company paid a call premium of $700,000
associated with the termination of the Second Lien Credit Agreement and the voluntary prepayment of the
amounts owed thereunder as of August 28, 2015, and expensed $2.5 million in deferred debt issuance costs

48

during the three-month period ended September 30, 2015. Also in connection with our entry into the Credit
Agreement, we recorded $2.4 million in deferred debt issuance costs as other assets in our consolidated balance
sheet.

Stock Repurchase Program

On September 9, 2015, we announced that our Board of Directors authorized a stock repurchase program, under
which we may repurchase up to $75 million of our outstanding common stock on or before September 6, 2016.

Under the terms of the program, we may repurchase shares from time to time in open market transactions, block
purchases or in private transactions in accordance with applicable federal securities laws and other legal
requirements. We may enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the
amount of the repurchases, if any, will be determined by management based on a number of factors, including
but not limited to share price, trading volume and general market conditions, as well as on working capital
requirements, general business conditions and other factors.

During 2015, pursuant to this program, we repurchased 116,859 shares of our common stock at a weighted
average price of $39.20 per share and a total cost of approximately $4.6 million. The repurchased shares are
classified as treasury shares.

Contractual Obligations and Medicare Liabilities

Our future contractual obligations and Medicare liabilities at December 31, 2015 were as follows (amounts in
millions):

Long-term obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest on long-term obligations (1) . . . . . . . . . . . . . . . . . . . . . . . . .
Operating leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Capital commitments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchase obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Uncertain tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total

$100.0
9.6
67.9
3.1
30.5
4.7

$215.8

Payments Due by Period

Less than
1 Year

1-3
Years

4-5
Years

After
5 Years

$ 5.0
2.4
23.5
3.1
9.3
0.6

$43.9

$80.0

$15.0
4.3
27.2
—
17.2
4.1 —

$—
2.9 —
5.5
11.7
—
—
4.0 —
—

$67.8

$98.6

$ 5.5

(1)

Interest on debt with variable rates was calculated using the current rate of that particular debt instrument at
December 31, 2015.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations is based upon our consolidated
financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). The preparation of these financial statements requires us to make estimates and judgments that
affect the reported amounts of assets, liabilities, revenue and expenses and related disclosures of contingent
assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue
recognition, collectability of accounts receivable, reserves related to insurance and litigation, goodwill, intangible
assets, income taxes and contingencies. We base these estimates on our historical experience and various other
assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources. Actual results experienced may vary materially and adversely from our estimates. To the extent there are
material differences between our estimates and the actual results, our future results of operations may be affected.

49

We believe the following critical accounting policies represent our most significant judgments and estimates used
in the preparation of our consolidated financial statements.

Revenue Recognition

We earn net service revenue through our home health and hospice care centers by providing a variety of services
almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode
of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions
established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day
episode of care as episodic-based revenue.

When we record our service revenue, we record it net of estimated revenue adjustments and contractual
adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We
believe, based on information currently available to us and based on our judgment, that changes to one or more
factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual
adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to
occur from period to period, will not materially impact our reported consolidated financial condition, results of
operations, cash flows or our future financial results.

Home Health Revenue Recognition

Medicare Revenue

Net service revenue is recorded under the Medicare prospective payment system (“PPS”) based on a 60-day
episode payment rate that is subject to adjustment based on certain variables. We make adjustments to Medicare
revenue on completed episodes to reflect differences between estimated and actual payment amounts, and our
discovered inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to
credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily
includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in
which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient
accounts receivable. In addition, management evaluates the potential for revenue adjustments and, when
appropriate, provides allowances based upon the best available information.

In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with
episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but
were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon
historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end
of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage
complete based on visits performed.

Non-Medicare Revenue

Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for
episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however,
these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at
amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded
for the difference between our standard rates and the contracted rates to be realized from patients, third parties
and others for services provided and are deducted from gross revenue to determine net service revenue and are
also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal
amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-
payment.

50

Hospice Revenue Recognition

Hospice Medicare Revenue

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated
payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we
deliver. We make adjustments to Medicare revenue for our discovered inability to obtain appropriate billing
documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of these
adjustments based on our historical experience, which primarily includes our historical collection rate on
Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as
a reduction to our outstanding patient accounts receivable.

Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for
each provider number, we monitor these caps and estimate amounts due back to Medicare if a cap has been
exceeded. We record these adjustments as a reduction to revenue and an increase in other accrued liabilities.
Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their estimated
cap liability by March 31st of the following year. As of December 31, 2015, we have settled our Medicare
hospice reimbursements for all fiscal years through October 31, 2012 and we have recorded $1.4 million for
estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31,
2013 through October 31, 2016. As of December 31, 2014, we had recorded $2.8 million for estimated amounts
due back to Medicare in other accrued liabilities for the Federal cap years ended October 31, 2013 through
October 31, 2015.

Hospice Non-Medicare Revenue

We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established
rates or estimated per visit rates, as applicable. Contractual adjustments are recorded for the difference between
our established rates and the amounts estimated to be realizable from patients, third parties and others for
services provided and are deducted from gross revenue to determine our net service revenue and patient accounts
receivable.

Patient Accounts Receivable – Allowance for Doubtful Accounts

Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other
third-party payors and patients. We fully reserve for accounts which are aged at 365 days or greater. We write off
accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be
uncollectible. We do not record an allowance for doubtful accounts for our Medicare patient accounts receivable,
which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above.

We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-
Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for
doubtful accounts to reduce the carrying amount to its estimated net realizable value. We estimate an allowance
for doubtful accounts based upon our assessment of historical and expected net collections, business and
economic conditions, trends in payment and an evaluation of collectability based upon the date that the service
was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately
provides for accounts that will not be collected due to credit risk.

Insurance

We are obligated for certain costs associated with our insurance programs, including employee health, workers’
compensation and professional liability. While we maintain various insurance programs to cover these risks, we
are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with
these costs in the period in which a claim is incurred, including with respect to both reported claims and claims

51

incurred but not reported, up to specified deductible limits. These costs have generally been estimated based on
historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by
us on a quarterly basis.

Goodwill and Other Intangible Assets

Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying
identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment
test. Tests are performed more frequently if events occur or circumstances change that would more likely than
not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include
but are not limited to, a significant adverse change in the business environment; regulatory environment or legal
factors; or a substantial decline in market capitalization of our stock. To determine whether goodwill is impaired,
we perform a two-step impairment test. In the first step of the test, the fair values of the reporting units are
compared to their aggregate carrying values, including goodwill. If the fair value of the reporting unit is greater
than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value
of the reporting unit is less than its carrying amount, we would proceed to step two of the test. In step two of the
test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the
fair value calculated in step one to all of the assets and liabilities of that reporting unit (including any recognized
and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the
fair value was reflective of the price paid to acquire the reporting unit. The implied fair value of goodwill is the
excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit’s assets and
liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the goodwill at the
analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is
less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that
variance.

We calculate the estimated fair value of our reporting units using discounted cash flows as well as a market
approach that compares our reporting units’ earnings and revenue multiples to those of comparable public
companies. To determine fair value we must make assumptions about a wide variety of internal and external
factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow
(including significant assumptions about operations, in particular expected organic growth rates, future Medicare
reimbursement rates, capital requirements and income taxes), long-term growth rates for determining terminal
value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to,
among other things, economic conditions, changes to our business model or changes in operating performance.
These factors increase the risk of differences between projected and actual performance that could impact future
estimates of fair value of all reporting units. Significant differences between these estimates and actual cash
flows could result in additional impairment in future periods.

Each of our operating segments described in the notes to our financial statements is considered to represent an
individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care
centers to constitute an individual business for which discrete financial information is available. However, since
these care centers have substantially similar operating and economic characteristics and resource allocation and
significant investment decisions concerning these businesses are centralized and the benefits broadly distributed,
we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied
this same aggregation principle to our hospice care centers and have also deemed them to be a single reporting
unit.

During 2015, we did not record any goodwill impairment charges and none of the goodwill associated with our
various reporting units were considered at risk of impairment as of October 31, 2015. Since the date of our last
annual goodwill impairment test, there have been no material developments, events, changes in operating
performance or other circumstances that would cause management to believe it is more likely than not that the
fair value of any of our reporting units would be less than its carrying amount.

52

licenses, acquired names, non-compete agreements and
Intangible assets consist of Certificates of Need,
reacquired franchise rights. We amortize non-compete agreements, acquired names that we do not intend to use
in the future and reacquired franchise rights on a straight-line basis over their estimated useful lives, which is
generally three years for non-compete agreements and up to five years for reacquired franchise rights and
acquired names.

Income Taxes

We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary
differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation
requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation
allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be
realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the
enactment date. As of December 31, 2015 and 2014 our net deferred tax assets were $125.2 million and $122.4
million, respectively.

Management regularly assesses the ability to realize deferred tax assets recorded in the Company’s entities based
upon the weight of available evidence, including such factors as the recent earnings history and expected future
taxable income. In the event future taxable income is below management’s estimates or is generated in tax
jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax
assets. This would result in an increase in our effective tax rate.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility and Term Loan
carry a floating interest rate which is tied to the Eurodollar rate (i.e. LIBOR) and the Prime Rate and therefore,
our consolidated statements of operations and our consolidated statements of cash flows will be exposed to
changes in interest rates. As of December 31, 2015, the total amount of outstanding debt subject to interest rate
fluctuations was $100.0 million. A 1.0% interest rate change would cause interest expense to change by
approximately $1.0 million annually.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

53

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders
Amedisys, Inc.:

We have audited the accompanying consolidated balance sheets of Amedisys, Inc. and subsidiaries as of
December 31, 2015 and 2014, and the related consolidated statements of operations, comprehensive (loss)
income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31,
2015. These consolidated financial statements are the responsibility of the Company’s management. Our
responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the
financial position of Amedisys, Inc. and subsidiaries as of December 31, 2015 and 2014, and the results of their
operations and their cash flows for each of the years in the three-year period ended December 31, 2015, in
conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), Amedisys Inc.’s internal control over financial reporting as of December 31, 2015, based on
criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO), and our report dated March 9, 2016, expressed an
unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

/s/ KPMG LLP

Baton Rouge, Louisiana
March 9, 2016

54

AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)

Current assets:

ASSETS

Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient accounts receivable, net of allowance for doubtful accounts of $16,526, and

$14,317 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property and equipment, net of accumulated depreciation of $141,793 and $146,438 . . . .
Goodwill
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible assets, net of accumulated amortization of $25,386 and $25,374 . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of December 31,
2014
2015

$ 27,502

$

8,032

125,010
8,110
14,641

175,263
42,695
261,663
44,047
125,245
36,172

99,325
8,493
19,708

135,558
137,455
205,587
33,193
124,788
33,161

Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$685,085

$669,742

Current liabilities:

LIABILITIES AND EQUITY

Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payroll and employee benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current portion of long-term obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current portion of deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term obligations, less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 25,682
72,546
71,965
5,000
—

175,193
95,000
4,456

$ 16,056
75,553
56,329
12,000
2,385

162,323
104,372
5,285

Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

274,649

271,980

Commitments and Contingencies – Note 10
Equity:

Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or

outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

—

Common stock, $0.001 par value, 60,000,000 shares authorized; 34,786,966, and

34,569,526 shares issued; and 33,607,282 and 33,594,572 shares outstanding . . . .
Additional paid-in capital
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treasury stock at cost 1,179,684, and 974,954 shares of common stock . . . . . . . . . . .
Accumulated other comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Amedisys, Inc. stockholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

35
504,290
(26,966)
15
(67,806)

409,568
868

35
481,762
(19,860)
15
(64,785)

397,167
595

Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

410,436

397,762

Total liabilities and equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$685,085

$669,742

The accompanying notes are an integral part of these consolidated financial statements.

55

AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of service, excluding depreciation and amortization . . . . . . . . . . . .
General and administrative expenses:

Salaries and benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Department of Justice settlement
Asset impairment charge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other income (expense):

Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity in earnings from equity method investments . . . . . . . . . . . . .
Miscellaneous, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total other income (expense), net . . . . . . . . . . . . . . . . . . . . . . .
(Loss) income before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax (expense) benefit
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Loss) income from continuing operations . . . . . . . . . . . . . . . . . . . . . . . .
Discontinued operations, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net (income) loss attributable to noncontrolling interests . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
Net (loss) income attributable to Amedisys, Inc.

Basic earnings per common share:

(Loss) income from continuing operations attributable to

Amedisys, Inc. common stockholders . . . . . . . . . . . . . . . . . . . . .
Discontinued operations, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . .
(Loss) income attributable to Amedisys, Inc. common

For the Years Ended December 31,

2015

2014

2013

$1,280,541
725,915

$1,204,554
691,061

$1,249,344
717,996

279,425
11,824
161,186
14,053
20,036
—
77,268
1,289,707
(9,166)

292,497
5,597
143,644
16,294
28,307
—
3,107
1,180,507
24,047

302,564
6,519
164,991
15,882
36,871
150,000
9,492
1,404,315
(154,971)

71
(10,783)
9,823
9,747
8,858
(308)
(2,004)
(2,312)
—
(2,312)
(709)
(3,021) $

94
(8,217)
2,991
2,061
(3,071)
20,976
(7,671)
13,305
(216)
13,089
(313)
12,776

54
(4,412)
1,520
4,334
1,496
(153,475)
58,773
(94,702)
(3,073)
(97,775)
1,597
$ (96,178)

(0.09) $

—

$

0.40
(0.01)

(2.98)
(0.10)

$

$

stockholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

(0.09) $

0.39

$

(3.08)

Weighted average shares outstanding . . . . . . . . . . . . . . . . . . . . . . . .

33,018

32,301

31,247

Diluted earnings per common share:

(Loss) income from continuing operations attributable to

Amedisys, Inc. common stockholders . . . . . . . . . . . . . . . . . . . . .
Discontinued operations, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . .
(Loss) income attributable to Amedisys, Inc. common

$

(0.09) $

—

$

0.40
(0.01)

(2.98)
(0.10)

stockholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

(0.09) $

0.39

$

(3.08)

Weighted average shares outstanding . . . . . . . . . . . . . . . . . . . . . . . .

33,018

32,823

31,247

Amounts attributable to Amedisys, Inc. common stockholders:

(Loss) income from continuing operations . . . . . . . . . . . . . . . . . . . .
Discontinued operations, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . .
Net (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

(3,021) $
—
(3,021) $

12,992
(216)
12,776

$ (93,105)
(3,073)
$ (96,178)

The accompanying notes are an integral part of these consolidated financial statements.

56

AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(Amounts in thousands)

Net (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(2,312) $13,089
—

—

$(97,775)

—

Comprehensive (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Comprehensive (income) loss attributable to non-controlling interests . . . . . . . . .

(2,312)
(709)

13,089
(313)

(97,775)
1,597

Comprehensive (loss) income attributable to Amedisys, Inc.

. . . . . . . . . . . . . . . .

$(3,021) $12,776

$(96,178)

For the Years Ended December 31,

2015

2014

2013

The accompanying notes are an integral part of these consolidated financial statements.

57

AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except common stock shares)

Common Stock

Total

Shares Amount

Additional
Paid-in
Capital

Treasury
Stock

Accumulated
Other
Comprehensive
Loss (Income)

Retained
Earnings

Noncontrolling
Interests

Balance, December 31, 2012 . . . . . . . . . $454,233 31,876,508
Issuance of stock – employee stock

32

450,792

(17,116)

15

18,617

1,893

purchase plan . . . . . . . . . . . . . . . . . . . .
Issuance of stock – 401(k) plan . . . . . . . .
Exercise of stock options . . . . . . . . . . . .
Issuance/(cancellation) of non-vested

stock . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash compensation . . . . . . . . . . . . .
Tax deficit from stock options exercised
and restricted stock vesting . . . . . . . . .
Surrendered shares . . . . . . . . . . . . . . . . .
Acquired noncontrolling interests . . . . . .
Noncontrolling interest distribution . . . .
Assets contributed to equity

3,181
8,581
261

—
6,519

(2,152)
(1,060)
145
(163)

investment . . . . . . . . . . . . . . . . . . . . . .
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . .

709
(97,775)

303,989 —
702,391

1
37,558 —

493,524 —
—

—

3,181
8,580
261

—
6,519

—
—
—

—
—

—
—
—
—

—
—

—
—
—
—

—
—

(2,152)
—
—
—

—
(1,060)
—
—

709
—

—
—

—
—
—

—
—

—
—
—
—

—
—

Balance, December 31, 2013 . . . . . . . . . 372,479 33,413,970
Issuance of stock – employee stock

33

467,890

(18,176)

15

purchase plan . . . . . . . . . . . . . . . . . . . .
Issuance of stock – 401(k) plan . . . . . . . .
Exercise of stock options . . . . . . . . . . . .
Issuance/(cancellation) of non-vested

stock . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash compensation . . . . . . . . . . . . .
Tax deficit from stock options exercised
and restricted stock vesting . . . . . . . . .
Surrendered shares . . . . . . . . . . . . . . . . .
Sale of noncontrolling interest
. . . . . . . .
Decrease in noncontrolling interest . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . .

2,433
7,062
564

—
5,597

(579)
(1,684)
(1,549)
350
13,089

176,796 —
430,919

1
28,229 —

519,612

1

—

—
—
—
—
—

—

—
—
—
—
—

2,433
7,061
564

(1)
5,597

(579)
—
(493)
(710)
—

—
—
—

—
—

—
(1,684)
—
—
—

—
—
—

—
—

—
—
—
—
—

—
—
—

—
—

—
—
—
—

—
(96,178)

(77,561)

—
—
—

—
—

—
—
—
—
12,776

Balance, December 31, 2014 . . . . . . . . . 397,762 34,569,526
Issuance of stock – employee stock

35

481,762

(19,860)

15

(64,785)

purchase plan . . . . . . . . . . . . . . . . . . . .
Issuance of stock – 401(k) plan . . . . . . . .
Exercise of stock options . . . . . . . . . . . .
Issuance/(cancellation) of non-vested

stock . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash compensation . . . . . . . . . . . . .
Tax benefit from stock options exercised
and restricted stock vesting . . . . . . . . .
Tax deficit from stock options exercised
and restricted stock vesting . . . . . . . . .
Surrendered shares . . . . . . . . . . . . . . . . .
Shares repurchased . . . . . . . . . . . . . . . . .
Noncontrolling interest distribution . . . .
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . .

2,204
6,032
399

—
11,824

2,073

(4)
(2,525)
(4,581)
(436)
(2,312)

79,323 —
184,412 —
15,380 —

(61,675) —
—

—

—

—
—
—
—
—

—

—
—
—
—
—

2,204
6,032
399

—
11,824

2,073

—
—
—

—
—

—

(4)

—
—
—
—

—
(2,525)
(4,581)
—
—

—
—
—

—
—

—

—
—
—
—
—

—
—
—

—
—

—

—
—
—
—
(3,021)

—
—
—

—
—

—
—
145
(163)

—
(1,597)

278

—
—
—

—
—

—
—
(1,056)
1,060
313

595

—
—
—

—
—

—

—
—
—
(436)
709

Balance, December 31, 2015 . . . . . . . . . $410,436 34,786,966

$ 35

$504,290 $(26,966)

$ 15

$(67,806)

$

868

The accompanying notes are an integral part of these consolidated financial statements.

58

AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)

Cash Flows from Operating Activities:
Net (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:

Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
401(k) employer match . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on disposal of property and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on sale of care centers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write off of deferred debt issuance costs/debt discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity in earnings from equity method investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of deferred debt issuance costs/debt discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Return on equity investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asset impairment charge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Changes in operating assets and liabilities, net of impact of acquisitions:

Patient accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Department of Justice settlement
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For the Years Ended December 31,

2015

2014

2013

$

(2,312)

$ 13,089

$ (97,775)

20,036
14,053
11,824
6,089
775
(184)
(677)
2,512
(9,823)
959
5,610
77,268

(36,493)
6,455
(3,523)
7,639
—
8,406
(829)

28,347
16,369
5,597
6,216
4,592
(2,967)
22,561
488
(2,991)
797
2,025
3,107

(5,290)
(6,269)
1,694
(3,168)
(150,000)
3,495
(3,226)

37,383
16,461
6,519
7,998
2,742
(1,752)
(57,095)
121
(1,520)
699
1,650
9,492

41,578
(501)
(1,596)
(9,876)
150,000
(6,104)
3,839

Net cash provided by (used in) operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

107,785

(65,534)

102,263

Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from the sale of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchases of deferred compensation plan assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchases of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchase of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from sale of investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisitions of businesses, net of cash acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from disposition of care centers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options and warrants . . . . . . . . . . . . . . . . . . .
Proceeds from issuance of stock to employee stock purchase plan . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax benefit from stock options exercised and restricted stock vesting . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-controlling interest distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from revolving line of credit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repayments of revolving line of credit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from issuance of long-term obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Debt issuance costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Principal payments of long-term obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchase of company stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,229
20,000
(19)
(21,429)
(3,485)
5,000
(69,130)
413

(67,421)

399
2,204
2,073
(436)
63,400
(78,400)
100,000
(2,553)
(103,000)
(4,581)

Net cash (used in) provided by financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(20,894)

Net increase (decrease) in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

19,470
8,032

Cash and cash equivalents at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 27,502

Supplemental Disclosures of Cash Flow Information:
Cash paid for interest

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

6,175

Cash paid for income taxes, net of refunds received . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (12,185)

11
3
(132)
(12,008)
(6,407)
—
—
4,233

128
1,809
(111)
(41,736)
(10,067)
—
(1,627)
5,146

(14,300)

(46,458)

564
2,433
—
—
241,800
(226,800)
68,250
(1,780)
(13,904)
—

70,563

(9,271)
17,303

261
3,181
57
(163)
25,500
(25,500)
—
(576)
(55,807)
—

(53,047)

2,758
14,545

8,032

$ 17,303

$

$

$

7,602

(1,766)

$

$

$

3,990

3,385

145

Supplemental Disclosures of Non-Cash Financing and Investing Activities:
(Sale) acquisition of non-controlling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

— $

(1,549)

The accompanying notes are an integral part of these consolidated financial statements.

59

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2015

1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL
STATEMENTS

Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (“Amedisys,” “we,” “us,” or “our”) are
a multi-state provider of home health and hospice services with approximately 80%, 82% and 84% of our
revenue derived from Medicare for 2015, 2014 and 2013, respectively. As of December 31, 2015, we owned and
operated 329 Medicare-certified home health care centers and 79 Medicare-certified hospice care centers in 34
states within the United States and the District of Columbia.

Use of Estimates

Our accounting and reporting policies conform with U.S. Generally Accepted Accounting Principles (“U.S.
GAAP”). In preparing the consolidated financial statements, we are required to make estimates and assumptions
that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results
could materially differ from those estimates.

Reclassifications and Comparability

Certain reclassifications have been made to prior periods’ financial statements in order to conform to the current
period’s presentation. Our exit activity during the last three years may affect the comparability of our operating
results. In accordance with applicable accounting guidance, the results of operations for the care centers closed,
sold or classified as held for sale during 2013 are presented in discontinued operations in our consolidated
financial statements. See Note 4 – Discontinued Operations and Assets Held for Sale for additional information
regarding our discontinued operations.

Principles of Consolidation

These consolidated financial statements include the accounts of Amedisys, Inc., and our wholly owned
subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying
consolidated financial statements, and business combinations accounted for as purchases have been included in
our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned
subsidiaries, we also have certain equity investments that are accounted for as set forth below.

Equity Investments

We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if
we have controlling interests in the entity, which is generally ownership in excess of 50%. During 2013, we
recorded a $1.3 million goodwill impairment charge related to an investment that was consolidated. Third party
equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated
financial statements.

We account for investments in entities in which we have the ability to exercise significant influence under the
equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which
we are the primary beneficiary. The book value of investments that we accounted for under the equity method of
accounting was $25.7 million as of December 31, 2015 and $18.8 million as of December 31, 2014. During 2015,
our investment in the Heritage Healthcare Innovation Fund, LP (“Heritage”), one of our equity method investees
with a carrying value of $19.9 million as of December 31, 2015, became a significant subsidiary. Summarized
financial information of Heritage as of and for the twelve-month period ended September 30, 2015, is as follows:
current assets of $3.5 million, total assets of $170.4 million, current and total liabilities of less than $0.1 million,
total investment income of $72.5 million, total expenses of $3.5 million and net increase in partners’ capital from
operations of $69.0 million. We record our share of the investment on a one quarter lag.

60

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

We account for investments in entities in which we have less than a 20% ownership interest under the cost
method of accounting if we do not have the ability to exercise significant influence over the investee. The
aggregate carrying amount of our cost method investment which was sold during 2015 was $5.0 million as of
December 31, 2014.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

We earn net service revenue through our home health and hospice care centers by providing a variety of services
almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode
of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions
established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day
episode of care as episodic-based revenue.

When we record our service revenue, we record it net of estimated revenue adjustments and contractual
adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We
believe, based on information currently available to us and based on our judgment, that changes to one or more
factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual
adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to
occur from period to period, will not materially impact our reported consolidated financial condition, results of
operations, cash flows or our future financial results.

Home Health Revenue Recognition

Medicare Revenue

Net service revenue is recorded under the Medicare prospective payment system (“PPS”) based on a 60-day
episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an
outlier payment if our patient’s care was unusually costly (capped at 10% of total reimbursement per provider
number); (b) a low utilization payment adjustment (“LUPA”) if the number of visits was fewer than five; (c) a
partial payment if our patient transferred to another provider or we received a patient from another provider
before completing the episode; (d) a payment adjustment based upon the level of therapy services required (with
various incremental adjustments made for additional visits, with larger payment increases associated with the
sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic
therapy assessments; (f) the number of episodes of care provided to a patient, regardless of whether the same
home health provider provided care for the entire series of episodes; (g) changes in the base episode payments
established by the Medicare Program; (h) adjustments to the base episode payments for case mix and geographic
wages; and (i) recoveries of overpayments. In addition, we make adjustments to Medicare revenue if we find that
we are unable to produce appropriate documentation of a face to face encounter between the patient and
physician.

We make adjustments to Medicare revenue to reflect differences between estimated and actual payment amounts,
our discovered inability to obtain appropriate billing documentation or authorizations and other reasons unrelated
to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily
includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in
which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient
accounts receivable. Therefore, we believe that our reported net service revenue and patient accounts receivable
will be the net amounts to be realized from Medicare for services rendered.

61

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with
episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but
were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon
historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end
of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage
complete based on visits performed. As of December 31, 2015 and 2014, the difference between the cash
received from Medicare for a request for anticipated payment (“RAP”) on episodes in progress and the associated
estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our
outstanding patient accounts receivable in our consolidated balance sheets for such periods.

Non-Medicare Revenue

Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for
episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however,
these rates can vary based upon the negotiated terms.

Non-episodic based Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at
amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded
for the difference between our standard rates and the contracted rates to be realized from patients, third parties
and others for services provided and are deducted from gross revenue to determine net service revenue and are
also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal
amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-
payment.

Hospice Revenue Recognition

Hospice Medicare Revenue

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated
payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we
deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care.
Routine care accounts for 99%, 98%, and 99% of our total net Medicare hospice service revenue for 2015, 2014
and 2013, respectively. We make adjustments to Medicare revenue for an inability to obtain appropriate billing
documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of
these adjustments based on our historical experience, which primarily includes our historical collection rate on
Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as
a reduction to our outstanding patient accounts receivable.

Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for
each provider number, we monitor these caps and estimate amounts due back to Medicare if we estimate a cap
has been exceeded. We record these adjustments as a reduction to revenue and an increase in other accrued
liabilities. Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their
estimated cap liability by March 31st of the following year. As of December 31, 2015, we have settled our
Medicare hospice reimbursements for all fiscal years through October 31, 2012 and we have recorded
$1.4 million for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years
ended October 31, 2013 through October 31, 2016. As of December 31, 2014, we had recorded $2.8 million for
estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31,
2013 through October 31, 2015.

62

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Hospice Non-Medicare Revenue

We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established
rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between
our established rates and the amounts estimated to be realizable from patients, third parties and others for
services provided and are deducted from gross revenue to determine our net service revenue and patient accounts
receivable.

Cash and Cash Equivalents

Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of
three months or less when purchased.

Patient Accounts Receivable

Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other
third-party payors and patients. As of December 31, 2015, there is one single payor, other than Medicare, that
accounts for more than 10% of our total outstanding patient receivables (approximately 10.5%). Thus, we believe
there are no other significant concentrations of receivables that would subject us to any significant credit risk in
the collection of our patient accounts receivable. We fully reserve for accounts which are aged at 365 days or
greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an
account to be uncollectible.

We believe the credit risk associated with our Medicare accounts, which represent 64% and 69% of our net
patient accounts receivable at December 31, 2015 and December 31, 2014, respectively, is limited due to our
historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor.
Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable,
which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above.
During 2015, 2014 and 2013, we recorded $6.1 million, $5.1 million and $9.0 million, respectively, in estimated
revenue adjustments to Medicare revenue.

We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-
Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for
doubtful accounts to reduce the carrying amount to its estimated net realizable value.

Medicare Home Health

For our home health patients, our pre-billing process includes verifying that we are eligible for payment from
Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure
that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP
for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for
any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the
episode is billed after the episode has been completed (“final billed”). The RAP received for that particular
episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days
from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will
be recouped by Medicare from any other claims in process for that particular provider number. The RAP and
final claim must then be resubmitted.

63

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Medicare Hospice

For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from
Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure
that our billings are accurate through the utilization of an electronic Medicare claim review. Once each patient
has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the
patient.

Non-Medicare Home Health and Hospice

For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient’s eligibility for
services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services
to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable
includes a detailed review of outstanding balances and special consideration to concentrations of receivables
from particular payors or groups of payors with similar characteristics that would subject us to any significant
credit risk. We estimate an allowance for doubtful accounts based upon our assessment of historical and expected
net collections, business and economic conditions, trends in payment and an evaluation of collectability based
upon the date that the service was provided. Based upon our best judgment, we believe the allowance for
doubtful accounts adequately provides for accounts that will not be collected due to credit risk.

Property and Equipment

Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful
lives of the assets. Additionally, we have internally developed computer software for our own use. Additions and
improvements (including interest costs for construction of qualifying long-lived assets) are capitalized.
Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or
disposed of and the related accumulated depreciation are eliminated from the property and related accumulated
depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.

We consider our reporting units to represent asset groups for purposes of testing long-lived assets for
impairment. We assess the impairment of a long-lived asset group whenever events or changes in circumstances
indicate that the asset’s carrying value may not be recoverable. Factors we consider important that could trigger
an impairment review include but are not limited to the following:

• A significant change in the extent or manner in which the long-lived asset group is being used.

• A significant change in the business climate that could affect the value of the long-lived asset group.

• A significant change in the market value of the assets included in the asset group.

If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying
value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the
carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is
recognized to the extent that the carrying value of the asset group exceeds its fair value.

We generally provide for depreciation over the following estimated useful service lives.

Building . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leasehold improvements . . . . . . . . . . . . . . . . . . . . . . . .
Equipment and furniture . . . . . . . . . . . . . . . . . . . . . . . . .
Vehicles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Computer software . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

39
Lesser of life or lease or expected useful life
3 to 7
5
3 to 7

Years

64

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

As of December 31, 2014, we had $75.8 million of internally developed software costs related to the
development of AMS3 Home Health and Hospice. Expanded beta testing to additional sites in February of 2015
demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the
system was not ready to be fully implemented and would require significant time and investment to redesign.
Therefore, during the three-month period ended March 31, 2015, we made the decision to discontinue AMS3 and
recorded a non-cash asset impairment charge of $75.2 million to write-off the software costs incurred related to
the development of AMS3 Home Health and Hospice.

During the three-month period ended September 30, 2015, we commenced an active program to sell our
corporate headquarters located in Baton Rouge, Louisiana. In accordance with U.S. GAAP, we classified this
asset as held for sale and reduced the carrying value of the asset to its estimated fair value less estimated costs to
sell the asset; no further depreciation expense for the asset was recorded. As a result, we recorded a non-cash
asset impairment charge of $2.1 million during the three-month period ended September 30, 2015. The asset was
sold during the three-month period ended December 31, 2015 and the Company now leases relevant office space.

The following table summarizes the balances related to our property and equipment for 2015 and 2014 (amounts
in millions):

Land . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Building and leasehold improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equipment and furniture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Computer software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ — $
2.3
89.6
92.6

3.2
25.3
97.2
158.2

As of December 31,

2015

2014

Less: accumulated depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

184.5
(141.8)

283.9
(146.4)

$ 42.7

$ 137.5

Depreciation expense for 2015, 2014 and 2013 was $20.0 million, $28.0 million and $35.2 million, respectively.

Goodwill and Other Intangible Assets

Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying
identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment
test. Tests are performed more frequently if events occur or circumstances change that would more likely than
not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include
but are not limited to, a significant adverse change in the business environment; regulatory environment or legal
factors; or a substantial decline in market capitalization of our stock. To determine whether goodwill is impaired,
we perform a two-step impairment test. In the first step of the test, the fair values of the reporting units are
compared to their aggregate carrying values, including goodwill. If the fair value of the reporting unit is greater
than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value
of the reporting unit is less than its carrying amount, we would proceed to step two of the test. In step two of the
test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the
fair value calculated in step one to all of the assets and liabilities of that reporting unit (including any recognized
and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the
fair value was reflective of the price paid to acquire the reporting unit. The implied fair value of goodwill is the
excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit’s assets and

65

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the goodwill at the
analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is
less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that
variance.

We calculate the estimated fair value of our reporting units using discounted cash flows as well as a market
approach that compares our reporting units’ earnings and revenue multiples to those of comparable public
companies. To determine fair value we must make assumptions about a wide variety of internal and external
factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow
(including significant assumptions about operations, in particular expected organic growth rates, future Medicare
reimbursement rates, capital requirements and income taxes), long-term growth rates for determining terminal
value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to,
among other things, economic conditions, changes to our business model or changes in operating performance.
These factors increase the risk of differences between projected and actual performance that could impact future
estimates of fair value of all reporting units. Significant differences between these estimates and actual cash
flows could result in additional impairment in future periods.

Each of our operating segments described in Note 15 – Segment Information is considered to represent an
individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care
centers to constitute an individual business for which discrete financial information is available. However, since
these care centers have substantially similar operating and economic characteristics and resource allocation and
significant investment decisions concerning these businesses are centralized and the benefits broadly distributed,
we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied
this same aggregation principle to our hospice care centers and have also deemed them to be a single reporting
unit.

During 2015, we did not record any goodwill impairment charges as a result of our annual impairment test and
none of the goodwill associated with our various reporting units was considered at risk of impairment as of
October 31, 2015. Since the date of our last annual goodwill impairment test, there have been no material
developments, events, changes in operating performance or other circumstances that would cause management to
believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying
amount.

licenses, acquired names, non-compete agreements and
Intangible assets consist of Certificates of Need,
reacquired franchise rights. We amortize non-compete agreements, acquired names that we do not intend to use
in the future and reacquired franchise rights on a straight-line basis over their estimated useful lives, which is
generally three years for non-compete agreements and up to five years for reacquired franchise rights and
acquired names.

Debt Issuance Costs

We amortize deferred debt issuance costs related to our long-term obligations over its term through interest
expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We
amortized $0.8 million, $0.7 million and $0.7 million in deferred debt issuance costs in 2015, 2014 and 2013,
respectively. As of December 31, 2015 and 2014, we had unamortized debt issuance costs of $3.4 million and
$2.8 million, respectively, recorded as other assets in our accompanying consolidated balance sheets. During the
third quarter of 2015, we expensed $1.0 million of unamortized debt issuance costs when we entered into our
new Credit Agreement. In connection with the new Credit Agreement we recorded an additional $2.4 million in

66

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

deferred debt issuance costs as other assets in our consolidated balance sheet. The unamortized debt issuance
costs of $3.4 million at December 31, 2015, will be amortized over a weighted-average amortization period of
4.6 years.

Fair Value of Financial Instruments

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and
the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:

• Level 1 – Quoted prices in active markets for identical assets and liabilities.

• Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted
prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that
are observable or can be corroborated by observable market data for substantially the full term of the
assets or liabilities.

• Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to

the fair value of the assets or liabilities.

Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For
our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts
payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts’ approximate
fair value. As of December 31, 2015, the carrying amount of our long-term debt is subject to a variable rate of
interest based on current market rates, and as such, the carrying value approximates fair value.

Income Taxes

We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary
differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation
requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation
allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be
realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the
enactment date. As of December 31, 2015 and 2014 our net deferred tax assets were $125.2 million and
$122.4 million, respectively.

Management regularly assesses the ability to realize deferred tax assets recorded in the Company’s entities based
upon the weight of available evidence, including such factors as the recent earnings history and expected future
taxable income. In the event future taxable income is below management’s estimates or is generated in tax
jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax
assets. This would result in an increase in our effective tax rate.

Share-Based Compensation

We record all share-based compensation as expense in the financial statements measured at the fair value of the
award. We recognize compensation cost on a straight-line basis over the requisite service period for each
separately vesting portion of the award. We reflect the excess tax benefits related to stock option exercises as
financing cash flows. Share-based compensation expense for 2015, 2014 and 2013 was $11.8 million,
$5.6 million and $6.5 million, respectively, and the total income tax benefit recognized for these expenses was
$4.7 million, $2.0 million and $2.5 million, respectively.

67

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Weighted-Average Shares Outstanding

Net (loss) income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock
method, is based on the weighted average number of shares outstanding during the period. The following table
sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding,
which are used to calculate our basic and diluted net earnings attributable to Amedisys, Inc. common
stockholders (amounts in thousands):

Weighted average number of shares outstanding – basic . . . . . . . . . . .
Effect of dilutive securities:

For the Years Ended December 31,

2015

2014

2013

33,018

32,301

31,247

Stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-vested stock and stock units . . . . . . . . . . . . . . . . . . . . . . . . .

—
—

1
521

—
—

Weighted average number of shares outstanding – diluted . . . . . . . . .

33,018

32,823

31,247

Anti-dilutive securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

922

106

688

Advertising Costs

We expense advertising costs as incurred. Advertising expense for 2015, 2014 and 2013 was $6.9 million,
$4.7 million and $3.9 million, respectively.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update
(“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize
the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to
customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the
FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,
to defer the effective date of the standard from January 1, 2017, to January 1, 2018, with an option that permits
companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions
reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not
permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The
Company is evaluating the effect that ASU 2014-09 and ASU 2015-14 will have on its consolidated financial
statements and related disclosures, its transition method and the effect of the standard on its ongoing financial
reporting.

In April 2015, the FASB issued ASU 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying
the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to
a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of
that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance
costs are not affected by the amendments in this ASU. ASU 2015-03 is effective for annual and interim periods
beginning on or after December 15, 2015. As of December 31, 2015, we have $3.4 million of unamortized debt
issuance costs that would be reclassified from a long-term asset to a reduction in the carrying amount of our debt.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740),
which simplifies the presentation of deferred income taxes. This ASU requires that deferred tax assets and

68

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

liabilities be classified as noncurrent in the balance sheet. The current requirement that deferred tax assets and
liabilities be offset and presented as a single amount was not affected by the amendments in ASU 2015-17. The
ASU is effective for annual and interim periods beginning on or after December 15, 2016. Early adoption is
permitted. We have chosen to early adopt this ASU on a prospective basis. Adoption of this ASU resulted in a
reclassification of our net current deferred tax liability to the net noncurrent deferred tax asset in our consolidated
balance sheet as of December 31, 2015. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which will require lessees to recognize a
lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement
date. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early
adoption is permitted. The standard requires a modified retrospective transition method which requires
application of the new guidance for all periods presented. The Company is evaluating the effect
that
ASU 2016-02 will have on its consolidated financial statements and related disclosures and the effect of the
standard on its ongoing financial reporting.

3. ACQUISITIONS

We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by
expanding our service base and enhancing our position in certain geographic areas as a leading provider of home
health and hospice services. The purchase price paid for acquisitions is negotiated through arm’s length
transactions, with consideration based on our analysis of, among other things, comparable acquisitions and
expected cash flows for each transaction. Acquisitions are accounted for as purchases and are included in our
consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is
recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the
expected contributions of the acquisitions to our overall corporate strategy.

On July 24, 2015, we acquired one hospice care center in Tennessee for a total purchase price of $5.8 million.
The purchase price was paid with cash on hand on the date of the transaction. In connection with the acquisition,
we recorded goodwill ($5.5 million) and other intangibles ($0.3 million).

On October 2, 2015, we acquired the regulatory assets of home health care center in Georgia for a total purchase
price of $0.3 million. The purchase price was paid with cash on hand on the date of the transaction. In connection
with the acquisition, we recorded goodwill ($0.3 million).

On December 31, 2015, we acquired Infinity HomeCare (“Infinity”) for a total purchase price of $63 million, net
of cash acquired (subject to certain adjustments), of which $3.2 million was placed in escrow for indemnification
purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of
the transaction. Infinity owned and operated 15 home health care centers servicing the state of Florida. In
connection with the acquisition, we recorded goodwill ($50.2 million), other intangibles ($10.9 million) and
other assets and liabilities, net ($1.9 million). Approximately $47.6 million of the $50.2 recorded as goodwill is
expected to be deductible for income tax purposes over approximately 15 years.

69

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

The following table contains unaudited pro forma condensed consolidated statement of operations information
assuming that the Infinity transaction closed on January 1, 2014, for the years ended December 31, 2015 and
2014 (amounts in millions, except per share data):

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Basic earnings per share . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diluted earnings per share . . . . . . . . . . . . . . . . . . . . . . . . . .

2015

2014

$1,327.3
(7.9)
0.2
0.01
0.01

$
$

$1,247.6
21.0
10.9
0.34
0.33

$
$

The pro forma information presented above includes adjustments for (i) interest expense, (ii) amortization of
identifiable intangible assets and (iii) income tax provision using the Company’s statutory tax rate. This
pro forma information is presented for illustrative purposes only and may not be indicative of the results of
operations that would have actually occurred. In addition, future results may vary significantly from the results
reflected in the pro forma information.

4. DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE

As part of our ongoing management of our portfolio of care centers, we review each care center’s current
financial performance, market penetration, forecasted market growth and the impact of proposed CMS payment
revisions. If the review indicates a care center should be closed, we first determine whether we can consolidate
the care center with a care center servicing the same market. If a consolidation is not viable, we evaluate whether
we have the opportunity to sell the care center or must close the care center. As a result of our review, we
consolidated 41 home health care centers and five hospice care centers with care centers servicing the same
markets, sold 19 home health care centers and one hospice care center and closed 10 home health care centers
during 2013. We had previously classified 28 of these care centers as held for sale during 2013 and three care
centers remained classified as held for sale at December 31, 2013. During 2014, we sold assets associated with
two of these care centers and consolidated one of these care centers with a care center servicing the same market.
There were no care centers classified as held for sale as of December 31, 2014.

As we exited certain geographical areas and in accordance with applicable accounting guidance, the care centers
which were closed, sold or classified as held for sale in 2013 (32 home health care centers and one hospice care
center) are presented as discontinued operations in our consolidated financial statements. The care centers
consolidated with care centers servicing the same markets are presented in continuing operations as we expect
continuing cash flows from these markets. For additional information on the care centers consolidated with care
centers servicing the same markets and the care centers sold, see Note 13 – Exit Activities and Restructuring
Activities.

Net revenues and operating results for the periods presented for those care centers classified as discontinued
operations are as follows (dollars in millions):

Net revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Loss) before income taxes . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax benefit

Discontinued operations, net of tax . . . . . . . . . . . . . . . . . .

70

For the Years Ended December 31,

2015

$—
—
—

$—

2014

$(0.3)
(0.3)
0.1

$(0.2)

2013

$31.2
(5.3)
2.2

$ (3.1)

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET

During 2015, we did not record any goodwill impairment charges as a result of our annual impairment test and
none of the goodwill associated with our various reporting units were considered at risk of impairment as of
October 31, 2015. Since the date of our last annual goodwill impairment test, there have been no material
developments, events, changes in operating performance or other circumstances that would cause management to
believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying
amount.

During the fiscal year 2014, we recognized a non-cash other intangible impairment charge of $0.9 million during
step one of our 2014 annual goodwill impairment test. In addition, we recorded non-cash impairment charges of
$2.2 million related to those care centers that were closed or consolidated during 2014 as discussed in Note 13 –
Exit and Restructuring Activities.

During the fiscal year 2013, we recognized the following: a non-cash goodwill impairment charge of $1.3 million
and a non-cash other intangibles impairment charge of $8.2 million. The non-cash goodwill impairment charge
related to an investment that was consolidated as discussed in Note 1- Nature of Operations, Consolidation and
Presentation of Financial Statements. Included in the non-cash other intangibles impairment charge discussed
above is $4.6 million recognized during step one of our 2013 annual goodwill impairment test and $3.6 million
related to intangibles associated with those care centers that were closed or consolidated during 2013 as
discussed in Note 13 – Exit and Restructuring Activities.

The following table summarizes the activity related to our goodwill for the 2015, 2014 and 2013 (amounts in
millions):

Balances at December 31, 2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-off (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment

Balances at December 31, 2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-off (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balances at December 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Goodwill

Home Health Hospice

Total

$18.2
0.1
(0.4)
(1.3)

16.6
(0.1)

16.5
50.6

$191.4
0.9
—
—

192.3
(3.2)

189.1
5.5

$209.6
1.0
(0.4)
(1.3)

208.9
(3.3)

205.6
56.1

Balances at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$67.1

$194.6

$261.7

(1) Write-off of goodwill related to the sale of care centers as discussed in Note 13 – Exit and Restructuring

Activities.

71

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

The following table summarizes the activity related to our other intangible assets, net for 2015, 2014 and 2013
(amounts in millions):

Other Intangible Assets, Net

Certificates of
Need and
Licenses

Acquired
Names of
Business

Non-Compete
Agreements &
Reacquired
Franchise
Rights

Balances at December 31, 2012 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-off (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balances at December 31, 2013 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-off (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balances at December 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-off (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$33.7
0.6
(1.1)
(7.8)
—

25.4
(0.2)
(2.1)
—

23.1
1.1
(0.3)
—

$11.5
—
—
(0.4)
—

11.1
—
(1.0)
—

10.1
4.1
—
—

$ 1.8
—
—
—
(1.6)

0.2
—
—
(0.2)

—
5.9
—
—

Total

$47.0
0.6
(1.1)
(8.2)
(1.6)

36.7
(0.2)
(3.1)
(0.2)

33.2
11.1
(0.3)
—

Balances at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . .

$23.9

$14.2

$ 5.9

$44.0

(1) Write-off of intangible assets related to the sale of care centers as discussed in Note 13 – Exit and

Restructuring Activities.

(2) The weighted average amortization period of our non-compete agreements is 3.0 years.

See Note 3 – Acquisitions for further details on additions to goodwill and other intangible assets, net.

The estimated aggregate amortization expense for each of the five succeeding years is as follows (amounts in
millions):

2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 2.0
2.0
1.9
—
—

$ 5.9

72

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

6. DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS

Additional information regarding certain balance sheet accounts is presented below (amounts in millions):

Other current assets:

Payroll tax escrow . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Medicare withholds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Due from joint ventures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other assets:

Workers’ compensation deposits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Health insurance deposits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other miscellaneous deposits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred financing fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Accrued expenses:

Health insurance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Workers’ compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Legal and other settlements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lease liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Charity care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Estimated Medicare cap liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hospice cost of revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OIG self-disclosure accrual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other long-term obligations:

Reserve for uncertain tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred compensation plan liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of December 31,

2015

2014

$ 6.2
—
0.5
1.8
6.1

$14.6

$ 0.3
1.2
1.5
3.4
25.7
4.1

$36.2

$11.7
23.9
10.5
0.6
0.7
1.4
6.8
4.7
5.1
6.6

$72.0

$ 0.7
2.8
0.9

$ 4.4

$ 1.0
0.1
15.0
1.4
2.2

$19.7

$ 0.3
1.2
0.7
2.8
23.8
4.4

$33.2

$11.2
19.8
5.2
0.8
0.7
2.8
5.7
—
4.3
5.8

$56.3

$ 0.5
3.3
1.5

$ 5.3

73

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

7. LONG-TERM OBLIGATIONS

Long-term debt consisted of the following for the periods indicated (amounts in millions):

$100.0 million Term Loan; principal payments plus accrued interest payable quarterly;
interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.42% at December 31, 2015); due August 28, 2020 . . . . . . . . . . .

$60.0 million Term Loan; $3.0 million principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus
the applicable percentage; due October 26, 2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$120.0 million Revolving Credit Facility; interest only quarterly payments; interest rate at
ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage;
due October 26, 2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$70.0 million Second Lien Loan; interest only quarterly payments; interest rate at ABR

Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due
July 28, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Discount on Second Lien Loan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Current portion of long-term obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of December 31,

2015

2014

$100.0

$ —

—

—

—
—

100.0
(5.0)

33.0

15.0

70.0
(1.6)

116.4
(12.0)

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 95.0

$104.4

Maturities of debt as of December 31, 2015 are as follows (amounts in millions):

2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Long-term
obligations

$

5.0
5.0
10.0
10.0
70.0

$100.0

Credit Agreement

On August 28, 2015, we entered into a Credit Agreement that provides for senior secured facilities in an initial
aggregate principal amount of up to $300 million (the “Credit Facilities”).

The Credit Facilities are comprised of (a) a term loan facility in an initial aggregate principal amount of
$100 million (the “Term Loan”); and (b) a revolving credit facility in an initial aggregate principal amount of up
to $200 million (the “Revolving Credit Facility”). The Revolving Credit Facility provides for and includes within
its $200 million limit a $25 million swingline facility and commitments for up to $50 million in letters of credit.
Upon lender approval, we may increase the aggregate loan amount under the Credit Facilities by a maximum
amount of $150 million.

The net proceeds of the Term Loan and existing cash on hand were used to pay off (i) our existing term loan
under our prior Credit Agreement, dated as of October 22, 2012, as amended (the “Prior Credit Agreement”) with

74

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

a principal balance of $27 million and (ii) our existing term loan under our prior Second Lien Credit Agreement
dated July 28, 2014 (the “Second Lien Credit Agreement”), with a principal balance of $70 million. The final
maturity of the Term Loan is August 28, 2020. The Term Loan will amortize beginning on March 31, 2016 in 18
quarterly installments (eight quarterly installments of $1.25 million followed by eight quarterly installments of
$2.5 million, followed by two quarterly installments of $3.1 million, subject to adjustment for prepayments), with
the remaining balance due upon maturity.

The Revolving Credit Facility may be used to provide ongoing working capital and for general corporate
purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit
Agreement. The final maturity of the Revolving Credit Facility is August 28, 2020 and will be payable in full at
that time.

The interest rate in connection with the Credit Facilities shall be selected from the following by us: (i) the Base
Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The “Base Rate” means a
fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime
rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate for an interest period of one
month plus 1% per annum. The “Eurodollar Rate” means the rate at which Eurodollar deposits in the London
interbank market for an interest period of one, two, three or six months (as selected by us) are quoted. The
“Applicable Rate” is based on the consolidated leverage ratio and is presented in the table below. As of
December 31, 2015, the Applicable Rate is 1.00% per annum for Base Rate Loans and 2.00% per annum for
Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the
Credit Facilities, as presented in the table below.

Consolidated Leverage Ratio
≥ 2.75 to 1.0
< 2.75 to 1.0 but ≥ 1.75 to 1.0
< 1.75 to 1.0 but ≥ 0.75 to 1.0
< 0.75 to 1.0

Margin for ABR
Loans

Margin for Eurodollar
Loans

Commitment
Fee

Letter of
Credit Fee

2.00%
1.50%
1.00%
0.50%

3.00%
2.50%
2.00%
1.50%

0.40%
0.35%
0.30%
0.25%

3.00%
2.50%
2.00%
1.50%

Our weighted average interest rate for our $100.0 million Term Loan, under our Credit Agreement, was 2.7% for
the period August 28, 2015 to December 31, 2015.

As of December 31, 2015, our availability under our $200.0 million Revolving Credit Facility was
$179.0 million as we had $21.0 million outstanding in letters of credit.

The Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of
funded indebtedness to EBITDA, as defined in the Credit Agreement, and (ii) a consolidated fixed charge
coverage ratio of EBITDA plus rent expense (less cash taxes less capital expenditures) to scheduled debt
repayments plus interest expense plus rent expense, all as defined in the Credit Agreement. Each of these
covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. As
of December 31, 2015, our consolidated leverage ratio was 0.9 and our consolidated fixed charge coverage ratio
was 3.7 and we are in compliance with the Credit Agreement. The Credit Agreement also contains customary
covenants, including, but not limited to, restrictions on: incurrence of liens; incurrence of additional debt; sales of
assets and other fundamental corporate changes; investments; and declarations of dividends. These covenants
contain customary exclusions and baskets.

The Credit Facilities are guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The
Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the

75

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-
owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70%
of consolidated adjusted EBITDA, subject to certain exceptions.

In connection with entering into the Credit Agreement, we entered into (i) a Security Agreement with the
Administrative Agent dated August 28, 2015 and (ii) a Pledge Agreement with the Administrative Agent dated as
of August 28, 2015 for the purpose of securing the payment of our obligations under the Credit Agreement.
Pursuant to the Security Agreement and the Pledge Agreement, as of the effective date of the Credit Agreement,
our obligations under the Credit Agreement are secured by (i) the grant of a first lien security interest in the non-
real estate assets of substantially all of our direct and indirect, wholly-owned subsidiaries (subject to exceptions)
and (ii) the pledge of the equity interests in (a) substantially all of our direct and indirect, wholly-owned
corporate, limited liability company and limited partnership subsidiaries and (b) those joint ventures which
constitute subsidiaries under the Credit Agreement (subject, in the case of the Pledge Agreement, to exceptions).

In connection with our entry into the Credit Agreement, on August 28, 2015, each of the Prior Credit Agreement
and the Second Lien Credit Agreement were terminated. The Company paid a call premium of $700,000
associated with the termination of the Second Lien Credit Agreement and the voluntary prepayment of the
amounts owed thereunder as of August 28, 2015, and expensed $2.5 million in deferred debt issuance costs
during the three-month period ended September 30, 2015. Also in connection with our entry into the Credit
Agreement, we recorded $2.4 million in deferred debt issuance costs as other assets in our consolidated balance
sheet.

8. INCOME TAXES

Income taxes attributable to continuing operations consist of the following (amounts in millions):

Current income tax expense/(benefit):

Federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
State and local

Deferred income tax expense/(benefit):

Federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
State and local
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For the Years Ended December 31,

2015

2014

2013

$ 2.2
0.5

2.7

(0.5)
(0.1)
(0.1)

(0.7)

$(13.9)
(1.1)

(15.0)

$ (2.0)
0.3

(1.7)

21.0
1.6
0.1

22.7

(43.2)
(13.9)
—

(57.1)

Income tax expense/(benefit) from continuing operations . . . . . . . .

$ 2.0

$ 7.7

$(58.8)

76

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Total income tax expense for the years ended December 31, 2015, 2014 and 2013 was allocated as follows
(amounts in millions):

Income from continuing operations . . . . . . . . . . . . . . . . . . . . . . . . . .
Income from discontinued operations . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stockholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For the Years Ended December 31,

2015

$ 2.0
—
0.2
(0.1)
(2.1)

$—

2014

$ 7.7
(0.1)
(0.1)
—
0.6

$ 8.1

2013

$(58.8)
(2.2)
0.1
—
2.2

$(58.7)

A reconciliation of significant differences between the reported amount of income tax expense and the expected
amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 35
percent to income before taxes from continuing operations is as follows:

Income tax expense/(benefit) at U.S. federal statutory rate . . . . .
State and local income taxes, net of federal income tax

benefit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Uncertain tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other items, net (2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For the Years Ended December 31,

2015 (1)

2014

2013

35.0 %

35.0 %

(35.0)%

(7.1)
79.1
136.0
(230.3)
(663.3)

5.8
1.5
(8.4)
0.6
2.1

(4.4)
—
(1.2)
2.3
—

Income tax expense/(benefit) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(650.6)%

36.6 %

(38.3)%

(1) The information provided for the year ended December 31, 2015 does not provide a meaningful
reconciliation of the effective tax rate or comparable to other periods. The effective tax rate for the year is
influenced by the relationship of the amount of “effective tax rate drivers” (i.e. non-deductible expenses,
non-taxable income, tax credits, valuation allowance, uncertain tax positions, etc.) to income or loss before
taxes. A significant asset impairment was recorded in the first quarter, resulting in a scenario where the
company’s loss before tax for the year was near zero. Consequently, for 2015, the relationship between the
“effective tax rate drivers” and loss before taxes is distorted.
Includes various items such as, non-deductible expenses, non-taxable income, return-to-accrual adjustments,
and foreign tax rate differential.

(2)

As of December 31, 2015 and 2014, the Company had income taxes receivable of $0.5 million and $15.0 million,
respectively, included in other current assets. The $15.0 million receivable at December 31, 2014, primarily
includes a U.S. federal tax receivable of $14.3 million from the carry back of U.S. federal net operating losses to
December 31, 2012 and 2011. During 2015, the Company received the $14.3 million U.S. federal refund from
the carry back claims.

77

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Deferred tax assets (liabilities) consist of the following components (amounts in millions):

As of December 31,

2015

2014

Deferred tax assets:
Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued bonus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Workers’ compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net operating loss carryforwards (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax credit carryforwards (2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

6.4
—
4.0
9.8
72.2
5.0
48.5
4.7
5.1

Gross deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

155.7
(0.3)

Net deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

155.4

Deferred tax (liabilities):
Property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gross deferred tax (liabilities) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(9.5)
(18.5)
(2.2)

(30.2)

$

5.6
1.2
—
8.1
89.2
3.3
59.3
2.6
1.8

171.1
(0.6)

170.5

(31.3)
(16.8)
—

(48.1)

Net deferred tax assets (liabilities) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$125.2

$122.4

(1) The net operating loss (“NOL”) carry forwards in the income tax returns include unrecognized tax benefits
resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the NOL carry
forwards, as of December 31, 2015 and 2014, are presented net of unrecognized tax benefits of $3.1 million.
(2) The tax credit carry forwards in the income tax returns include unrecognized tax benefits resulting from
uncertain tax positions. Accordingly, the deferred tax assets recognized for the tax credit carry forwards, as
of December 31, 2015 and 2014, are presented net of unrecognized tax benefits of $0.7 million and $0.3
million, respectively.

Classification in the consolidated balance sheet (amounts in millions):

Current deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Noncurrent deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of December 31,

2015(1)

—
125.2

2014

(2.4)
124.8

Net deferred tax assets (liabilities) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$125.2

$122.4

(1)

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (Topic
740), which required that deferred tax liabilities and assets be classified as noncurrent. Since early adoption
is permitted, the Company has decided to apply ASU 2015-17 to the current period, resulting in a
classification of all December 31, 2015 deferred tax assets and liabilities as noncurrent. The Company has
not, however, retrospectively adjusted the prior period balances.

78

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

As of December 31, 2015, we have U.S. NOL carry forwards of $116.3 million that are available to reduce future
taxable income and begins to expire in 2034. In addition, we have research and development tax credits,
employment tax credits, and alternative minimum tax credits of $1.9 million, $0.4 million and $1.0 million,
respectively, available to reduce future U.S. federal income taxes. The research and development tax credits and
tax credits begin to expire in 2032, and the alternative minimum tax credits are available
employment
indefinitely.

As of December 31, 2015, we have state NOL carry forwards of $254.3 million that are available to reduce future
taxable income. In addition, we have $3.1 million of various state tax credits available to reduce future taxable
income. The state NOL and tax credit carry forwards begin to expire at various times.

The valuation allowance for deferred tax assets as of December 31, 2015 and 2014 was $0.3 million and $0.6
million, respectively. The net change in the total valuation allowance for the year ended December 31, 2015 and
December 31, 2014 was a decrease of $0.3 million and an increase of $0.3 million, respectively. The valuation
allowance during 2015 and 2014 was primarily related to certain state NOL and state tax credit carry forwards.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that
some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income in those jurisdictions during the periods in which those
temporary differences become deductible. Management considers the scheduled reversal of deferred tax
liabilities (including the impact of available carry back and carry forward periods), projected future taxable
income, and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the
Company will need to generate future taxable income before the expiration of the carry forwards governed by the
tax code. Based on the current level of pretax earnings (excluding the significant asset impairment recorded
during the three-month period ended March 31, 2015) and estimates of future taxable income, the Company will
generate the minimum amount of future taxable income to support the realization of the deferred tax assets. As a
result, management believes that it is more likely than not that we will realize the benefits of these deferred tax
assets, net of the existing valuation allowances at December 31, 2015. The amount of the deferred tax asset
considered realizable, however, could be reduced in the near term if estimates of future taxable income during
the carry forward period are reduced.

Uncertain Tax Positions

We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in
millions):

Balance at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additions for tax positions related to current year . . . . . . . . . . . .
Additions for tax positions related to prior year . . . . . . . . . . . . . .
Reductions for tax positions related to prior years . . . . . . . . . . . .
Lapse of statute of limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Settlements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balance at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For the Years Ended December 31,

2015

$ 4.0
—
1.0
—
(0.3)
—

$ 4.7

2014

$ 3.9
0.3
—
—
(0.2)
—

$ 4.0

79

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

As of December 31, 2015, there are $0.2 million, $0.7 million and $3.8 million of unrecognized tax benefits
recorded in accrued expenses, other long-term obligations and deferred income taxes, respectively, within the
consolidated balance sheet.

Included in the balance of unrecognized tax benefits at December 31, 2015 is $4.7 million of tax benefits that, if
recognized in future periods, would impact our effective tax rate.

During the years ended December 31, 2015 and 2014, we recognized interest and penalties of $0.2 million and
$0.1 million, respectively, as components of penalties or interest expense in connection with our reserve for
uncertain tax positions. Interest and penalties, related to uncertain tax positions, included in the consolidated
balance sheet at December 31, 2015 and 2014 were less than $0.2 million for each year.

We are subject to income taxes in the U.S. and in many of the 50 individual states, with significant operations in
Louisiana, Alabama, Georgia, and Tennessee. We are open to examination in the U.S. and in various individual
states for tax years ended December 31, 2012 through December 31, 2015. We are also open to examination in
various states for the years ended 2001 – 2015 resulting from net operating losses generated and available for
carry forward from those years.

We believe that it is reasonably possible that decreases of up to $0.6 million in unrecognized tax benefits, each of
which are individually insignificant, may be recognized by the end of December 31, 2016 as a result of an
anticipated settlement and lapse of the statute of limitations.

9. CAPITAL STOCK AND SHARE-BASED COMPENSATION

We are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par
value and 5,000,000 shares of preferred stock, $0.001 par value. As of December 31, 2015, there were
34,786,966 and 33,607,282 shares of common stock issued and outstanding, respectively, and no shares of
preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms,
conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred
stock.

Share-Based Awards

Our 2008 Omnibus Incentive Compensation Plan (the “Plan”) authorizes the grant of various types of equity-
based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible
participants, which include all of our employees and all employees of our 50% or more owned subsidiaries, our
non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued
employment (or, for our non-employee directors, continued service on the Board of Directors) and/or
achievement of certain pre-determined performance goals. We refer to stock awards subject to service-based
vesting conditions as “non-vested stock” and restricted stock units subject to service-based and performance-
based or market-based vesting conditions as “non-vested stock units.” The Plan is administered by the
Compensation Committee of our Board of Directors, which determines, within the provisions of the Plan, those
eligible employees to whom, and the times at which, awards shall be granted. The Compensation Committee, in
its discretion, may delegate its authority and duties under the Plan to specified officers; however, only the
Compensation Committee may approve the terms of awards to our executive officers.

Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately
5.5 million shares of common stock, and we had approximately 1.3 million shares available at December 31,
2015. The price per share for stock options shall be of no less than the greater of (a) 100% of the fair value of a

80

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

share of common stock on the date the option is granted or (b) the aggregate par value of the shares of our
common stock on the date the option is granted. If a stock option is granted to any owner of 10% or more of our
total combined voting power of us and our subsidiaries, the price is to be at least 110% of the fair value of a share
of our common stock on the date the award is granted. Each equity-based award vests ratably over a 12 month-
to-six year period, with the exception of those issued under contractual arrangements that specify otherwise, that
may be exercised during a period as determined by our Compensation Committee or as otherwise approved by
our Compensation Committee. The contractual terms of stock options exercised shall not exceed ten years from
the date such option is granted.

Employee Stock Purchase Plan (“ESPP”)

We have a plan whereby our eligible employees may purchase our common stock at 85% of the market price at
the time of purchase. On June 7, 2012, our stockholders ratified an amendment adopted by our Board of
Directors to increase the total number of shares of our common stock authorized for the issuance under our ESPP
from 2,500,000 shares to 4,500,000 shares, and as of December 31, 2015, there were 1,522,288 shares available
for future issuance. The following is a detail of the purchases that were made or pending Board of Director
approval under the plan:

Employee Stock Purchase Plan Period

2013 and Prior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
January 1, 2014 to March 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
April 1, 2014 to June 30, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
July 1, 2014 to September 30, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
October 1, 2014 to December 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
January 1, 2015 to March 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
April 1, 2015 to June 30, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
July 1, 2015 to September 30, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
October 1, 2015 to December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Shares Issued

Price

2,755,337
52,718
38,679
32,573
20,221
24,368
15,750
18,984
19,082

2,977,712

$13.67
12.66
14.23
17.14
24.95
22.76
33.77
32.27
33.42

ESPP expense included in general and administrative expense in our accompanying consolidated statements of
operations was $0.4 million, $0.4 million and $0.5 million for 2015, 2014 and 2013, respectively.

Stock Options

We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were no
stock options granted during 2013; there were 590,647 and 250,000 options granted during 2015 and 2014,
respectively. Stock option compensation expense included in general and administrative expense in our
accompanying consolidated statements of operations was $3.8 million and $0.1 million for 2015 and 2014,
respectively.

The fair value of the 2015 awards were estimated using the following assumptions:

Risk Free Rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected Volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected Term . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted Average Fair Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1.46% – 1.93%
53.87% – 58.05%
5.50 – 6.76 years
$13.45 – $23.21

81

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

We used the simplified method to estimate the expected term for the stock options granted during 2015.

The following table presents our stock option activity for 2015:

Outstanding options at January 1, 2015 . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled, forfeited or expired . . . . . . . . . . . . . . . . . . . . . . .

Number of
Shares

277,536
590,647
(15,380)
(14,309)

Outstanding options at December 31, 2015 . . . . . . . . . . . . . . . . .

838,494

Exercisable options at December 31, 2015 . . . . . . . . . . . . . . . . .

62,500

Weighted
Average Exercise
Price

Weighted
Average Contractual
Life (Years)

$26.40
31.73
25.93
25.16

$30.18

$26.65

8.99

9.31

8.96

The aggregate intrinsic value of our outstanding options and exercisable options at December 31, 2015 was
$8.1 million and $0.8 million, respectively. Total
intrinsic value of options exercised was $0.2 million,
$0.1 million and $0.2 million for 2015, 2014 and 2013, respectively.

The following table presents our non-vested stock option award activity for 2015:

Non-vested stock options at January 1, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Number of
Shares

250,000
590,647
(62,500)
(2,153)

Non-vested stock options at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . .

775,994

Weighted Average
Grant Date Fair
Value

$26.65
31.73
26.65
43.63

$30.47

At December 31, 2015, there was $9.8 million of unrecognized compensation cost related to stock options that
we expect to be recognized over a weighted-average period of 2.6 years.

Non-Vested Stock

We issue shares of non-vested stock with vesting terms ranging from one to six years. The compensation expense
is determined based on the market price of our common stock at the date of grant applied to the total number of
shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and
administrative expenses in our accompanying consolidated statements of operations was $5.0 million,
$4.6 million and $5.2 million for 2015, 2014 and 2013, respectively.

82

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

The following table presents our non-vested stock award activity for 2015:

Number of Shares

Weighted Average
Grant Date Fair
Value

Non-vested stock at January 1, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled, forfeited or expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

917,959
93,256
(355,396)
(154,931)

Non-vested stock at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

500,888

$15.17
28.48
14.69
14.34

$18.24

The weighted average grant date fair value of non-vested stock granted was $28.48, $16.38 and $10.91 in 2015,
2014, and 2013, respectively.

At December 31, 2015, there was $4.1 million of unrecognized compensation cost related to non-vested stock
award payments that we expect to be recognized over a weighted average period of 1.4 years.

Non-Vested Stock Units – Service-Based

We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with
vesting terms ranging from one to six years. Based on the terms and conditions of these awards, we determine if
the awards should be recorded as either equity or liability instruments. The compensation expense is determined
based on the market price of our common stock at the date of grant, applied to the total number of units that are
anticipated to vest, unless the award specifies differently. We account for such awards similar to our non-vested
stock awards; however, no shares of stock are issued to the recipient until the stock unit awards have vested and
after the pre-determined delivery date has occurred. Service-based non-vested stock unit compensation expense
included in general and administrative expenses in our accompanying consolidated statements of operations was
$1.0 million for 2015.

The following table presents our service-based non-vested stock units activity for 2015:

Number of Shares

Weighted Average
Grant Date Fair
Value

Non-vested stock units at January 1, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled, forfeited or expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Non-vested stock units at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . .

—
186,314
—
(2,982)

183,332

$ —

37.98
—
43.63

$37.89

The weighted average grant date fair value of service-based non-vested stock units granted was $37.98 in 2015.

At December 31, 2015, there was $5.9 million of unrecognized compensation cost related to our service-based
non-vested stock units that we expect to be recognized over a weighted average period of 2.7 years.

83

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Non-Vested Stock Units – Service-Based and Performance-Based Awards

During 2015, we awarded performance-based awards to certain employees. The target level established by the
award, which is based on the Company’s 2015 adjusted earnings before interest,
taxes and depreciation
(“EBITDA”), provided for the recipients to receive 154,732 non-vested stock units if the target was achieved.
The target number of shares to be potentially awarded has been reduced by forfeitures as indicated in the table
below. Performance-based non-vested stock units compensation expense included in general and administrative
expenses in our consolidated statements of operations was $1.3 million for 2015.

The following table presents our performance-based non-vested stock units activity for 2015:

Number of Shares

Weighted Average
Grant Date Fair
Value

Non-vested stock units at January 1, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled, forfeited or expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Non-vested stock units at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . .

—
154,732
—
(3,669)

151,063

$ —

39.54
—
43.63

$39.44

The weighted average grant date fair value of performance-based non-vested stock units granted was $39.54 in
2015.

At December 31, 2015, there were $4.6 million in unrecognized compensation costs related to our performance-
based non-vested stock units that we expect to be recognized over a weighted average period of 2.2 years.

Non-Vested Stock Units – Service-Based and Market-Based Awards

During 2013, we awarded market-based awards to certain employees. The target level established by the award,
which is based on our average December 2015 stock price, provided for the recipients to receive 417,330 non-
vested stock units if the target is achieved. If the target objective is surpassed to the point of achieving the
projected maximum payout, the recipients would receive 667,728 non-vested stock units. The target number of
shares to be potentially awarded has been reduced by forfeitures as indicated in the table below.

For market-based awards, the effect of the market condition is reflected in the fair value of the awards at the date
of grant using a Monte-Carlo simulation model. A Monte-Carlo simulation model estimates the fair value of the
market-based award based upon the expected term, risk-free interest rate and expected volatility. Compensation
expense for market-based awards is recognized over the vesting period regardless of whether the market
conditions are expected to be achieved. Market-based non-vested stock units compensation expense included in
general and administrative expenses in our accompanying consolidated statements of operations was $0.3
million, $0.5 million and $0.8 million for 2015, 2014 and 2013, respectively. The fair value of the 2013 award
was estimated using the following assumptions:

Forward Interest Rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected Volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Requisite Service Period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fair Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

0.327 % – 1.460%
54.38%
3 years
$ 10.51

84

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

The following table presents our market-based non-vested stock units activity for 2015:

Number of Shares

Weighted Average
Grant Date Fair
Value

Non-vested stock units at January 1, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Canceled, forfeited or expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Non-vested stock units at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . .

225,745
—
—
(61,211)

164,534

$10.51
—
—
10.51

$10.51

The weighted average grant date fair value of market-based non-vested stock units granted was $10.51 in 2013.

At December 31, 2015, there were $0.2 million in unrecognized compensation costs related to our market-based
non-vested stock units that we expect to be recognized over a weighted average period of 0.3 years.

10. COMMITMENTS AND CONTINGENCIES

Legal Proceedings – Ongoing

We are involved in the following legal actions:

Securities Class Action Lawsuits

On June 10, 2010, a putative securities class action complaint was filed in the United States District Court for the
Middle District of Louisiana (the “District Court”) against the Company and certain of our current and former
senior executives. Additional putative securities class actions were filed in the District Court on July 14, July 16,
and July 28, 2010.

On January 18, 2011, the Co-Lead Plaintiffs filed an amended, consolidated class action complaint (the
“Securities Complaint”) which supersedes the earlier-filed securities class action complaints. The Securities
Complaint alleges that the defendants made false and/or misleading statements and failed to disclose material
facts about our business, financial condition, operations and prospects, particularly relating to our policies and
practices regarding home therapy visits under the Medicare home health prospective payment system and the
related alleged impact on our business, financial condition, operations and prospects. The Securities Complaint
seeks a determination that the action may be maintained as a class action on behalf of all persons who purchased
the Company’s securities between August 2, 2005 and September 28, 2010 and an unspecified amount of
damages.

All defendants moved to dismiss the Securities Complaint. On June 28, 2012, the District Court granted the
defendants’ motion to dismiss the Securities Complaint. On July 26, 2012, the Co-Lead Plaintiffs filed a motion
for reconsideration, which the District Court denied on April 9, 2013.

On May 3, 2013, the Co-Lead Plaintiffs appealed the dismissal of the Securities Complaint to the United States
Court of Appeals for the Fifth Circuit (the “Fifth Circuit”). On October 2, 2014, a three-judge panel of the Fifth
Circuit issued a decision reversing the District Court’s dismissal of the Securities Complaint. On October 16,
2014, all defendants filed a petition with the Fifth Circuit to review the three-judge panel’s decision en banc, or
as a whole court. On December 29, 2014, the Fifth Circuit denied the defendants’ motion for en banc review of
the Fifth Circuit panel’s decision reversing the District Court’s dismissal of the Securities Complaint. The case

85

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

then returned to the District Court for further proceedings. On March 30, 2015, the defendants filed a Petition for
Writ of Certiorari (the “Petition”) with the United States Supreme Court asking the Supreme Court to consider
whether the Fifth Circuit erred in reversing the District Court’s dismissal of the Securities Complaint. The
Supreme Court denied the Petition on June 29, 2015, which did not affect the ongoing proceedings before the
District Court, including the District Court’s consideration of a motion filed on April 3, 2015, by the Co-Lead
Plaintiffs for leave to amend the Securities Complaint, which motion was granted by the District Court. On
December 15, 2015, the defendants filed a motion to dismiss the Co-Lead Plaintiffs’ First Amended Consolidated
Complaint. All discovery in the case is currently stayed pursuant to federal law. No assurances can be given
about the timing or outcome of this matter.

Wage and Hour Litigation

thereby denying them overtime pay. Moreover,

On July 25, 2012, a putative collective and class action complaint was filed in the United States District Court for
the District of Connecticut against us in which three former employees allege wage and hour law violations. The
former employees claim that they were not paid overtime for all hours worked over 40 hours in violation of the
Federal Fair Labor Standards Act (“FLSA”), as well as the Pennsylvania Minimum Wage Act. More specifically,
they allege they were paid on both a per-visit and an hourly basis, and that such a pay scheme resulted in their
in response to a
misclassification as exempt employees,
Company motion arguing that plaintiffs’ complaint was deficient in that it was ambiguous and failed to provide
fair notice of the claims asserted and plaintiffs’ opposition thereto, the Court, on April 8, 2013, held that the
complaint adequately raises general allegations that the plaintiffs were not paid overtime for all hours worked in
a week over 40, which may include claims for unpaid overtime under other theories of liability, such as alleged
off-the-clock work, in addition to plaintiffs’ more clearly stated allegations based on misclassification. On behalf
of themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek
attorneys’ fees, back wages and liquidated damages going back three years under the FLSA and three years under
the Pennsylvania statute. On October 8, 2013, the Court granted plaintiffs’ motion for equitable tolling requesting
that the statute of limitations for claims under the FLSA for plaintiffs who opt-in to the lawsuit be tolled from
September 24, 2012, the date upon which plaintiffs filed their original motion for conditional certification, until
90 days after any notice of this lawsuit is issued following conditional certification. Following a motion for
reconsideration filed by the Company, on December 3, 2013, the Court modified this order, holding that putative
class members’ FLSA claims are tolled from October 29, 2012 through the date of the Court’s order on
plaintiffs’ motion for conditional certification. On January 13, 2014, the Court granted plaintiffs’ July 10, 2013
motion for conditional certification of their FLSA claims and authorized issuance of notice to putative class
members to provide them an opportunity to opt in to the action. On April 17, 2014, that notice was mailed to
putative class members. The period within which putative class members were permitted to opt into the action
expired on July 16, 2014.

On September 10, 2014, the plaintiffs in the Connecticut case filed a motion for leave to amend their complaint
to add a new claim under the Kentucky Wage and Hour Act (“KWHA”) alleging that the Company did not pay
certain home health clinicians working in the Commonwealth of Kentucky all of the overtime wages they were
owed, either because the Company misclassified them as exempt from overtime or, while treating them as
overtime eligible, did not properly pay them overtime for all hours worked over 40 in a week. On behalf of
themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek
attorneys’ fees, back wages and liquidated damages going back five years before the filing of their original
complaint under the KWHA. On October 1, 2014, the Company filed an opposition to the plaintiffs’ motion to
amend. On October 15, 2014, plaintiffs filed a reply brief in support of their motion. On December 12, 2014, the
Court granted the plaintiffs’ motion to amend the complaint to add the claims under the KWHA. The Company
and the plaintiffs agreed to explore the possibility of a mediated settlement of the Connecticut case, and on

86

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

February 23, 2015 filed a joint motion to stay proceedings for six months to pursue that process, which was
granted by the Court on February 24, 2015.

On June 10, 2015, the Company and plaintiffs participated in a mediation whereby they agreed to fully resolve
all of plaintiffs’ claims in the lawsuit for $8.0 million, subject to approval by the Court. The settlement
agreement will be submitted to the Court for preliminary approval and plaintiffs will request certification of
Pennsylvania and Kentucky classes for the sole purpose of this proposed settlement. If the Court grants
preliminary approval, notice will be issued to members of the settlement classes to provide them with an
opportunity to object to the settlement and, in the case of members of the Pennsylvania and Kentucky classes, opt
out of the settlement. Following this notice period, the Court will hold a final fairness hearing for the purpose of
considering objections and deciding whether to grant final approval of the settlement. As of September 30, 2015,
we had an accrual of $8.0 million for this matter. On January 29, 2016, the Court approved the final settlement of
this case. The settlement became effective on February 26, 2016. As a result of the final amount calculated by the
settlement administrator based on claims timely submitted, we have reduced our accrual to $5.3 million as of
December 31, 2015.

On September 13, 2012, a putative collective and class action complaint was filed in the United States District
Court for the Northern District of Illinois against us in which a former employee alleges wage and hour law
violations. The former employee claims she was paid on both a per-visit and an hourly basis, and that such a pay
scheme resulted in her misclassification as an exempt employee, thereby denying her overtime. The plaintiff
alleges violations of federal and state law and seeks damages under the FLSA and the Illinois Minimum Wage
Law. Plaintiff seeks class certification of similar employees who were or are employed in Illinois and seeks
attorneys’ fees, back wages and liquidated damages going back three years under the FLSA and three years under
the Illinois statute. On May 28, 2013, the Court granted the Company’s motion to stay the case pending
resolution of class certification issues and dispositive motions in the earlier-filed Connecticut case referenced
above. On December 23, 2015 the parties agreed to explore the possibility of a mediated settlement of the Illinois
case, and a mediation is scheduled to occur on April 18, 2016.

We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from
the securities litigation described above. The Company intends to continue to vigorously defend itself in the
securities litigation matter but, if decided adverse to the Company, its impact could be material. No assurances
can be given as to the timing or outcome of the securities matter described above or the impact of any of the
inquiry or litigation matters on the Company, its consolidated financial condition, results of operations or cash
flows, which could be material, individually or in the aggregate.

Frontier Litigation

for

On April 2, 2015, Frontier Home Health and Hospice, L.L.C. (“Frontier”) filed a complaint against us in the
the District of Connecticut alleging breach of contract, negligent
United States District Court
misrepresentation and unfair and deceptive trade practices under Conn. Gen. Stat. §42-110b. Frontier acquired
our interest in five home health and four hospice care centers in Wyoming and Idaho in April 2014. The
complaint alleges that certain of the hospice patients on service at the time of the acquisition did not meet
Medicare eligibility requirements and that we breached certain of the representations and warranties under the
purchase agreement and therefore, the businesses were worth less than the purchase price. Under the complaint,
Frontier seeks declaratory judgment from the District Court that, under the terms of the purchase agreement with
Frontier, we are obligated to determine the amount of the alleged Medicare overpayments and reimburse the
government for the same in a timely manner, as well as unspecified compensatory and punitive damages,
attorneys’ fees and pre- and post-judgment interest.

87

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from
the Frontier litigation described above. The Company has engaged an independent auditing firm to perform a
clinical audit of the hospice locations in question and intends to defend itself in the Frontier litigation matter. No
assurances can be given as to the timing or outcome of the audit, the Frontier litigation matter described above or
the impact of any of the audit or litigation matters on the Company, its consolidated financial condition, results of
operations or cash flows, which could be material, individually or in the aggregate. In accordance with our
corporate integrity agreement (“CIA”) with the Office of Inspector General-HHS (“OIG”) as discussed below
under “Other Investigative Matters – Corporate Integrity Agreement”, we have notified the OIG of this matter.

Subpoena Duces Tecum Issued by the U.S. Department of Justice

On May 21, 2015, we received a Subpoena Duces Tecum (“Subpoena”) issued by the U.S. Department of Justice.
The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States
Attorney’s Office for the District of Massachusetts. It also requests the delivery of documents relating to our
hospice clinical and business operations and related compliance activities. The Subpoena generally covers the
period from January 1, 2011, through the present. We are fully cooperating with the U.S. Department of Justice
with respect to this investigation. No assurance can be given as to the timing or outcome of this investigation.

Civil Investigative Demand Issued by the U.S. Department of Justice

On November 3, 2015, we received a civil investigative demand (“CID”) issued by the U.S. Department of
Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for
hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests
the delivery of information to the United States Attorney’s Office for the Northern District of West Virginia
regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business
operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through
August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation.
No assurance can be given as to the timing or outcome of this investigation.

In addition to the matters referenced in this note, we are involved in legal actions in the normal course of
business, some of which seek monetary damages, including claims for punitive damages. We do not believe that
these normal course actions, when finally concluded and determined, will have a material impact on our
consolidated financial condition, results of operations or cash flows.

Legal Proceedings – Settled

Shareholder Derivative Action

On August 24, 2015, Michael Bonhette, an alleged shareholder of the Company filed a derivative lawsuit in the
United States District Court for the Middle District of Louisiana, purporting to assert claims on behalf of the
Company against certain of our officers and directors. We were named as a nominal defendant in this action. The
derivative complaint alleged that certain of our officers and directors breached their fiduciary duties to the
Company by agreeing to allegedly unlawful provisions in the Company’s Credit Agreement dated as of
October 22, 2012, as amended (the “Prior Credit Agreement”), and the Company’s Second Lien Credit
Agreement dated as of July 28, 2014 (the “Second Lien Credit Agreement”). Each of the Prior Credit Agreement
and the Second Lien Credit Agreement were terminated on August 28, 2015.

88

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

On October 14, 2015, the United Stated District Court for the Middle District of Louisiana issued an order
granting a motion for dismissal voluntarily filed by the plaintiffs in this matter. Effective as of such date, the
derivative lawsuit was dismissed without prejudice and at the cost of the plaintiffs.

Other Investigative Matters

Corporate Integrity Agreement

On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the
U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry
into this agreement, we entered into a corporate integrity agreement (“CIA”) with the Office of Inspector General
-HHS (“OIG”). The CIA formalizes various aspects of our already existing ethics and compliance programs and
contains other requirements designed to help ensure our ongoing compliance with federal health care program
requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive
compliance committee and compliance committee of the Board of Directors; provide certain compliance training;
continue screening new and current employees to ensure they are eligible to participate in federal health care
programs; engage an independent review organization to perform certain auditing and reviews and prepare
certain reports regarding our compliance with federal health care programs, our billing submissions to federal
health care programs and our compliance and risk mitigation programs; and provide certain reports and
management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial
overpayments that we discover we have received from federal health care programs, as well as probable
violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain
stipulated penalties, or could be excluded from participation in federal health care programs. The corporate
integrity agreement has a term of five years.

During the course of our compliance with the CIA we have identified several such reportable events and have
notified the OIG as required. The final resolution of these matters is still pending. As of December 31, 2015, we
have an accrual in the amount of $4.7 million to cover all repayments of extrapolated overpayments, damages
and penalties that we believe could be assessed.

Computer Inventory and Data Security Reporting

On March 1 and March 2, 2015, we provided official notice under federal and state data privacy laws concerning
the outcome of an extensive risk management process to locate and verify our large computer inventory. The
process identified approximately 142 encrypted computers and laptops for which reports were required under
federal and state data privacy laws. The devices at issue were originally assigned to Company clinicians and
other team members who left the Company between 2011 and 2014. We reported these devices to the U.S.
Department of Health and Human Services, state agencies, and individuals whose information may be involved,
as required under applicable law because we could not rule out unauthorized access to patient data on the
devices. The Office of Civil Rights, U.S. Department of Health and Human Services (“OCR”) is reviewing our
compliance with applicable laws, as is typical for any data breach involving more than 500 individuals. We are
cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate
with applicable regulatory authorities. In accordance with our CIA, we have notified the OIG of this matter.

Third Party Audits

From time to time, in the ordinary course of business, we are subject to audits under various governmental
programs in which third party firms engaged by CMS conduct extensive review of claims data to identify
potential improper payments under the Medicare program.

89

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

In January 2010, our subsidiary that provides home health services in Dayton, Ohio received from a Medicare
Program Safeguard Contractor (“PSC”) a request for records regarding 137 claims submitted by the subsidiary
paid from January 2, 2008 through November 10, 2009 (the “Claim Period”) to determine whether the underlying
services met pertinent Medicare payment requirements. Based on the PSC’s findings for 114 of the claims, which
were extrapolated to all claims for home health services provided by the Dayton subsidiary paid during the Claim
Period, on March 9, 2011, the Medicare Administrative Contractor (“MAC”) for the subsidiary issued a notice of
overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately $5.6 million. We
dispute these findings, and our Dayton subsidiary has filed appeals through the Original Medicare Standard
Appeals Process, in which we are seeking to have those findings overturned. A consolidated administrative law
judge (“ALJ”) hearing was held in late March 2013. In January 2014, the ALJ found fully in favor of our Dayton
subsidiary on 74 appeals and partially in favor of our Dayton subsidiary on eight appeals. Taking into account the
ALJ’s decision, certain determinations that our Dayton subsidiary decided not to appeal as well as certain
determinations made by the MAC, of the 114 claims that were originally extrapolated by the MAC, 76 claims
have now been decided in favor of our Dayton subsidiary in full, 10 claims have been decided in favor of our
Dayton subsidiary in part, and 28 claims have been decided against or not appealed by our Dayton subsidiary.
The ALJ has ordered the MAC to recalculate the extrapolation amount based on the ALJ’s decision. The
Medicare Appeals Council can decide on its own motion to review the ALJ’s decisions. As of December 31,
2015, we have recorded no liability with respect to the pending appeals as we do not believe that an estimate of a
reasonably possible loss or range of loss can be made at this time.

In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone
Program Integrity Contractor (“ZPIC”) a request for records regarding a sample of 30 beneficiaries who received
services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the “Review Period”)
to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the
hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before
and after our ownership of these hospice operations. Based on the ZPIC’s findings for 16 beneficiaries, which
were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review
Period, on June 6, 2011, the MAC for the subsidiary issued a notice of overpayment seeking recovery from our
subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals
through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings
overturned. An ALJ hearing was held in early January 2015. On January 18, 2016 we received a letter dated
January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision
was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million
including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals
Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample
was not valid. No assurances can be given as to the timing or outcome of the Medicare Appeals Council
decision. In the event we pay any amount of this alleged overpayment, we are indemnified by the prior owners of
the hospice operations for amounts relating to the period prior to August 1, 2009. As of December 31, 2015, we
have recorded no liability for this claim as we do not believe that an estimate of a reasonably possible loss or
range of loss can be made at this time.

Operating Leases

We have leased office space at various locations under non-cancelable agreements that expire between 2016 and
2026, and require various minimum annual rentals. Our typical operating leases are for lease terms of one to
seven years and may include, in addition to base rental amounts, certain landlord pass-through costs for our pro-
rata share of the lessor’s real estate taxes, utilities and common area maintenance costs. Some of our operating
leases contain escalation clauses, in which annual minimum base rentals increase over the term of the lease.

90

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Total minimum rental commitments as of December 31, 2015 are as follows (amounts in millions):

2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Future years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$23.5
16.0
11.2
7.4
4.3
5.5

$67.9

Rent expense for non-cancelable operating leases was $23.7 million, $26.5 million and $29.8 million for 2015,
2014 and 2013.

Insurance

We are obligated for certain costs associated with our insurance programs, including employee health, workers’
compensation and professional liability. While we maintain various insurance programs to cover these risks, we
are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with
these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to
both reported claims and claims incurred but not reported. These costs have generally been estimated based on
historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by
us on a quarterly basis.

The following table presents details of our insurance programs, including amounts accrued for the periods
indicated (amounts in millions) in accrued expenses in our accompanying balance sheets. The amounts accrued
below represent our total estimated liability for individual claims that are less than our noted insurance coverage
amounts, which can include outstanding claims and claims incurred but not reported.

Type of Insurance

Health insurance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Workers’ compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Professional liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Less: long-term portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

As of December 31,

2015

$11.7
23.9
4.1

39.7
(0.9)

2014

$11.2
20.8
3.9

35.9
(1.0)

$38.8

$34.9

The retention limit per claim for our health insurance, worker’s compensation and professional liability is $0.9
million, $0.5 million and $0.3 million, respectively.

Employment Contracts

We have commitments related to employment contracts with a number of our senior executives. These contracts
generally commit us to pay severance benefits under certain circumstances.

91

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Other

We are subject to various other types of claims and disputes arising in the ordinary course of our business. While
the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters
will not have a significant effect on our consolidated financial condition, results of operations and cash flows.

11. EMPLOYEE BENEFIT PLANS

401(K) Benefit Plan

We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have
reached 21 years of age, effective the first month after hire date. Under the plan, eligible employees may elect to
defer a portion of their compensation, subject to Internal Revenue Service limits.

During 2015, 2014 and 2013, our match of contributions to be made to each eligible employee contribution is
$0.375 for every $1.00 of contribution made up to the first 6% of their salary. The match is discretionary and
thus is subject to change at the discretion of management. These contributions are made in the form of our
common stock, valued based upon the fair value of the stock as of the end of each calendar quarter end. We
expensed approximately $6.1 million, $6.2 million and $7.8 million for 2015, 2014 and 2013, respectively.

Deferred Compensation Plan

We had a Deferred Compensation Plan for additional tax-deferred savings to a select group of management or
highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a
rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred
Compensation Plan as deemed fit, thus the assets are not necessarily reflective of the same investment choices
made by the participants.

Effective January 1, 2015, all prospective salary deferrals ceased. Participants will be allowed to make
transactions with any remaining account balances as they wish per plan guidelines.

12. STOCK REPURCHASE PROGRAM

On September 9, 2015, we announced that our Board of Directors authorized a stock repurchase program, under
which we may repurchase up to $75 million of our outstanding common stock. Purchases may be made from
time to time in open market transactions, block purchases or in private transactions in accordance with applicable
federal securities laws and other legal requirements. We may enter into Rule 10b5-1 plans to effect some or all of
the repurchases. The stock repurchase program is scheduled to expire on September 6, 2016.

The timing and the amount of the repurchases, if any, will be determined by management based on a number of
factors, including but not limited to share price, trading volume and general market conditions, as well as on
working capital requirements, general business conditions and other factors.

During 2015, pursuant to this program, we repurchased 116,859 shares of our common stock at a weighted
average price of $39.20 per share and a total cost of approximately $4.6 million. The repurchased shares are
classified as treasury shares.

92

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

13. EXIT AND RESTRUCTURING ACTIVITIES

As of December 31, 2013, we reported three home health care centers as held for sale. During 2014, we sold
assets associated with two of these care centers for cash consideration of approximately $0.8 million and
recognized a gain of approximately $0.8 million which is included in discontinued operations. The remaining
care center classified as held for sale was consolidated with a care center servicing the same market during 2014.

During 2014, the Company sold its interest in five home health and four hospice care centers in Wyoming and
Idaho for approximately $5.0 million and recognized a gain of $2.1 million. We also exited our hospice inpatient
unit in New Hampshire and recognized a loss of $0.5 million.

In addition to the exit activity related to the care centers mentioned above, we consolidated 21 operating home
health care centers and four operating hospice care centers with care centers servicing the same markets and
closed 22 home health care centers and four hospice care centers during 2014. In connection with these care
centers, we recorded non-cash charges of $2.2 million in other intangibles impairment expense related to the
write-off of intangible assets, $2.1 million in other general and administrative expenses related to lease
termination costs and $2.1 million in salaries and benefits related to severance costs. These care centers were not
concentrated in certain selected geographical areas and did not meet the criteria to be classified as discontinued
operations in accordance with applicable accounting guidance.

During 2013, we sold assets associated with two home health care centers in Alaska and Washington, as well as a
hospice care center in Washington for cash consideration of approximately $1.6 million and recognized a gain of
approximately $1.0 million which is included in discontinued operations. We also sold our membership interest
in one of our unconsolidated joint ventures for cash consideration of approximately $0.5 million and recognized
a loss of approximately $0.7 million, which is included in other income (expense).

We also reported 28 care centers as held for sale and sold assets associated with 17 of these home health care
centers for cash consideration of approximately $1.4 million and recognized a gain of approximately $0.7 million
which is included in discontinued operations. We closed eight of our home health care centers previously
classified as held for sale and recorded charges of $0.1 million for the write-off of intangible assets and
$0.5 million related to lease termination costs which are included in discontinued operations. Three of these
home health care centers remained classified as held for sale as of December 31, 2013.

In addition to the sale and available for sale care centers mentioned above, we consolidated 41 operating home
health care centers and five operating hospice care centers with care centers servicing the same markets and
closed two home health care centers as of December 31, 2013. In connection with these care centers, we recorded
charges of $3.6 million in goodwill and other intangibles impairment expense related to the write-off of
intangible assets, $1.5 million in other general and administrative expenses related to lease termination costs and
$1.8 million in salaries and benefits related to severance costs during 2013.

The care centers that were closed or sold in 2013 are presented in discontinued operations in our consolidated
financial statements. See Note 4 – Discontinued Operations and Assets Held For Sale for additional information.

Restructuring Activity

During 2014, we restructured our regional leadership and corporate support functions. As such, we recorded
charges of $3.4 million in salaries and benefits related to severance costs. In addition, during 2014, William F.
Borne stepped down from his positions as Chief Executive Officer, Chairman and a member of our Board of
Directors and we recorded charges of $2.3 million in salaries and benefits related to severance costs.

93

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

Our reserve activity for our 2014 and 2013 exit and restructuring activity is as follows (amounts in millions):

2014 Exit Activity

2013 Exit Activity

Lease
Termination

Severance

Lease
Termination

Severance

Balances at December 31, 2012 . . . . . . . . . . . . . . . . . . . . . . . . . .
Charge in 2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash expenditures in 2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$—
—
—

Balances at December 31, 2013 . . . . . . . . . . . . . . . . . . . . . . . . . .
Charge in 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash expenditures in 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balances at December 31, 2014 . . . . . . . . . . . . . . . . . . . . . . . . . .
Charge in 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash expenditures in 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—
2.1
(1.6)

0.5
—
(0.4)

$—
—
—

—
7.8
(5.5)

2.3
—
(1.9)

$—
2.0
(0.5)

1.5
—
(1.2)

0.3
—
(0.2)

$—
1.8
(0.5)

1.3
—
(1.3)

—
—
—

Balances at December 31, 2015 . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 0.1

$ 0.4

$ 0.1

$—

14. VALUATION AND QUALIFYING ACCOUNTS

The following table summarizes the activity and ending balances in our allowance for doubtful accounts and
estimated revenue adjustments (amounts in millions):

Allowance for Doubtful Accounts

Year End

Balance at
Beginning of Year

Provision for
Doubtful
Accounts(1)

2015 . . . . . . . . . . . . . . . . . . . .
2014 . . . . . . . . . . . . . . . . . . . .
2013 . . . . . . . . . . . . . . . . . . . .

$14.3
14.2
21.0

$14.1
16.4
16.4

Write-Offs

$(11.9)
(16.3)
(23.2)

Balance at End
of Year

$16.5
14.3
14.2

(1)

Includes $0.1 million and $0.6 million from discontinued operations for the years ended December 31, 2014
and 2013, respectively.

Estimated Revenue Adjustments

Year End

Balance at
Beginning of Year

Provision for
Estimated
Revenue

Adjustments(1) Write-Offs

Balance at End
of Year

2015 . . . . . . . . . . . . . . . . . .
2014 . . . . . . . . . . . . . . . . . .
2013 . . . . . . . . . . . . . . . . . .

$3.1
3.9
6.4

$6.1
5.1
9.4

$ (5.2)
(5.9)
(11.9)

$4.0
3.1
3.9

(1)

Includes $0.1 million and $0.4 million from discontinued operations for the years ended December 31, 2014
and 2013, respectively.

94

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

15. SEGMENT INFORMATION

Our operations involve servicing patients through our two reportable business segments: home health and
hospice. Our home health segment delivers a wide range of services in the homes of individuals who may be
recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential
activities of daily living. Our hospice segment provides palliative care and comfort to terminally ill patients and
their families. The “other” column in the following tables consists of costs relating to executive management and
administrative support functions, primarily information services, accounting, finance, billing and collections,
legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources
and administration.

Management evaluates performance and allocates resources based on the operating income of the reportable
segments, which includes an allocation of corporate expenses directly attributable to the specific segment and
includes revenues and all other costs directly attributable to the specific segment. Segment assets are not
reviewed by the company’s chief operating decision maker and therefore are not disclosed below (amounts in
millions).

For the Year Ended December 31, 2015

Home Health Hospice

Other

Total

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of service, excluding depreciation and amortization . . . . . . . . . .
General and administrative expenses . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill and other intangibles impairment charge . . . . . . . . . . . . . .

$1,005.1
584.2
263.2
12.2
5.2
—

$275.4 $ — $1,280.5
725.9
—
141.7
452.4
126.5
62.7
14.1
—
1.9
20.0
13.4
1.4
77.3
77.3
—

Operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

864.8

207.7

217.2

1,289.7

Operating income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 140.3

$ 67.7

$(217.2) $

(9.2)

For the Year Ended December 31, 2014

Home Health Hospice

Other

Total

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of service, excluding depreciation and amortization . . . . . . . . . .
General and administrative expenses . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill and other intangibles impairment charge . . . . . . . . . . . . . .

Operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$956.9
559.4
269.0
14.8
9.0
1.6

853.8

$247.6
131.7
58.3
1.5
2.1
1.5

$ — $1,204.5
691.1
441.7
16.3
28.3
3.1

—
114.4
—
17.2
—

195.1

131.6

1,180.5

Operating income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$103.1

$ 52.5

$(131.6) $

24.0

95

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

For the Year Ended December 31, 2013

Home Health Hospice

Other

Total

Net service revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of service, excluding depreciation and amortization . . . . . . . . . .
General and administrative expenses . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Department of Justice settlement . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill and other intangibles impairment charge . . . . . . . . . . . . . .

Operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$987.7
578.9
304.8
10.2
10.3
—
8.5

912.7

$261.6
139.1
64.7
5.7
2.1
—
1.0

$ — $1,249.3
718.0
474.0
15.9
36.9
150.0
9.5

—
104.5
—
24.5
150.0
—

212.6

279.0

1,404.3

Operating income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 75.0

$ 49.0

$(279.0) $ (155.0)

16. UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION

2015:
1st Quarter (2)(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2nd Quarter (3)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3rd Quarter (2)(3)(5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4th Quarter (3)(4)(5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2014:
1st Quarter (6)(7) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2nd Quarter (8)(9) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3rd Quarter (9)(10)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4th Quarter (6) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net Income (Loss)
Attributable to
Amedisys, Inc.
Common
Stockholders(1)

Basic

Diluted

$(1.07) $(1.07)
0.32
0.25
0.38

0.32
0.25
0.39

$(0.09) $(0.09)

$(0.39) $(0.39)
0.23
0.26
0.28

0.24
0.26
0.28

$ 0.39

$ 0.39

Net Income (Loss)
Attributable to
Amedisys, Inc.

$(35.0)
10.6
8.4
12.9

$ (3.0)

$(12.4)
7.6
8.4
9.1

$ 12.8

Revenue

$ 301.6
314.1
326.4
338.4

$1,280.5

$ 298.7
305.0
300.3
300.5

$1,204.5

(1) Because of the method used in calculating per share data, the quarterly per share data may not necessarily

total to the per share data as computed for the entire year.

(2) During the first quarter of 2015, we recorded a non-cash asset impairment charge to write-off the software
costs incurred related to the development of AMS3 Home Health and Hospice in the amount of
$45.5 million, net of income taxes. During the third quarter of 2015, we recorded a non-cash asset
impairment charge related to our corporate headquarters in the amount of $1.2 million, net of income taxes.
(3) During each of the four quarters of 2015, we incurred certain costs associated with various legal matters.
Net of income taxes, these costs amounted to $1.3 million, $4.8 million, $0.2 million and $(1.1) million for
the three-month periods ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015,
respectively.

(4) During the fourth quarter of 2015, we recorded an accrual related to an OIG Self-Disclosure matter. Net of

income taxes, this charge amounted to $3.4 million.

96

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
December 31, 2015

(5) During the third and fourth quarters of 2015, we incurred certain costs associated with the implementation
of Homecare Homebase. Net of income taxes, these costs amounted to $1.2 million and $1.4 million for the
three-month periods ended September 30, 2015 and December 31, 2015, respectively.

(6) During the first and fourth quarters of 2014, we recognized non-cash other intangibles impairment charges

of $1.4 million and $0.6 million, net of income taxes.

(7) During the first quarter of 2014, we recorded charges for the accrual of various relators’ attorneys’ fees and
expenses in connection with the settlement agreement
to resolve the U.S. Department of Justice
investigation and the Stark Law Self-Referral matter and exit and restructuring activity costs. Net of income
taxes, these charges amounted to $2.4 million and $6.1 million, respectively.

(8) During the second quarter of 2014, we recorded an accrual related to an OIG Self-Disclosure matter. Net of
income taxes, this charge amounted to $0.9 million. Additionally, our results included a software write-off
in the amount of $0.9 million, net of income taxes.

(9) Our results for the second quarter of 2014, included a gain related to the sale of care centers in the amount
of $1.3 million, net of income taxes. Our results for the three months ended September 30, 2014, included a
loss related to the disposal of our in-patient facility in the amount of $0.3 million, net of income taxes.
(10) During the third quarter of 2014, we recorded a charge related to the write-off of deferred financing fees in

the amount of $0.3 million, net of income taxes.

17. SUBSEQUENT EVENT

On March 1, 2016, we acquired Associated Home Care, a private-duty home healthcare company with nine care
centers for a purchase price of $28 million.

97

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND

FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures which are designed to provide reasonable assurance of
achieving their objectives and to ensure that information required to be disclosed in our reports filed under the
Exchange Act is recorded, processed, summarized, disclosed and reported within the time periods specified in the
SEC’s rules and forms. This information is also accumulated and communicated to our management and Board
of Directors to allow timely decisions regarding required disclosure.

In connection with the preparation of this Annual Report on Form 10-K, as of December 31, 2015, under the
supervision and with the participation of our management, including our principal executive officer and principal
financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as
such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.

Based on this evaluation, our principal executive officer and principal financial officer concluded that our
disclosure controls and procedures were effective at a reasonable assurance level as of December 31, 2015, the
end of the period covered by this Annual Report on Form 10-K.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over our financial
reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Under
the supervision and with the participation of our management, including our principal executive officer and our
principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial
reporting based on the framework in Internal Control – Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in
Internal Control – Integrated Framework, our management concluded our internal control over financial
reporting was effective as of December 31, 2015.

Our internal control system is designed to provide reasonable assurance to our management and Board of
Directors regarding the preparation and fair presentation of published financial statements. All internal control
systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be
effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

In conducting this evaluation, management did not include an assessment of internal control over financial
reporting at Infinity HomeCare. As previously disclosed, on December 31, 2015, the Company completed the
acquisition of Infinity HomeCare and consolidated the financial results of Infinity effective as of such date.
Infinity accounted for approximately 1% of total assets and no revenue as of and for the year ended
December 31, 2015. As a result of its evaluation, management has concluded that the Company’s internal control
over financial reporting was effective as of December 31, 2015 based on those criteria.

KPMG LLP, the independent registered public accounting firm that audited our consolidated financial statements
included in this Form 10-K, has issued a report on our internal control over financial reporting, which is included
herein.

Changes in Internal Controls

During 2015, we began the implementation of Homecare Homebase (“HCHB”) with a total of 84 care centers
operating on HCHB as of December 31, 2015. The Company has included the changes to processes, information
technology systems and other components of internal controls over financial reporting as part of its ongoing
implementation activities as part of its review of internal controls over financial reporting.

98

There have been no other changes in our internal control over financial reporting (as defined in Exchange Act
Rule 13a-15(f)) that have occurred during the quarter ended December 31, 2015 that have materially affected, or
are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer and principal financial officer, does not expect that
our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all
fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute,
assurance that the control system’s objectives will be met. The design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further,
because of the inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud,
if any, have been detected. These inherent limitations include the realities that judgments in decision-making can
be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented
by the individual acts of some persons, by collusion of two or more people, or by management override of the
controls. The design of any system of controls is based in part on certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in achieving its stated goals under all
potential future conditions. Projections of any evaluation of controls’ effectiveness to future periods are subject
to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the
degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to
provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and
procedures, our principal executive officer and our principal financial officer concluded our disclosure controls
and procedures were effective at a reasonable assurance level as of December 2015, the end of the period covered
by this Annual Report.

99

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders
Amedisys, Inc.:

We have audited Amedisys, Inc.’s internal control over financial reporting as of December 31, 2015, based on
criteria established in Internal Control – Integrated Framework (2013), issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). Amedisys, Inc.’s management
is responsible for
maintaining effective internal control over financial reporting and for its assessment of the effectiveness of
internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal
Control over Financial Reporting under Item 9A. Our responsibility is to express an opinion on the Company’s
internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether effective internal control over financial reporting was maintained in all material respects. Our audit
included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on
the assessed risk. Our audit also included performing such other procedures as we considered necessary in the
circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. A company’s internal control over financial reporting
includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
company’s assets that could have a material effect on the financial statements.

internal control over financial reporting may not prevent or detect
Because of its inherent
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.

limitations,

In our opinion, Amedisys, Inc. maintained, in all material respects, effective internal control over financial
reporting as of December 31, 2015, based on criteria established in Internal Control – Integrated Framework
(2013), issued by COSO.

Amedisys, Inc. acquired Infinity HomeCare on December 31, 2015, and management excluded from its
assessment of the effectiveness of Amedisys, Inc.’s internal control over financial reporting as of December 31,
2015, Infinity HomeCare’s internal control over financial reporting associated with approximately 1% of total
assets and no revenues included in the consolidated financial statements of Amedisys, Inc as of and for the year
ended December 31, 2015. Our audit of internal control over financial reporting of Amedisys, Inc. also excluded
an evaluation of the internal control over financial reporting of Infinity HomeCare.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), the consolidated balance sheets of Amedisys, Inc. and subsidiaries as of December 31, 2015 and
2014, and the related consolidated statements of operations, comprehensive (loss) income, stockholders’ equity,
and cash flows for each of the years in the three-year period ended December 31, 2015, and our report dated
March 9, 2016, expressed an unqualified opinion on those consolidated financial statements.

/s/ KPMG LLP
Baton Rouge, Louisiana
March 9, 2016

100

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item is incorporated by reference to the 2016 Proxy Statement to be filed with
the SEC within 120 days after the end of the year ended December 31, 2015.

Code of Conduct and Ethics

We have adopted a code of ethics that applies to all of our directors, officers and employees, including our
principal executive officer, principal financial officer and principal accounting officer. This code of ethics, which
is entitled Code of Ethical Business Conduct, is posted at our internet website, http://www.amedisys.com. Any
amendments to, or waivers of the code of ethics will be disclosed on our website promptly following the date of
such amendment or waiver.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this item is incorporated by reference to the 2016 Proxy Statement to be filed with
the SEC within 120 days after the end of the year ended December 31, 2015.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

AND RELATED STOCKHOLDER MATTERS

The information required by this item is incorporated by reference to the 2016 Proxy Statement to be filed with
the SEC within 120 days after the end of the year ended December 31, 2015.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR

INDEPENDENCE

The information required by this item is incorporated by reference to the 2016 Proxy Statement to be filed with
the SEC within 120 days after the end of the year ended December 31, 2015.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this item is incorporated by reference to the 2016 Proxy Statement to be filed with
the SEC within 120 days after the end of the year ended December 31, 2015.

101

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)

1. Financial Statements

All financial statements are set forth under Part II, Item 8 of this report.

2. Financial Statement Schedules

There are no financial statement schedules included in this report as they are either not applicable or
included in the financial statements.

3. Exhibits

The Exhibits are listed in the Exhibit Index required by Item 601 of Regulation S-K immediate
following the signature pages of this report, which is incorporated by reference.

102

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

AMEDISYS, INC.

By:

/S/ PAUL B. KUSSEROW

Paul B. Kusserow,
President, Chief Executive Officer and
Member of the Board

Date: March 9, 2016

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed
below by the following persons on behalf of the registrant and in the capacities and on the date indicated:

Signature

Title

Date

/S/ PAUL B. KUSSEROW
Paul B. Kusserow

/S/ RONALD A. LABORDE
Ronald A. LaBorde

/S/ SCOTT G. GINN
Scott G. Ginn

/S/ LINDA J. HALL
Linda J. Hall

/S/

JAKE L. NETTERVILLE
Jake L. Netterville

/S/ BRUCE D. PERKINS
Bruce D. Perkins

President, Chief Executive Officer
and Member of the Board (Principal
Executive Officer)

Vice Chairman, Chief Financial
Officer and Member of the Board
(Principal Financial Officer)

Senior Vice President of Finance and
Accounting and Controller (Principal
Accounting Officer)

Director

Director

Director

March 9, 2016

March 9, 2016

March 9, 2016

March 9, 2016

March 9, 2016

March 9, 2016

/S/ DONALD A. WASHBURN
Donald A. Washburn

Non-Executive Chairman of
Board

the

March 9, 2016

/S/ NATHANIEL M. ZILKHA
Nathaniel M. Zilkha

Director

March 9, 2016

103

EXHIBIT INDEX

The exhibits marked with the cross symbol (†) are filed and the exhibits marked with a double cross (††) are
furnished with this Form 10-K. Any exhibits marked with the asterisk symbol (*) are management contracts or
compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K. The registrant
agrees to furnish to the Commission supplementally upon request a copy of any schedules or exhibits omitted
pursuant to Item 601(b)(2) of Regulation S-K of any material plan of acquisition, disposition or reorganization
set forth below.

Document Description

Report or Registration Statement

Exhibit
Number

3.1

3.2

of

Composite
of
Incorporation of the Company inclusive
of all amendments through June 14, 2007

Certificate

Composite of By-Laws of the Company
inclusive of all amendments through
February 24, 2014

4.1

Common Stock Specimen

10.1

Form of Director
Agreement dated February 12, 2009

Indemnification

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

3.1

0-24260

3.2

333-145582

4.8

0-24260

10.1

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2007

The Company’s Annual
Report on Form 10-K for the
year ended December 31,
2013

The Company’s Registration
Statement on Form S-3 filed
August 20, 2007

The Company’s Annual
Report on Form 10-K for the
year ended December 31,
2008

10.2*

10.3*

10.4*

10.5*

10.6*

Amended and Restated Amedisys, Inc.
Employee Stock Purchase Plan dated
June 7, 2012

The Company’s Current
Report on Form 8-K filed
June 8, 2012

0-24260

10.1

Inc.

Composite
2008
Amedisys,
Omnibus Incentive Compensation Plan
(inclusive of Plan amendments dated
June 7, 2012 and October 25, 2012,
April 23, 2015 and June 4, 2015 and the
full
text of the Amedisys, Inc. 2008
Omnibus Incentive Compensation Plan)

to

Appendix
the
A
Company’s Annual Report
on Form 10-K for the year
ended December 31, 2013

0-24260

10.3

Form of Nonvested Stock Award
Agreement Issued under the Amedisys,
Inc.
Incentive
Compensation Plan

Omnibus

2008

Restricted

Form of
Stock Unit
Agreement Issued under the Amedisys,
Incentive
Inc.
Compensation Plan

Omnibus

2008

Form of Stock Option Award Agreement
Issued under the Amedisys, Inc. 2008
Omnibus Incentive Compensation Plan

104

The Company’s Quarterly
Report on Form 10-Q for the
quarter ended June 30, 2008

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2008

The Company’s Annual
Report on Form 10-K for the
year ended December 31,
2014

0-24260

10.3

0-24260

10.4

0-24260

10.6

Exhibit
Number

10.7*

Document Description

Report or Registration Statement

Form of Performance Stock Option
the
Award Agreement
Amedisys, Inc. 2008 Omnibus Incentive
Compensation Plan

Issued under

The Company’s Annual
Report on Form 10-K for
the
ended
December 31, 2014

year

Form of Restricted
Stock Award
Agreement Issued under the Amedisys,
Inc.
Incentive
Compensation Plan

Omnibus

2008

The Company’s Annual
Report on Form 10-K for the
year ended December 31,
2014

Form of Restricted Performance Stock
the
Award Agreement
Amedisys, Inc. 2008 Omnibus Incentive
Compensation Plan

Issued under

The Company’s Annual
Report on Form 10-K for the
year ended December 31,
2014

Composite Amedisys, Inc. 1998 Stock
Option Plan (inclusive of amendments
dated June 10, 2004, June 8, 2006 and
June 22, 2006 and the full text of the
Amedisys, Inc. 1998 Stock Option Plan)

Company’s
The
Registration Statement on
Form S-8 filed June 22,
2007

Composite Director’s Stock Option Plan
(inclusive of Plan amendments dated
June 10, 2004, and the full text of the
Directors Stock Option Plan)

The Company’s Annual
Report on Form 10-K for
the
ended
December 31, 2005

year

Agreement

Employment
dated
December 11, 2014 by and among
Amedisys,
Inc., Amedisys Holding,
L.L.C. and Paul B. Kusserow

The Company’s Annual
Report on Form 10-K for the
year ended December 31,
2014

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

10.7

0-24260

10.8

0-24260

10.9

333-143967

4.2

0-24260

10.4

0-24260

10.12

Agreement

Employment
dated
November 1, 2011 by and among
Inc., Amedisys Holding,
Amedisys,
L.L.C. and Ronald A. LaBorde

Amendment No. 1 dated December 29,
2011 to Employment Agreement dated
November 1, 2011 by and among
Amedisys,
Inc., Amedisys Holding,
L.L.C. and Ronald A. LaBorde

Amendment No. 2 dated December 19,
2012 to Employment Agreement dated
November 1, 2011 by and among
Amedisys,
Inc., Amedisys Holding,
L.L.C. and Ronald A. LaBorde

Amendment No. 3 dated May 1, 2014 to
Employment
dated
November 1, 2011 by and among
Amedisys,
Inc., Amedisys Holding,
L.L.C. and Ronald A. LaBorde

Agreement

105

The Company’s Current
Report on Form 8-K filed
November 2, 2011

The Company’s Current
Report on Form 8-K filed
December 30, 2011

0-24260

10.1

0-24260

10.2

The Company’s Annual
Report on Form 10-K for
the
ended
December 31, 2013

year

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

0-24260

10.10.3

0-24260

10.4

10.8

10.9*

10.10*

10.11*

10.12*

10.13.1*

10.13.2*

10.13.3*

10.13.4*

Exhibit
Number

10.14*

10.15.1*

10.15.2*

10.15.3*

10.16.1*

10.16.2*

10.16.3*

10.16.4*

10.17.1*

Document Description

Report or Registration Statement

Agreement by and among Amedisys,
Inc., Amedisys Holding, L.L.C. and Dale
E. Redman dated as of March 24, 2014

The Company’s Current
Report on Form 8-K dated
March 19, 2014

Amended and Restated Employment
Agreement dated January 3, 2011 by and
Inc., Amedisys
among Amedisys,
Holding, L.L.C. and Jeffrey D. Jeter

to Amended

Amendment No. 1 dated December 19,
2012
and Restated
Employment Agreement dated January
3, 2011 by and among Amedisys, Inc.,
Amedisys Holding, L.L.C. and Jeffrey
D. Jeter

Amendment No. 2 dated May 1, 2014 to
Amended and Restated Employment
Agreement dated January 3, 2011 by and
Inc., Amedisys
among Amedisys,
Holding L.L.C. and Jeffrey D. Jeter

Amended and Restated Employment
Agreement dated July 23, 2010 by and
Inc., Amedisys
among Amedisys,
Holding, L.L.C. and David R. Bucey

Amendment No. 1 dated January 3, 2011
to Amended and Restated Employment
Agreement dated July 23, 2010 by and
among Amedisys,
Inc., Amedisys
Holding, L.L.C. and David R. Bucey

to Amended

Amendment No. 2 dated December 19,
2012
and Restated
Employment Agreement dated July 23,
2010 by and among Amedisys,
Inc.,
Amedisys Holding, L.L.C. and David R.
Bucey

Amendment No. 3 dated May 1, 2014 to
Amended and Restated Employment
Agreement dated July 23, 2010 by and
among Amedisys,
Inc., Amedisys
Holding, L.L.C. and David R. Bucey

Amended and Restated Employment
Agreement dated July 23, 2010 by and
Inc., Amedisys
among Amedisys,
Holding, L.L.C.
and Michael O.
Fleming, M.D.

The Company’s Current
Report on Form 8-K filed
January 7, 2011

The Company’s Annual
Report on Form 10-K for
ended
the
December 31, 2013

year

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

The Company’s Current
Report on Form 8-K filed
July 27, 2010

The Company’s Current
Report on Form 8-K filed
January 7, 2011

The Company’s Annual
Report on Form 10-K for
the
ended
December 31, 2013

year

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

The Company’s Current
Report on Form 8-K filed
July 27, 2010

106

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

99.1

0-24260

10.2

0-24260

10.11.12

0-24260

10.6

0-24260

10.2

0-24260

10.7

0-24260

10.13.3

0-24260

10.7

0-24260

10.1

Document Description

Report or Registration Statement

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

10.6

The Company’s Current
Report on Form 8-K filed
January 7, 2011

The Company’s Annual
Report on Form 10-K for
the
ended
December 31, 2013

year

0-24260

10.12.3

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

0-24260

10.5

The Company’s Current
Report on Form 8-K dated
December 22, 2015

0-24260

10.1

The Company’s Current
Report on Form 8-K filed
on October 30, 2012

0-24260

10.1

Exhibit
Number

10.17.2*

10.17.3*

10.17.4*

10.18

10.19.1

Amendment No. 1 dated January 3, 2011
to Amended and Restated Employment
Agreement dated July 23, 2010 by and
Inc., Amedisys
among Amedisys,
Holding, L.L.C.
and Michael O.
Fleming, M.D.

to Amended

Amendment No. 2 dated December 19,
2012
and Restated
Employment Agreement dated July 23,
Inc.,
2010 by and among Amedisys,
Amedisys Holding, L.L.C. and Michael
O. Fleming, M.D.

Amendment No. 3 dated May 1, 2014 to
Amended and Restated Employment
Agreement dated July 23, 2010 by and
Inc., Amedisys
among Amedisys,
Holding, L.L.C.
and Michael O.
Fleming, M.D.

Amedisys Holding, L.L.C. Severance
Plan for Key Executives dated as of
2015
April
all
thereto adopted on or
amendments
before December 17, 2015)

(inclusive

30,

of

RBS

Inc.
as

among Amedisys,

Credit Agreement dated October 26,
and
2012
Amedisys Holding, L.L.C.,
co-
borrowers, the several banks and other
financial institutions party thereto from
time to time, BOKF, NA DBA Bank of
Texas, Compass Bank, Fifth Third Bank
as
and
Citizens,
Documentation
of
America, N.A., as Syndication Agent,
as
JPMorgan Chase Bank, N.A.,
Administrative Agent, and J.P. Morgan
Securities LLC and Merrill Lynch,
Pierce, Fenner & Smith Incorporated, as
Joint
Co-Lead
Bookrunners

N.A.,
Bank

Arrangers

Agents,

and

107

Exhibit
Number

10.19.2

10.19.3

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

10.1.1

Document Description

Report or Registration Statement

The Company’s Quarterly
Report on Form 10-Q for
the
ended
September 30, 2013

quarter

Inc.
as

among Amedisys,

First Amendment and Limited Waiver
dated as of September 4, 2013 to the
Credit Agreement dated October 26,
and
2012
Amedisys Holding, L.L.C.,
co-
borrowers, the several banks and other
financial institutions party thereto from
time to time, BOKF, NA DBA Bank of
Texas, Compass Bank, Fifth Third Bank
and
as
Citizens,
of
Documentation
America, N.A., as Syndication Agent,
JPMorgan Chase Bank, N.A.,
as
Administrative Agent, and J.P. Morgan
Securities LLC and Merrill Lynch,
Pierce, Fenner & Smith Incorporated, as
Co-Lead
Joint
Bookrunners

N.A.,
Bank

Arrangers

Agents,

RBS

and

The Company’s Quarterly
Report on Form 10-Q for
the
ended
September 30, 2013

quarter

0-24260

10.1.2

as

other

dated

banks

Second Amendment
of
November 11, 2013 to the Credit
Agreement dated October 26, 2012
Inc. and Amedisys
among Amedisys,
the
Holding, L.L.C., as co-borrowers,
several
financial
and
institutions party thereto from time to
time, BOKF, NA DBA Bank of Texas,
Compass Bank, Fifth Third Bank and
RBS Citizens, N.A., as Documentation
Agents, Bank of America, N.A., as
Syndication Agent,
JPMorgan Chase
Bank, N.A., as Administrative Agent,
and J.P. Morgan Securities LLC and
Merrill Lynch, Pierce, Fenner & Smith
Incorporated, as Co-Lead Arrangers and
Joint Bookrunners

108

Exhibit
Number

10.19.4

10.19.5

10.20

10.21

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

10.3

Document Description

Report or Registration Statement

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended March 31,
2014

Third Amendment dated as of April 17,
2014 to the Credit Agreement dated
October 26, 2012 among Amedisys, Inc.
and Amedisys Holding, L.L.C., as co-
borrowers, the several banks and other
financial institutions party thereto from
time to time, BOKF, NA DBA Bank of
Texas, Compass Bank, Fifth Third Bank
and
as
Citizens,
Documentation Agents, Bank of America,
N.A., as Syndication Agent, JPMorgan
Chase Bank, N.A., as Administrative
Agent, and J.P. Morgan Securities LLC
and Merrill Lynch, Pierce, Fenner &
Co-Lead
Incorporated,
Smith
Arrangers and Joint Bookrunners

N.A.,

RBS

as

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

0-24260

10.1.2

The Company’s Quarterly
Report on Form 10-Q for
ended
the
September 30, 2013

quarter

0-24260

10.2

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

0-24260

10.8

Fourth Amendment dated as of July 28,
2014 to the Credit Agreement dated
October 26, 2012 among Amedisys, Inc.
and Amedisys Holding, L.L.C., as co-
borrowers, the several banks and other
financial institutions party thereto from
time to time, BOKF, NA DBA Bank of
Texas, Compass Bank, Fifth Third Bank
and
as
Citizens,
Documentation Agents, Bank of America,
N.A., as Syndication Agent, JPMorgan
Chase Bank, N.A., as Administrative
Agent, and J.P. Morgan Securities LLC
and Merrill Lynch, Pierce, Fenner &
Co-Lead
Incorporated,
Smith
Arrangers and Joint Bookrunners

N.A.,

RBS

as

Security and Pledge Agreement dated as
of November
among
11,
2013,
Inc., Amedisys Holding,
Amedisys,
L.L.C., the Guarantors party thereto and
JPMorgan Chase Bank, N.A., not in its
individual
as
capacity
Administrative Agent

solely

but

Second Lien Credit Agreement dated as
of
July 28, 2014 by and among
Amedisys, Inc. and Amedisys Holding,
L.L.C., as co-borrowers, the banks and
other
institutions or entities
from time to time parties thereto as
lenders, and Cortland Capital Market
Services LLC, as Administrative Agent

financial

109

Exhibit
Number

10.22

10.23

10.24.1

10.24.2

Document Description

Report or Registration Statement

Second Lien Security
and Pledge
Agreement dated as of July 28, 2014 by
and among Amedisys, Inc., Amedisys
Holding, L.L.C,
the guarantors party
thereto and Cortland Capital Market
individual
Services LLC, not
capacity, but solely as collateral agent
for the secured parties

in its

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

10.9

The Company’s Quarterly
Report on Form 10-Q for
the quarter ended June 30,
2014

0-24260

10.10

The Company’s Current
Report on Form 8-K filed
September 2, 2015

0-24260

10.1

The Company’s Current
Report on Form 8-K filed
September 2, 2015

0-24260

10.2

Intercreditor Agreement dated as of July
28, 2014 by and among JPMorgan Chase
Bank, N.A., as Administrative Agent for
the first priority secured parties, Cortland
as
Capital Market
the second
Administrative Agent
priority secured parties, and the direct
and indirect subsidiaries of Amedisys,
Inc. and Amedisys Holding, L.L.C. from
time to time party thereto

Services LLC,

for

Inc.

among Amedisys,

Credit Agreement dated as of August 28,
2015,
and
Amedisys Holding, L.L.C., as borrowers,
certain subsidiaries of Amedisys, Inc.
party thereto as guarantors, Bank of
America, N.A., as Administrative Agent,
and L/C Issuer,
Swingline Lender
as
JPMorgan Chase Bank, N.A.,
Syndication Agent, Citizens Bank, N.A.,
Compass Bank, Fifth Third Bank, and
Regions Bank, as Co-Documentation
Agents, the lenders party thereto, Merrill
Lynch,
Fenner & Smith
Incorporated, Citizens Bank N.A., Fifth
Third Bank and J.P. Morgan Securities
LLC, as
Joint Lead Arrangers, and
Merrill Lynch, Pierce, Fenner & Smith
Incorporated and J.P. Morgan Securities
LLC, as Joint Bookrunners

Pierce

Security Agreement dated as of August
28, 2015, among Amedisys, Inc. and
Amedisys Holding, L.L.C., as borrowers,
certain
as
parties
“grantors” on the signature pages thereto
and Bank of America, N.A.,
in its
capacity as Administrative Agent

identified

other

110

Exhibit
Number

10.24.3

10.25

10.26

† 10.27

† 10.28

† 21.1

† 23.1

† 31.1

Document Description

Report or Registration Statement

Pledge Agreement dated as of August 28,
2015, among Amedisys, Inc. and Amedisys
Holding, L.L.C., as borrowers, certain other
identified as “pledgers” on the
parties
thereto, and Bank of
signature pages
as
in
America, N.A.,
Administrative Agent

capacity

its

The Company’s Current
Report on Form 8-K filed
September 2, 2015

SEC File or
Registration
Number

Exhibit
or Other
Reference

0-24260

10.3

The Company’s Current
Report on Form 8-K filed
on April 24, 2014

0-24260

10.1

Settlement Agreement effective April 23,
2014 by and among (a) the United States of
America, acting through the United States
Department of Justice and on Behalf of the
Office
the
Department of Health and Human Services,
(b) Amedisys, Inc. and Amedisys Holding,
L.L.C. and (c) the various Relators named
therein

Inspector General

of

of

Corporate Integrity Agreement effective
April 22, 2014 between the Office of
Inspector General of the Department of
Health and Human Services and Amedisys,
Inc. and Amedisys Holding, L.L.C.

The Company’s Current
Report on Form 8-K filed
on April 24, 2014

0-24260

10.2

Care West,

Agreement and Plan of Merger dated
October 31, 2015 by and among Amedisys
Health
IHC
Acquisitions, L.L.C., Infinity Home Care,
L.L.C., Axiom HealthEquity Holdings
Management, LLC,
Infinity Healthcare
Holdings, LLC, and Amedisys, Inc.

L.L.C.,

Agreement of Purchase and Sale dated as of
November 25, 2015, between Amedisys,
Inc., through its wholly-owned subsidiary,
Amedisys Property, L.L.C., as seller and
Franciscan Missionaries of Our Lady of the
Lake Heath System, Inc., as purchaser.

Subsidiaries of the Registrant

Consent of KPMG LLP

of

Certification
Paul B. Kusserow,
President and Chief Executive Officer
(principal executive officer), pursuant
to
Section 302 of the Sarbanes-Oxley Act of
2002

111

Exhibit
Number

† 31.2

††32.1

††32.2

Document Description

Report or Registration Statement

SEC File or
Registration
Number

Exhibit
or Other
Reference

Certification of Ronald A. LaBorde, Vice
Chairman and Chief Financial Officer
(principal
to
Section 302 of the Sarbanes-Oxley Act of
2002

financial officer), pursuant

of

Paul B. Kusserow,
Certification
President and Chief Executive Officer
(principal executive officer), pursuant
to
18 U.S.C. Section 1350,
adopted
pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002

as

Certification of Ronald A. LaBorde, Vice
Chairman and Chief Financial Officer
to
(principal
18 U.S.C. Section 1350,
adopted
pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002

financial officer), pursuant

as

†101.INS XBRL Instance

†101.SCH XBRL Taxonomy Extension

Schema

Document

†101.CAL XBRL Taxonomy Extension Calculation

Linkbase Document

†101.DEF XBRL Taxonomy Extension Definition

Linkbase

†101.LAB XBRL

Taxonomy
Linkbase Document

Extension

Labels

†101.PRE XBRL Taxonomy Extension Presentation

Linkbase Document

112

Exhibit 31.1 

I, Paul B. Kusserow, certify that:  

CERTIFICATION  

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2015, of Amedisys, Inc.;  

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact 
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading 
with respect to the period covered by this report;  

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all 
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods 
presented in this report;  

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and 
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined 
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:  

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed 
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, 
is made known to us by others within those entities, particularly during the period in which this report is being prepared;  

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be 
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the 
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our 
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this 
report based on such evaluation; and  

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the 
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has 
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over 
financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing 
the equivalent functions):  

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial 
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report 
financial information; and  

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the 
registrant’s internal control over financial reporting.  

Date: March 9, 2016  

/S/ Paul B. Kusserow
Paul B. Kusserow
President and Chief Executive Officer 
(Principal Executive Officer) 

  
Exhibit 31.2 

I, Ronald A. LaBorde, certify that:  

CERTIFICATION  

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2015, of Amedisys, Inc.;  

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact 
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading 
with respect to the period covered by this report;  

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all 
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods 
presented in this report;  

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and 
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined 
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:  

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed 
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, 
is made known to us by others within those entities, particularly during the period in which this report is being prepared;  

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be 
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the 
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our 
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this 
report based on such evaluation; and  

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the 
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has 
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over 
financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing 
the equivalent functions):  

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial 
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report 
financial information; and  

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the 
registrant’s internal control over financial reporting.  

Date: March 9, 2016  

/S/ Ronald A. LaBorde
Ronald A. LaBorde 
Vice Chairman and Chief Financial Officer
(Principal Financial Officer)

  
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  

In connection with the Annual Report of Amedisys, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015 (the 
“Report”), I, Paul B. Kusserow, President and Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:  

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of 
operations of the Company.  

Exhibit 32.1 

Date: March 9, 2016  

/S/ Paul B. Kusserow 
Paul B. Kusserow 
President and Chief Executive Officer
(Principal Executive Officer)

  
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  

In connection with the Annual Report of Amedisys, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015 (the 
“Report”), I, Ronald A. LaBorde, Vice Chairman and Chief Financial Officer of the Company, hereby certify to my knowledge, 
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:  

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of 
operations of the Company.  

Exhibit 32.2 

Date: March 9, 2016  

/S/ Ronald A. LaBorde 
Ronald A. LaBorde 
Vice Chairman and Chief Financial Officer 
(Principal Financial Officer)

  
COMPANYLEADERSHIP

BOARD OF DIRECTORS

EXECUTIVE OFFICERS

Donald A. Washburn  
Non-Executive Chairman of the Board 
Private Investments 

Linda J. Hall 
Entrepreneur-in-Residence  
Carlson School of Business at the University of 
Minnesota

Julie Klapstein* 
Former CEO 
Availity

Paul B. Kusserow 
President and Chief Executive Officer 
Amedisys, Inc.

Ronald A. LaBorde 
Vice Chairman and Chief Financial Officer 
Amedisys, Inc.

Richard Lechleiter* 
President  
Catholic Education Foundation 
Retired Executive Vice President and Chief Financial 
Officer, Kindred Healthcare, Inc.

Jake L. Netterville 
Chairman, Emeritus, of the Board of Directors 
Postlethwaite & Netterville, A Professional 
Accounting Corporation

Bruce D. Perkins 
Former President of Healthcare Services  
Humana

Jeffrey A. Rideout, M.D., M.A., FACP* 
President and CEO  
the Integrated Healthcare Association

Nathaniel M. Zilkha 
Head of Credit and Global 
Co-Head of Special Situations  
KKR

Paul B. Kusserow 
President and Chief Executive Officer

Ronald A. LaBorde 
Vice Chairman and Chief Financial Officer 

Jeffrey D. Jeter 
Chief Compliance Officer

Jane E. Carmody, DNP, MBA, RN, CENP 
Chief Clinical Operations Officer

Martin B. Howard 
Chief Information Officer

David L. Kemmerly 
General Counsel and Senior Vice President of 
Government Affairs

Daniel P. McCoy 
Chief Operating Officer

Larry R. Pernosky 
Chief Human Resources Officer

Stephen E. Seim 
Chief Strategy Officer

* Board member as of April 20, 2016

Performance Graph

Independent Accountants

Stock Listing

Form 10-K Exhibits

A performance graph 
comparing the cumulative 
total stockholder return on our 
common stock for the five-
year period ended December 
31, 2015, with the cumulative 
total return on the NASDAQ 
composite Index and peer-
group Index over the same 
period is Included in the Form 
10-K.

KPMG LLP 
Baton Rouge, Louisiana

Annual Meeting

The annual meeting of 
stockholders will take place 
on June 2, 2016, at 12:00 
p.m. (CDT) at the company’s 
corporate headquarters, 3854 
American Way, Suite A, Baton 
Rouge, Louisiana.

The company’s common 
stock is listed on the NASDAQ 
Global Select Market under 
the symbol “AMED.”

Transfer Agent and Registrar

American Stock Transfer & 
Trust Company, LLA 
6201 15th Avenue 
Brooklyn, New York 11219 
800.937.5449

A copy of all exhibits to the 
company’s Annual Report 
on Forms 10-K as filed with 
the Securities and Exchange 
Commission is available free 
of charge on our website at 
www.amedisys.com or by 
contacting:

Amedisys, Inc.  
3854 American Way, Suite A, 
Baton Rouge, LA 70816 
Investor@amedisys.com

Amedisys on the Internet
Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company 
information. Important information, including press releases, analyst presentations and financial information regarding our 
company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking 
on the tab labeled “Investors” on our website home page. We also use our website to expedite public access to time-critical 
information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the 
same information. Therefore, investors should look to the “Investors” subpage of our website for important and time-critical 
information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new 
information is made available on the “Investors” subpage of our website. In addition, we make available on the “Investors” subpage 
of our website (under the link “SEC filings”) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, 
current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable 
after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of 
Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Nominating and 
Corporate Governance, Quality of Care and Compliance and Ethics Committees of our Board are also available on the “Investors” 
subpage of our website (under the link “Corporate Governance”).

Forward-Looking Statements

When included in this document, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” 
“might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private 
Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could 
cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited 
to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional 
care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing Federal 
and state laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the 
home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments 
associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract 
and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending 
by Federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing 
due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply 
with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and 
manage our information systems, our ability to comply with the requirements stipulated in our corporate integrity agreement, 
and changes in law or developments with respect to any litigation relating the Company, including various other matters, many of 
which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or 
quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any 
obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the 
forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement 
may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see 
Part I, Item 1A—“Risk Factors” and Part II, Item 7—“Critical Accounting Policies” within “Management’s Discussion and Analysis of 
Financial Condition and Results of Operations” set forth in our Annual Report on Form 10-K for the year ended December 31, 2015.

www.amedisys.com